












Resistance to antimicrobial agents is an increasing problem, especially in developing
countries where resistant strains have undermined the effectiveness of antimicrobial
agents such as trimethoprim. Since the commensal faecal flora are strongly implicated as
a reservoir for resistant organisms. A survey was conducted in South Africa to determine
the incidence of resistance in aerobic Gram-negative commensal faecal flora.
Faecal specimens from 272 out of 361 (75%) healthy volunteers carried trimethoprim-
resistant bacteria; 357 trimethoprim-resistant strains were isolated. Trimethoprim
resistance was transferable by conjugation in 55% of the isolates. The majority of the
isolates were resistant to other antimicrobial agents including ampicillin 71.4% and
tetracycline 88%. Most of these resistance phenotypes co-transferred with trimethoprim
resistance. Analysis of 189 plasmids revealed 107 different restriction profiles which
indicated that there is a large gene pool of trimethoprim-resistant plasmids in the faecal
flora.
High-level resistance to trimethoprim (MIC > 1024mg/l) occurred in 98.6% of the
isolates suggesting that resistance in these isolates was mediated by the production of
additional trimethoprim resistant dihydrofolate reductase (DHFR) genes. To determine
the epidemiology of these genes, oligonucleotide probes were designed from the
nucleotide sequence of a heterogeneous region which occurs within all trimethoprim
resistant DHFR genes. Hybridisation experiments revealed that contrary to all previous
data, the most prevalent DHFR of the transferable genes which hybridised was the type
lb (30%), followed by the type VIII (23%), V (13%), la (6%), VII (3%) and XII
(0.5%). On the other hand the type VII, (38%) was the most prevalent dihydrofolate
reductase gene in the 161 (45%) isolates which did not transfer their resistance factors,
followed by type la (25%), type lb (12%), type V (2%) and type VIII (0.5%).
In selected isolates which were unable to transfer trimethoprim resistance, the potential
mechanisms of spread of resistance were investigated. The type lb and V DHFR genes
were shown to occur on non-transferable plasmids which is in stark contrast to the types
la and VII DHFRs, the majority of which were integrated into the chromosome, and
were associated with the integrase genes of Tn7 and Tn27 respectively. These data show
that resistant DHFR genes have distinct preferences for their genetic location.
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The DHFR gene from one of the isolates which did not hybridise to any of the gene
probes was further studied. This gene exhibited unique biochemical properties, and
subsequent cloning and sequencing of the gene revealed a novel DNA sequence which
shared 85% nomology with the type XII DHFR gene. The gene was flanked by the ORF
of the integrase gene of Tn2I and appears to be inserted in a cassette-like manner. The
remaining unidentified DHFR genes were probed with a specific oligonucleotide probe
for this gene and were detected in 50% (45/90) of the isolates which failed to hybridise
to any of the DHFR probes. This unique gene has been named dhfrXIII and its
translation product DHFR type XIII.
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"Everything is a matter ofdegree."
Bart Kosko "Fuzzy Thinking"
1.1 Development of diaminopyrimidines
The discovery of sulphonamides by Domagk (1935) and the subsequent elucidation of
their mechanism of action by Woods (1940) led to the concept of an antimetabolite.
This concept was exploited at Burroughs Wellcome who set up a laboratory in 1942
under George H. Hitchings and was a productive interaction between basic
biochemistry and attempts to synthesise new antimicrobial agents (Burchall 1979).
While Hitchings et al (1950) focused on purine and pyrimidine analogues in particular
antithymines, other workers focused on folate-like inhibitors such as the close





Figure. 1.1. Structures of dihydrofolate and the analogue inhibitor,
methotrexate.
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It was found that the folic acid analogue 'X-methylfolate' (amethopterin) could
synthetically induce the characteristics of nutritional deficiencies in animals which
occur as the result of folate deprivation (Franklin et al 1947). Aminopterin
synthesised by Seeger et al (1947) from Lederle Laboratories was also found to
induce this deficiency state and was the first antifolate compound to undergo clinical
evaluation. This work did not produce any folate-like compounds with superior
activity over methotrexate. These compounds have made important contributions in
the treatment of neoplasms (Burchall 1979).
Meanwhile Hitchings et al (1948) continued their work on small molecule
antimetabolites and showed that the diaminopyrimidine derivatives such as
2,6-diaminopurine and 2,4-diamino-6,7-dimethylpteridine were antagonists of folic
acid. Hitchings et al (1950) later published the results of a study of thymine analogues
that showed that their activity was essentially antifolate rather than antithymine in
Lactobacillus casei. These molecules produced diverse antimicrobial effects and in
order to optimise their antimalarial and antibacterial properties, a large number of
5-benzyl-2,4-diaminopyrimidines was synthesised (Falco et al 1951; Roth et al 1962).
This structural class was regarded as being more important since Roth et al (1962)
noted that substitutes other than 2,4-diaminosubstituents at the pyrirnidine ring were
not active.
These compounds were also tested for antimalarial activity, and it turned out that for
high antimalarial activity the 6-position in the pyrimidine ring had to be substituted
with an alkyl (optimally methyl) group, and the benzene ring should preferably carry a
halo- or nitro-substituent in the para position. This led to the development of the
antimalarial agent pyrimethamine. Removal of the 6-alkyl substituent considerably
depressed antimalarial activity, but increased antibacterial activity (Roth et al 1962).
Following the observation that for high antibacterial activity, the
2,4-diaminopyrimidines required H in the 6-position and suitable substituents in the
3,4 and 5 positions of the benzyl ring, these substituents were optimised. Figure 1.2
(Then 1993) shows the structures of some of the antimicrobial
2,4-diaminopyrimidines. It was found that 3-methoxy was superior to 3-ethoxy
against Proteus vulgaris, and this holds for the 4-position. Higher alkoxyl groups
decreased activity against P. vulgaris, but increased activity against Staphylococcus
aureus (Roth et al 1962).
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Figure 1.2. Structures of antimicrobial diaminopyrimidines.
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During this work it was shown that one particular compound, the 3,4,5-trimethoxyl
derivative stood out for its broad spectrum of antibacterial activity. Consequently 2,4-
diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine was selected for clinical trial in 1959
(Roth et al 1962) and was given the name trimethoprim (BW 56-72).
Clinical trials with the early inhibitors produced malaise and nausea in some patients.
In retrospect, the doses chosen were unnecessarily high (l-2g/day). However, with
experiments on monkeys, it was shown that these side effects were not a property of
all diaminopyrimidines, and trimethoprim was essentially free of these side effects and
was selected for further development in 1959. The first clinical results with
trimethoprim were presented in 1961 (Then 1993). Trimethoprim was released in the
late 1960s as a combination with sulphamethoxazole called co-trimoxazole (Bushby
and Hitchings 1968). Since then a number of other diaminopyrimidines have been
approved for clinical and veterinary use on their own and in combination with
sulphonamides as shown in table 1.1 (Then 1993). In 1993 brodimoprim was
approved for clinical use, and shows a similar spectrum of activity to trimethoprim,
but has improved pharmacokinetics and a longer half-life (Weidekamm 1993).
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Table 1.1. Marketed DHFR-inhibitors and their sulphonamide combinations.
For human use
Combination Use Tradename
Trimethoprim Antibacterial Trimpex, Proloprim
Trimethoprim-sulfamethoxazole Antibacterial Bactrim, Septrin, Sultrim
Trimethoprim-sulfadiazine Antibacterial Nibrisin, Triglobe, Codiazine
Trimethoprim-sulfamoxole Antibacterial Supristol, Adisept
Trimethoprim-sulfametrol Antibacterial Lidaprim, Maderan
Trimethoprim-Sulfamerazine Antibacterial Berlocombin
Trimethoprim-sulfamethopyrazine Antibacterial Kelfiprim
Tetroxoprim-sulfadiazine Antibacterial Tibirox, Sterinor, Prim, Berco-B
Pyrimethamine Antimalarial Daraprim















1.2 Mechanism of action of trimethoprim
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Between 1950 to 1958 the details of the folate pathway were elucidated. Figure 1.3
shows the pathway of the synthesis of tetrahydrofolate and its roles in bacterial
metabolism as reviewed by Hartman (1993).
dihydropteridine
p-amino benzoic acid N> | dihydropteroate synthetase
dihydropteroate
L-giutamate H | dihydrofolate synthetase
| dihydrofolate











Figure 1.3. The biosynthesis of tetrahydrofolate and its role in cell metabolism.
Osborn et al (1958) showed that methotrexate inhibited chicken liver DHFR at known
concentrations. Burchall and Hitchings (1965) published results that showed that the
diaminopyrimidines also inhibited DHFR and showed that the differences in the
selectivity of these compounds occurred at the molecular level and not at the
pharmacokinetic level. They performed extensive studies in which they analysed the
binding of various inhibitors to DHFR from different sources. It was from these
studies that they realised that the diaminopyrimidines, unlike methotrexate, exhibited a
high degree of selectivity for the bacterial DHFR, but not the mammalian enzyme
(Table 1.2). They also noted a strong correlation between the in vitro activity and the
strong binding of antibacterial diaminopyrimidines to E. coli DHFR. Then and
Angehrn (1979) found that the low trimethoprim sensitivity of Bacteroides and
Clostridium species was due to the production of a trimethoprim-resistant DHFR.
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This lack of effect on the anaerobic bowel flora can be regarded as an advantage
(Burchall 1979).
Table 1.2. Trimethoprim inhibition of DHFR from various sources.
DHFR IDsn (nM)
Source of DHFR Trimethoprim Pyrimethamine Methotrexate
Escherichia coli 5 25 000 6
Proteus vulgaris 4 15 000 5
Staphylococcus aureus 5 3 000 1
Plasmodium berghei 7 000 50 70
rabbit 370 000 500 60
rat 260 000 700 90
human 300 000 1 800 90
At first sight the inhibition of the reduction of dihydrofolate (FH2) to tetrahydrofolate
(FH4) may not appear as effective as for example the prevention of cell wall
biosynthesis by (3-lactam antibiotics. However the importance of the product of the
reaction catalysed by DHFR, tetrahydrofolate, lies in its involvement in a whole
variety of other biosynthetic reactions as a cofactor, carrier of one carbon moieties
and reducing agent. Thus the biosynthesis of thymidylate, purine nucleotides,
methionine, serine, glycine and several other compounds are dependent on a supply of
tetrahydrofolate (reviewed by Hartman 1993). Most bacteria must synthesise folates
de novo as shown in figure 1.3 and although a few bacteria do have uptake systems
for folates, the reduction of dihydrofolate to tetrahydrofolate is a universal
requirement (Hitchings 1973).
In most of the reactions tetrahydrofolate acts as a cofactor shuttling one carbon units
in various oxidative states, bound to the N5 and N10 atoms. In most of these reactions
the tetrahydrofolate is not used up, it merely cycles from loaded to unloaded states
(Hitchings 1973). If this were the only type of reaction in which tetrahydrofolate was
involved, tetrahydrofolate depletion would only be possible by dilution of the
tetrahydrofolate pool caused by consecutive cell divisions (Hartman 1993). This is not
an effective method of preventing cell growth. However one reaction, thymidylate
synthesis, involves the reduction of a single carbon moeity at the expense of the H
atoms from C-6 of the pyrimidine ring of tetrahydrofolate and therefore oxidises
tetrahydrofolate back to dihydrofolate (Dale and Greenberg 1972). This reaction
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creates a demand for the restoration of the tetrahydrofolate pool which is a
prerequisite for cell growth. Figure 1.4 shows the thymidylate cycle and the role it
plays in the reduction of the tetrahydrofolate pool.
I
de novo synthesis
Figure 1.4. The thymidylate cycle.
The nature of the antibacterial activity of trimethoprim in vivo has been poorly
defined. In vitro experiments on E. coli showed that the presence of thymine or
thymidine in the growth media antagonises the activity of trimethoprim. If minimal
salts medium is used, a rapid halt in the synthesis of DNA, RNA and proteins is
observed, even at high trimethoprim concentrations. The halt in macromolecule
synthesis does not significantly affect the viability of the cells, suggesting that under
these conditions, the action of trimethoprim is bacteriostatic (Then and Angehrn
1973). When the minimal salts medium is supplemented with the amino acids
methionine and glycine plus a purine nucleoside, there is a rapid decrease in the
viability of the cells, and trimethoprim becomes bactericidal (Amyes and Smith
1974a).
The cells undergo a phenomenon that has been described by Cohn (1971) as
thymineless death. As a result of thymine starvation, the cell replaces thymine with
uracil bases. The subsequent excision of these bases may lead to DNA fragmentation
and cell death (Ayusawa et al 1983). The exact quantities of thymine, methionine,
glycine and purines available in biological fluids is difficult to determine. Since
methionine, glycine and purines are exogenously available, it can be assumed that cell
death occurs as a result of thymine starvation (Then and Angehrn 1973).
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1.3 Rationale behind co-trimoxazole
Daniel and co-workers (1947) found that analogues of pteridines such as certain
diaminopyrimidines possess antibacterial activity which is antagonised by folic acid.
Potter (1951) showed that two inhibitors which act on different enzymes of the same
metabolic sequence can produce a greater inhibitory effect when used in combination
than the sum of the inhibitory effect of the individual inhibitors. This phenomenon was
explained as the sequential blockade of a metabolic pathway. Hitching's group realised
the close similarity between the antimetabolite action of analogues of pterins and para-
amino benzoic acid (Figure 1.5). They therefore pursued the sequential blockade
concept with these two inhibitors where sulphonamides inhibited the biosynthesis of
folic acid and diaminopyrimidines prevented the conversion of dihydrofolate to
tetrahydrofolate. Synergy could be demonstrated when sub-inhibitory doses of
diaminopyrimidines and sulphonamides were combined, they were capable of
inhibiting cell growth. The combination was shown to be so potent in vitro that about
one tenth as much of each moiety, in terms of effective dose was required for growth
inhibition (Elion et al 1954).
p-amino benzoic acid sulphamethoxazole
Figure 1.5. Structure of p-amino benzoic acid and sulphamethoxazole.
Bushby and Hitchings (1968) intensively studied the synergy between different
sulphonamides and DHFR inhibitors. For antibacterial use they selected trimethoprim
as a potentiator of sulphonamides because of its broad spectrum of antibacterial
activity, a high degree of selectivity for bacterial dihydrofolate reductase and suitable
pharmacodynamic and pharmacokinetic properties. Several sulphonamides were
studied in vitro and in vivo and eventually sulphamethoxazole was chosen as the
sulpha-compound which matched the half life of trimethoprim.
Several points argued in favour of the combination. Species such as Bordetella,
Haemophilus and Neisseria which show borderline sensitivity to the individual drugs
are more susceptible to the combination. The greater potency of the combination may
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be regarded as greater effectiveness at the higher dose levels, or as a reduction in the
potential side-effects made possible by diminishing the doses. The combination is
bactericidal where the individual components are bacteriostatic. The combination was
said to be less vulnerable to the development of resistant strains than the individual
components (Bushby and Hitchings 1968). Initially, trimethoprim was recommended
for use only in a fixed 1:5 ratio with sulphamethoxazole (Brumfitt et al 1973).




Although trimethoprim was released as a potentiator of sulphamethoxazole (Bushby
and Hitchings 1968), it was shown that trimethoprim was an effective agent on its
own (Brumfitt et al 1973). Synergy occurs in vitro at an optimum ratio of one part
trimethoprim to 20 parts sulphamethoxazole (Bushby and Hitchings 1968). In vivo
synergy is unlikely to occur as results show that the 1:5 commercial ratio produces a
1:20 ratio only in the blood, and for a limited time only. In tissue and sputum,
trimethoprim has much better penetration than sulphamethoxazole and reaches
concentrations higher than the MIC of susceptible pathogens (Brumfitt and Hamilton-
Miller 1993). The concentration of sulphamethoxazole in sputum was shown to be
one tenth of that reached in plasma (Brumfitt et al 1973). In these situations, synergy
as a result of the sulphonamide moiety is unlikely to contribute to the inhibitory
effects of trimethoprim (Lacey 1979). In urine, the ratio produced by the combination
of the two drugs is 1:1 where the trimethoprim concentration far exceeds the MIC for
susceptible pathogens, to the extent that no clinically significant synergy can occur
(Brumfitt and Hamilton-Miller 1993). In urine, the action of co-trimoxazole has been
shown to be bacteriostatic (Lewis et al 1974). Greenwood (1979) showed in an
experimental model of the bladder that sulphamethoxazole does not contribute to the
activity of trimethoprim. Clinical results have shown that there are no significant
advantages in using the combination over trimethoprim in infections of the urinary and
respiratory tracts (Brumfitt and Pursell 1972; Kasanen and Sundquist 1982; Amyes et
al 1986a). The exception where co-trimoxazole may be an advantage is in the
treatment of organisms which are moderately susceptible or resistant to trimethoprim
e.g. Pneumocystis carinii, Streptococcus pneumoniae, Neisseria spp., Brucella spp.,
and Moraxella. (Csonka 1969; Lacey 1982; Brumfitt and Hamilton-Miller 1993). For
most of these species co-trimoxazole is not usually the therapy of choice. Attempts to
improve co-trimoxazole by changing the pharmacokinetics of the sulphonamide
component have not been a commercial success (Brumfitt and Hamilton-Miller 1993).
Poe (1976) suggested that synergy between the two agents was not the result of a
sequential blockade of the folic acid pathway, as suggested by Burchall (1979), but
rather the simultaneous binding of the two agents to the E. coli DHFR. Then (1977)
showed that p-amino benzoic acid at high concentrations abolished the synergy
between the two components; however, Lacey (1979) showed that synergy still does
occur at high sulphonamide concentrations in the presence of p-amino benzoic acid.
Lacey (1979) also found that synergy did not occur in isolates that were resistant to
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sulphonamides. The underlying mechanism of resistance to sulphonamides in the
isolates tested was not determined. These conflicting results suggest that
sulphonamides may have two points of action in producing synergy.
The claim that the diminished doses of each constituent reduces adverse side effects
has been challenged. Clinical experience has shown that the most common side effect
(allergic skin reaction) occurs in 3-13% of patients taking co-trimoxazole, most of
these occurred as a result of the sulphonamide moiety. While most of these side
effects are mild, there is a risk of progression to erythema multiforme and toxic
epidermal necrolysis with fatal results. This aspect has recently received significant
publicity. Haematological and hepatotoxicity have also been recognised as side effects
of sulphonamides. Most patients with these side effects can take trimethoprim on its
own. There are also more drug interactions associated with sulphonamides than with
trimethoprim (Brumfitt and Hamilton-Miller 1993).
The claim that co-trimoxazole will slow down the emergence of resistance does not
seem to have taken place. In Finland, the first country where trimethoprim was
approved as an agent on its own, resistance did not emerge more rapidly than other
parts of Europe (Kasanen and Sundquist 1982; Huovinen et al 1982; Huovinen et al
1985b). There was no significant increase in the incidence of trimethoprim resistance
in other countries after trimethoprim was released as a single agent (Brumfitt et al
1983). The high incidence of sulphonamide resistance (25% to >50% in most
countries) suggests that sulphamethoxazole can do little to suppress the emergence of
resistance to trimethoprim (Griineberg 1979; Hamilton-Miller 1979; O'Brien et al
1982).
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1.5 Mechanisms of resistance to trimethoprim
The development of resistance as the response of bacteria to a challenge by
antimicrobial agents is inevitable, trimethoprim being no exception. Trimethoprim is a
chemically synthesised molecule, and no naturally occurring substance has been found
that mimics its action. Therefore it seems unlikely that a resistance mechanism to
trimethoprim has evolved specifically in the past (Kotch 1981). A number of
mechanisms of resistance to trimethoprim have been described in organisms
intrinsically resistant to trimethoprim. Anaerobes such as Bacteroides and Clostridium
produce a chromosomal DHFR which is insensitive to inhibition by trimethoprim
(Then and Angehern 1979). Species such as Pseudomonas aeruginosa have been
shown to be resistant to a number of antimicrobials including trimethoprim, as a result
of the poor penetration of the agent through the cell envelope (Grey and Hamilton-
Miller 1977). Degradation of trimethoprim by the ruminal flora of cows has been
demonstrated by Nielsen et al (1978). Most of the attention has been focused on the
acquired mechanisms of resistance by organisms which are intrinsically sensitive to
trimethoprim.
1.5.1 Thymineless mutants
Thymidylate synthase is responsible for the conversion of deoxyuridine
monophosphate to thymine and in the reaction tetrahydrofolate is oxidised to
dihydrofolate. This reaction creates a drain on the pool of tetrahydrofolate cofactors
in the cell. A deficiency in the activity of thymidylate synthase has a dramatic cofactor
sparing effect which greatly reduces the demand for the activity of DHFR. Such
mutants are highly resistant to DHFR inhibitors such as aminopterin and
trimethoprim, but are dependent on an external supply of thymine and thymidine for
growth (Amyes and Smith 1975). These mutants arise readily in vitro in the presence
of thymine and trimethoprim (Stacey and Simson 1965). It was thought that these
mutants would be unlikely to arise during trimethoprim therapy as a result of the low
levels of thymine in blood and in body tissue, however these mutants have been
reported during therapy on a number of occasions (King et al 1983; Masked et al
1977; Piatt et al 1983). Studies by Jobanputra and Datta (1974), Grey et al (1979)
and Acar and Goldstein (1982) showed that these mutants accounted for less than 2%
of trimethoprim-resistant isolates, suggesting that the overall clinical significance of
these mutants is low. These mutants are usually associated with trimethoprim and or
sulphonamide therapy and do not grow on Mueller-Hinton agar and growth on
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MacConkey agar is variable (King et al 1983). Medium lacking in thymine or
thymidine which is suitable for trimethoprim sensiuvity testing is unable to support the
growth of these mutants (Amyes and Smith 1974a; King et al 1983).
1.5.2 Impermeability
Resistance to trimethoprim can result from the acquisition of a mutation which
decreases the permeability of the cell to trimethoprim. This mechanism of resistance
appears to be common, however there is little evidence to support this, since isolates
which fail to show changes in the nature or the expression of DHFR are often
relegated to this category despite the failure to detect such a mechanism (Thomson
1993). Acar and Goldstein (1982) reported clinical isolates which showed cross
resistance to trimethoprim, nalidixic acid and chloramphenicol in Klebsiella,
Enterobacter and Serratia spp. Similar mutants displaying resistance to all three
agents could be isolated in vitro by one-step selection procedures. These mutants
showed reduced uptake of glucose and chloramphenicol; however no differences in
DHFR expression were found, and binding of chloramphenicol to ribosomes was
normal. Examination of the outer membrane proteins showed a reduction in the
amount of a major uptake protein of about 40KDa (Gutmann et al 1985). The MIC
range of trimethoprim in these isolates was between 128-256mg/l. Mutants showing
cross resistance to trimethoprim and nalidixic acid have also been recorded by Then
and Herman (1981). Williams Smith (1976) showed that these mutants arose in 27 of
32 epidemiologically unrelated strains of Klebsiella pneumoniae belonging to 20
different capsular types. These mutants arose in chicks that were experimentally
infected with these organisms and then fed on antibiotic containing diets. These data
suggest that these mutants may have clinical significance.
1.5.3 Alterations in chromosomal DHFR
Most of the earlier work done on the mechanisms of resistance to antifolates involved
methotrexate resistance. Although there is some cross resistance between
methotrexate and trimethoprim, this has been poorly studied (Hamilton-Miller 1979).
In vitro mutants resistant to methotrexate showed an overproduction of DHFR in
E. coli (Poe et al 1972) and in Streptococcus pneumoniae (McCuen and Sirotnak
1974). Similar mutants were selected using trimethoprim in E. coli K12 (Baccanari et
al 1975). Sheldon and Brenner (1976) showed that chromosomally located, low-level
resistance to trimethoprim could be induced in vitro in E. coli: resistance was due
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either to a mutationally altered dihydrofolate reductase with a decreased sensitivity for
trimethoprim or to a mutational change in regulation leading to increased levels of the
chromosomal enzyme. In a survey conducted by Grey et al (1979) of 34 clinical
strains (11 E. coli, 16 K. aerogenes and 7 P. mirabilis) which were not carrying R-
factors conferring transferable trimethoprim resistance, most of the resistance was due
to the production of DHFR with a reduced susceptibility to trimethoprim. In some
isolates there was an increase in the specific activity of DHFR which was sufficient to
account for the levels of resistance in these isolates. These isolates had intermediate
levels of resistance, with trimethoprim MICs 5-500mg/l.
In a clinical survey (Tennhammer-Ekman and Skold 1979), several bacterial strains
were found that showed high-level resistance to trimethoprim, and this resistance was
not plasmid borne. These strains had the common property of overproducing DHFR.
One of these strains was further studied and showed an approximately 200-fold
overproduction of DHFR activity. The restriction mapping and DNA hybridisation
showed that the enzyme was similar to the E. coli K12 chromosomal DHFR but it
differed in that it had a slower electrophoretic mobility, the K( value for trimethoprim
was three times higher and the turnover rate was 1.4 times higher. This isolate was
also characterised by a 15-fold increase in the production of DHFR mRNA (Flensburg
and Skold 1984). The amount of enzyme present was shown to be inducible, and
increased with increasing trimethoprim concentrations (6-fold increase at 100mg/l).
The induction mechanism was dependent on protein synthesis and could not be
induced by other folate analogues or thymine starvation (Tennhammer-Ekman et al
1986). DNA sequence analysis of this DHFR revealed two amino acid changes
compared to the E. coli K12 chromosomal DHFR sequenced by Smith and Calvo
(1980), a glycine residue was substituted for tryptophan at position 30 and a
glutamine for glutamic acid substitution occurred at position 158. The amino acid
change at position 30 which occurs within the active site of the DHFR is thought to
relate to the increase in AT; of the DHFR. Furthermore, a cytosine to thymine
transition was found in the -35 region of the promoter, increasing its homology with
the E. coli consensus promoter sequence. In the ribosome binding area of the resistant
strain, seven base changes were observed, two of which resulted in a five-base
sequence of complementarity with the 3'-end of ribosomal 16S RNA. These changes
are thought to increase the transcription and translation of the DHFR (Flensburg and
Skold 1987).
Introduction 16
More recently, clinical strains of Haemophilus influenzae were isolated which
expressed intermediate levels of resistance to trimethoprim (MIC 10-200mg/l) (de
Groot et al 1988). Nucleotide sequence comparisons between resistant and
susceptible isolates showed changes in the -35 promoter sequence making it
homologous to that of E. coli mutants overproducing DHFR. Changes in the
structural gene were also observed, glutamic acid was substituted for a lysine residue
at position 69 and aspartic acid was substituted for an asparagine residue at position
77 (de Groot et al 1991).
It appears that mutants with altered chromosomal DHFR are restricted to clinical
environments where there is strong selection pressure for trimethoprim resistance.
Their occurrence in Enterobacteriaceae is not often clinically significant and is of
lesser importance than plasmid-mediated resistance (Steen and Skold 1985).
1.5.4 Production of an additional resistant DHFR
The production of an additional DHFR which is less sensitive to inhibition by
trimethoprim than the chromosomal DHFR (Amyes and Smith 1974b; Skold and
Widh 1974) is by far the most important mechanism of resistance to trimethoprim.
Plasmids carrying these genes were first identified by Fleming et al (1972) and were
shown to confer high-level resistance to trimethoprim (MIC >1000mg/l). Since many
of these resistant DHFR genes are located on transferable plasmids, this mechanism of
resistance was originally referred to as plasm id-borne resistance, however this is not
altogether true, since many of these genes are located on the chromosome as a result
of transposase activity (Heikkila et al 1991). To date, 16 of these DHFR genes have
been identified and the biochemical properties, DNA sequence and/or amino acid
sequence for each of these have been determined. The biochemical properties of these
enzymes are shown in table 1.3.
Pattishall et al (1977) distinguished two different types of plasmid-encoded enzyme
which could be distinguished entirely by their biochemical properties. The type I
enzymes were produced in greater quantity and were 10 000 times more resistant than
the chromosomal enzyme. The type II enzymes were produced in similar quantities to
the chromosomal enzyme and are >1000 times more resistant than the type I enzymes.
Following the subsequent discovery of the type III DHFR (Anderson 1980) which
expressed intermediate levels of resistance (MIC 64mg/l) and the type IV DHFR
which was inducible (Young and Amyes 1986a), all the DHFR types were still
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la 57.0 4.4 0.5 5.6 7.4 35 157 >1000 a
lb 32.0 2.8 1.2 11.0 41 24.5 157 >1000 b
V 23.0 3.5 * 15.5 3.2 5 157 >1000 c
VI 200.0 7.3 0.4 31.2 75.0 10 157 >1000 d
vn 30.0 3.0 1.5 20.0 7.0 11.5 157 >1000 e
Family 2
Ila 70 000 1100 >15 4.1 6100 37 78 >2000 f
lib 80 000 750 >15 8.3 150 35 78 >1000 g
lie 20 000 1000 >15 4.2 400 34 78 >1000 h
Ungrouped
Ilia 2.0 0.02 >12 0.4 0.019 16.9 162 64 i
Illb 2.0 0.02 >12 9.5 0.4 17 - 128 j
IIIc/VIII 3.0 0.007 8 3.1 0.5 22 169 256 k
IV 0.2 0.02 >12 37.0 0.063 46.7 144 10 1
IX 20 - - - - 19.9 178 250 m
X - - - - - 21.2 182 500 n
XH 700 - - - - - 165 >2000 0
SI 50.0 0.002 >12 10.8 11.6 19.7 161 >1000 P
E. coli K12 0.007 0.006 >12 3.2 0.0004 22 159 0.5 q
#As determined by sephadex gel filtration. *Dependent on protein concentration, a Patfishall
et al (1977); b Young and Amyes (1985); c Thomson and Amyes (1988); dWylie et al
(1988); e Amyes et al (1989); f,g,h Pattishall et al (1977); Amyes and Smith (1978); Broad
and Smith (1982); i Joyner et al (1984); j,k Barg et al (1990); 1 Young and Amyes (1986a);
Tait (1993); m Jansson and Skold (1991); n Parsons et al (1991); o Heikkila et al (1993); p
Young et al (1987); q Baccanari et al (1975); Pattishall et al (1977).
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distinguishable by their biochemical properties. However the subsequent recognition
of DHFR types lb, Illb, IIIc, V, VI, VII, VIII, IX, X and XII and the elucidation of
the nucleotide and amino acid sequence of these DHFR genes created a dilemma with
the original classification system based on biochemical properties alone (Amyes et al
1992b). For example, the type Illb and IIIc DHFRs, although originally classed as
subtypes of the type III, they share less than 50% amino acid identity with each other
despite their similar biochemical properties. With the exception of the type IIIc DHFR
which is identical to and has been renamed the type VIII (Barg et al 1995) the
subtypes (lb, Ha, lib, lie, Illb) retain their original names (Amyes et al 1992b),
furthermore, the type I has been renamed the type la so as to avoid confusion with the
type lb, and likewise, the type III is referred to as the type Ilia (Amyes and Towner
1990). The trimethoprim-resistant DHFRs have now been reclassified based on their
nucleotide and amino acid sequence. Phylogenetic analysis has revealed that two
subgroups of related trimethoprim-resistant DHFRs occur (Huovinen et al 1995).
1.5.4.1 Family 1 dihydrofolate reductases
The first group of enzymes, family 1 (type I like enzymes) includes enzyme types la
(Fling and Richards 1983), lb (Young et al 1994), V (Sundstrom et al 1988), VI
(Wylie and Koornhof 1991) and VII (Sundstrom et al 1993). These enzymes share
between 64% to 88% amino acid identity. Nucleotide sequence identity is the highest
between the type lb and V DHFR (88%) and ranges between 58-65% for the types la,
VI and VII DHFRs (Young et al 1994). Table 1.6 shows the amino acid identity
between the family 1 DHFRs.
Ia 100
lb 71 100
V 75 88 100
VI 63 64 61 100
VII 71 66 66 64 100
Ia lb V VI VII
Figure 1.6. Percent amino acid identity between the family 1 DHFR enzymes.
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These enzymes have a polypeptide length of 157 amino acids. The type lb may be
exceptional in that the nucleotide sequence reveals an open reading frame (ORF) of
160 amino acids between the AUG start codon at position 226, and the UAA stop
codon at position 706. Sequence alignment with the types la, V, VI and VII DHFRs,
suggests that the UUG codon at position 235 may function as an alternative initiation
codon producing an ORF of 157 amino acids (Young et al 1994). A UUG triplet has
been confirmed as the start codon of the type VII DHFR (Sundstrom et al 1993). The
apparent molecular weights of these enzymes all appear to be different as determined
by sephadex gel filtration and at least the type la is homodimeric (Novak et al 1983).
All the enzymes in this class carry a glutamate corresponding to the aspartate residue
at position 27 of the E. coli chromosomal enzyme (Sundstrom et al 1993). Since an
aspartic acid residue is found within the folate binding site of the chromosomal
DHFRs of trimethoprim susceptible bacteria, and a glutamate residue is found in the
corresponding site of the DHFRs of vertebrates which are insusceptible to
trimethoprim (Appleman et al 1990) it is thought that this may relate to the high
trimethoprim MICs (>1000mg/l) mediated by this family of enzymes. These enzymes
are all relatively unstable and lose >50 % of their activity in less than three minutes at
45°C. The stability of the type V and VI enzymes are dependent on background
protein concentrations (Thomson and Amyes 1988; Wylie et al 1988). With the
exception of the type VI which is more resistant (Wylie et al 1988), the ID50 for these
enzymes for trimethoprim and methotrexate range from 20-57|iM and 2.3-4.4(iM
respectively. The Ki values for these enzymes range from 7.0-75(iM; the highest Ki
was recorded for the type VI DHFR (Wylie et al 1988).
1.5.4.2 Family 2 dihydrofolate reductases
The second group, family 2 remains unchanged from the classification systems of
Amyes and Towner (1990) and Amyes et al (1992b) which includes all the type II
subtypes. The enzyme encoded by plasmid R67 is termed Ha (Stone and Smith 1979)
and the type lib and lie dihydrofolate reductases are encoded by plasmids R388
(Swift et al 1981) and R751 (Flensburg and Steen 1986) respectively. These enzymes
are remarkably different from other DHFRs in that they are virtually insensitive to
antifolates including the broad spectrum DHFR inhibitor, methotrexate (Amyes and
Smith 1976). These enzymes are unique in that they share no homology with other
DHFRs, which are all similar in amino acid sequence, size, and active site residues.
This suggests that these enzymes have completely different evolutionary origins (Swift
et al 1981). The relative molecular weight of the type II enzymes as determined by gel
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filtration suggest that they are tetrameric (Pattishall et al 1977; Amyes and Smith 1978).
Matthews et al (1986) showed that the crystalline form of the DHFR produced by
R67 is dimeric, however Nichols et al (1993) showed that for the pH range 5-8,
tetrameric R67 DHFR reversibly dissociates into dimers, as monitored by
ultracentrifugation and molecular sieving techniques. Modification of histidine
residues stabilises dimeric R67 DHFR and causes a 200-600-fold decrease in catalytic
efficiency. Decreased catalytic activity in dimeric R67 DHFR is presumably due to
loss of the putative single active site pore found in tetrameric R67 DHFR (Nichols et
al 1993). Stone and Smith (1979) suggested that an active site resembling that of a
conventional DHFR may be formed as a result of the secondary structure formed by
the active tetramers. However the complete lack of affinity of these enzymes to close
folate analogues such as methotrexate suggest otherwise (Matthews et al 1986). An
antibody which binds to all three type II enzymes does not cross react with the type la
and T4 phage DHFR (Fling and Elwell 1980). It has been suggested that these
enzymes may not be "classical" DHFRs, but rather a different type of oxidoreductase
which has lost some degree of substrate specificity but has acquired the ability to
reduce dihydrofolate as a consequence (Smith et al 1979; Matthews et al 1986). DNA
and amino acid sequence of these enzymes have shown that they code for a
polypeptide of 78 amino acids and share between 78 and 86% amino acid identity
with each other (Stone and Smith 1979; Swift et al 1981; Brisson and Hohn 1984;
Flensburg and Steen 1986). The C and N terminals of the monomers appear to be less
conserved within this group (Brisson and Hohn 1984). The biochemical properties of
these enzymes are summarised in table 1.3.
1.5.4.3 Ungrouped resistant dihydrofolate reductases
The remaining DHFR types Ilia, Illb, IV, VIII, IX, X, XII and SI share between 20
and 50% amino acid identity with each other and the E. coli chromosomal enzyme
(Huovinen et al 1995). Similar levels of DHFR sequence homology occurs in the
range 27-31% between different bacteria species, with higher levels of identity
occurring between more closely related species (Fling et al 1988). There is therefore
no phylogenetic basis by which these enzymes can be grouped. The biochemical
properties of these enzymes are shown in table 1.3.
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Type Ilia
The type Ilia was the first plasmid encoded DHFR conferring intermediate resistance
to trimethoprim (MIC 64mg/l) to be discovered (Anderson 1980; Fling et al 1982).
The enzyme is a monomer of 162 residues and is closely related to the E. coli
chromosomal enzyme: the nucleotide sequence shares 57% identity, with some short
stretches (11/12 bases) of perfect match (Fling et al 1988). Kinetic analysis showed
that trimethoprim binds quite tightly to the enzyme (with a Kp= 0.019(iM which is
about 50 times less than the E. coli chromosomal enzyme), however the isolates are
about 320-fold more resistant. Since the fractional activity of an enzyme in the
presence of a competitive inhibitor is dependent upon both the IIK[ and S/Km ratios,
the level of resistance is thought to occur as a combination of the enzyme's 8-fold
greater affinity for dihydrofolate (ATm=0.4|iM) together with the 50-fold reduced
sensitivity to trimethoprim. The specific activity of the enzyme produced by plasmid
pAZl is 75% of that of the host's enzyme and is therefore unlikely to contribute
significantly to resistance levels in the host (Joyner et al 1984).
Type Illb
The type Illb DHFR shares almost identical biochemical properties with the type Ilia,
and was originally thought to be a subtype. This enzyme differs from the type Ilia in
that it has a higher A) and a different isoelectric point (Barg et al 1990). Subsequent
N-terminal amino acid sequence analysis has revealed that the proposed relationship
with the type Ilia is superficial. Amino acid identity with the type Ilia for the first 47
residues is 31%. Most of the identical amino acids occur within the conserved
dihydrofolate binding sites of the enzymes (Thomson et al 1990a).
Type IIIc/VIII
The type IIIc is another enzyme which confers intermediate trimethoprim MICs, and
shares very similar biochemical properties to the type Ilia and IIIb enzymes. This
enzyme is extremely sensitive to inhibition by methotrexate, but is slightly more
resistant to trimethoprim than the types Ilia and Illb (Barg et al 1990). Subsequent
nucleotide sequence analysis has revealed it to be identical to the type VIII DHFR
(Sundstrom et al 1991; Barg et al 1995). Since it shares only 30% identity with the
type Ilia, the subtype name has been dropped and it has been renamed the type VIII
(Barg et al 1995).
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Type IV
The type IV is an unusual DHFR in that the expression of its gene product is
dependent on the concentrations of methionine, glycine and purines in the growth
medium. In complex media containing these nutrients, the expression of the resistant
DHFR is suppressed: MIC=5mg/l on Mueller-Hinton (Difco) and Iso-Sensitest agar
(Oxoid). However the expression of this enzyme can be induced by a deficiency in
these nutrients: in minimal medium the trimethoprim MIC is 160mg/l (Young and
Amyes 1986a). Increasing trimethoprim concentrations were shown to reduce the
number of viable cells, but increase the expression of the enzyme in the surviving
cells. The enzyme is only twice as resistant as the E. coli chromosomal DHFR
(trimethoprim ID50 =0.2(iM) and has a low affinity for dihydrofolate (Km=37): as a
result, the suggested mechanism of resistance is said to be similar to that of mutants
which over-express the chromosomal DHFR (Young et al 1986a). The enzyme
produced by the clinical plasmid was thought to be a monomer and was shown to
have a molecular weight of 46.7KDa by gel filtration and non-denaturing PAGE.
However under SDS denaturing conditions, the purified protein revealed a major band
of 33KDa and several minor bands which formed multiples of lOKDa. The N-terminal
amino acid sequence of the purified protein revealed two polypeptides, the first 50
residues of the one polypeptide closely resembled those of the E. coli chromosomal
DHFR (40% identity); the second polypeptide was identical to the NS1 DNA binding
protein. This suggests that the protein produced by the clinical isolate is a heterodimer
of these two proteins. A clone of the DHFR was shown to be active without the
presence of the NS1 DNA binding protein (Thomson et al 1990b). Subsequent
nucleotide sequence analysis of this clone has shown that the enzyme shares 26%
amino acid homology with the chromosomal DHFR of E. coli. Amino acid homology
with other resistant DHFRs is also low, and ranges between 19 and 30 percent (Tait
1993).
Type IX
The type IX DHFR also confers intermediate levels of resistance to trimethoprim
(MIC 250mg/l) but its biochemical properties are unlike the type III like enzymes in
that it has a significantly higher ID50 (20jiM) for trimethoprim. This is almost in the
ID50 range of the family 1 enzymes- the lower MIC conferred by the type IX could be
explained by the low intracellular levels of the enzyme produced. The amino acid
sequence of 178 residues shares only 26% similarity with the type I and the E. coli
chromosomal DHFR (Jansson and Skold 1991).
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Type X
The type X DHFR confers an intermediate MIC for trimethoprim of 500mg/l. The
biochemical properties of this enzyme have not been determined, however nucleotide
sequence analysis has revealed that it is unrelated to other DHFR types (Parsons et al
1991).
Type XII
The type XII DHFR is unique in that it confers similar levels of resistance
(MIC>2000mg/l; ID50 =700|iM) to the atypical type II enzymes, but still shares close
homology with other DHFRs in terms of structure and substrate binding sites
(Heikkila et al 1993). With the exception of the family 1 enzymes, the type XII DHFR
is the only other resistant DHFR to carry a glutamate corresponding to the aspartate
residue at position 27 of the E. coli chromosomal enzyme (Huovinen et al 1995). The
type XII DHFR shares between 32% and 39% amino acid identity with DHFR types
I, III, V, VI and VII (Singh et al 1992b).
SI DHFR
All the DHFR types have so far been detected in Gram-negative bacteria. It was not
until 1983 that the first transferable trimethoprim resistance was detected in
Staphylococcus aureus in Australia (Townsend et al 1984). A resistant DHFR was
later identified as the mechanism of resistance. The enzyme confers high-level
trimethoprim resistance (MIC>1000mg/l) and is 1000-fold more resistant to
trimethoprim (ID50=50(iM) than the chromosomal DHFR (ID50=0.04p.M). Unlike
other resistant DHFRs, it does not confer resistance to methotrexate (Young et al
1987). Since this gene has been detected only in Staphylococci, it is designated the SI
DHFR. The nucleotide sequence of the S1 DHFR does not show close homology to
other resistant DHFR types (Rouch et al 1989). The N-terminal amino acid sequence
of the first 35 residues of the S. aureus chromosomal DHFR shares 80% identity with
the SI DHFR suggesting it may have evolved from the chromosomal DHFR
(Burdeska et al 1990).
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1.6 Molecular epidemiology of resistant DHFRs
24
DNA hybridisation provides a useful epidemiological tool to monitor the distribution
and spread of antibiotic resistance genes in a population and to obtain information
regarding the evolutionary relationships of these genes (Towner 1992). In most cases
gene probes are constructed from cloned sections of the resistance gene. These probes
are often relatively large in size (up to several kilobases) and are not often efficient at
distinguishing between closely related genes (Towner 1992; Qumsieh and Young
1991). Since resistance genes often share similar flanking sequences such as those of
integrons and IS-elements, gene probes containing these overlapping regions have the
potential to cross-hybridise, and as a result overestimate the frequency of a resistance
gene in a population (Sundstrom et al 1987; Agodi et al 1990). These problems can
be overcome by synthesising small oligonucleotide probes that are capable of
recognising single base differences (Mabilat and Courvalin 1990).
A number of hybridisation studies have been done to determine the distribution of
resistant DHFR genes at various centres. Comparisons between these data are difficult
because of discrepancies in sample collection and differences in the probes and
hybridisation methods used. The gene probes for many of the more recently
discovered DHFR types are often not available and as a result few of these studies are
comprehensive. Table 1.4 shows the incidence of trimethoprim-resistant DHFRs from
studies at various centres around the world.
Type la
The type la DHFR is by far the most widely distributed trimethoprim-resistant DHFR,
and has been detected in most collections of resistant isolates (Table 1.4). This
enzyme has been shown to occur in more than 50% of resistant isolates in Sweden,
Finland, France and the UK (Figure 1.7). However at centres outside Europe, the type
la DHFR appears to account for a smaller percentage of resistant isolates.
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Table 1.4. Incidence of resistant DHFRs at various centres around the world.
DHFR types %
Country Isolates year la 11 Ilia IV V VII Other N. H.
Nottingham Urinary 1978- 86 0 1 0 10 1 - 1 a
UK plas~ids 1983
Nottingham Urinary 1987- 62 1 20 0 6 7.2 - 3 b
UK plasmids 1988
















57 3 0 - 0.5 ~ - 41 f
Turku, Urinary 1984- 70 0.5 0 - 0 1 - 29 g
Finland 1988
Finish Shigella spp. 1985- 85 0 0 - 3 - - 12 h
Travellers 1988
Sweden Porcine E. coli 1984-89 59 2 - - 0 0 IX 11 10 i
Greece Urinary
Enterobacter
1991 18 58 - - 2 - - 32 j
Greece Urinary E. coli 1991 44 19 - - 2 - - 41 k
Sicily, Italy S. sonnei 1985-87 0 0 - 0 38 - - 63 1
USA S. sonnei 1985-
1987
27 0 0 - - - IIIc 73
Illb 13
0 m





52 38 - - - - - 21 o
Taiwan Urinary 1987-89 45 0 0 0 10 - - 45 P






22 0 - - - - - 78 r
Sri Lanka Enterobacteria
plasmids
1985 5 0 0 - >9 - - - s
Vellore, India Faecal plasmids 1990 31 0 0 19 36 0 Ib 14 0 t
(N.H.) Percentage of isolates which did not hybridise to any of the DHFR probes; (-) Isolates not
tested with this probe; (*) Type II DHFR probe >700bp; a Towner et al (1991); b Towner et al
(1991); c Towner et al (1994); d Goldstein et al (1986); e Papadopoulou et al (1986); f Heikkila et al
(1990a); g Heikkila et al (1990b); h Heikkila et al (1990c); i Jansson et al (1992); j Tsakris et al
(1992); k Tsakris et al (1993); 1 Agodi et al (1990); m Barg et al (1990); n Singh et al (1992b);
o Fling et al (1982); p Chang et al (1992); q Campbell et al (1986); r Wylie and Koornhof (1989);
s Sundstrom et al (1987); t Tait and Amyes (1994).
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Figure 1.7. Prevalence of the type la DHFR in various countries.





The type la DHFR was first detected in a urinary E. coli isolate from a London
Hospital and was located on plasmid R483 (Jobanputra and Datta 1974). Barth et al
(1976) demonstrated that a segment of DNA from R483 could be transposed onto
plasmids or onto the chromosome and postulated that the mobile element was a
transposon (TnC, renamed Tn7) which had distinct genetic boundaries. Identical
elements were later demonstrated to occur within different clinical plasmids (Barth
and Datta 1977). The majority of isolates harbouring the type la DHFR, have been
shown to hybridise positively to a Tn7 specific probe (Steen and Skold 1985; Heikkila
et al 1991; Jansson et al 1992; Tsakris et al 1993; Towner et al 1994). Much of the
success of the type la DHFR is based on its ability to integrate as part of Tn7 into the
attTn7 site on the chromosome of E. coli and other bacteria (Lichtenstein and
Brenner 1981). This mechanism is believed to account for the increase in non¬
transferable high-level resistance observed by Towner et al (1982), Amyes et al
(1986b) and Papadopoulou ct al (1986).
The type la DHFR is found as part of a cassette-like structure thus giving it the
potential to be inserted by integrase activity into integron-like structures of different
genetic elements. The type la DHFR has been found within integron structures of Tn7
(Sundstrom et al 1991b) and the antimicrobial resistance integron of the
predominantly plasmid located transposon Tn27 (Sundstrom and Skold 1990). A
study by Heikkila et al (1991) found the type la DHFR on the chromosome in 75 out
Introduction 27
of 76 isolates. Nine of these isolates carried the type la DHFR on both the plasmid
and chromosome and only one isolate carried the gene on a plasmid only. Of these
isolates, 61 (80%) probed positive for the tnsC gene suggesting an active Tn7. Fifty
of these isolates (82%) had Tn7 located in the attTn7 site.
Type lb
The type lb DHFR was first detected harboured on clinical plasmid pUK163 which
was isolated from a urinary pathogen isolated in Edinburgh. The DHFR gene occurred
on Tn4132, a Tn7 related transposon which could be mobilised onto plasmid RP4
(Young and Amyes 1985). The nucleotide sequence of the 3' end of the gene was
identical to the 59-base element which is present downstream of the type V DHFR
(Young et al 1994) and is believed to play a role in the site-specific insertion of gene
cassettes into integron structures. The 500-bp Hindi fragment of pUK1224
developed as a specific gene probe for the type lb enzyme by (Qumsieh and Young
1991), was shown to hybridise to the type V gene. An increase in the stringency of the
washes reduced the level of cross hybridisation with this probe. Based on the
sequence alignment of the types lb and V DHFRs, oligonucleotide probes developed
from the most dissimilar regions of these genes could clearly distinguish between the
two (Young et al 1994). Subsequent hybridisation experiments using these probes
showed that the type lb enzyme was the predominant DHFR type in clinical plasmids
from Dundee (Young et al 1994). Of the trimethoprim-resistant DHFRs from South
India which were originally identified as being type V, 39% were subsequendy shown
to be type lb enzymes (Tait and Amyes 1994). These data suggest that the type lb is
far more widespread than originally thought. The oligonucleotide probe for the type V
DHFR described by Sundstrom et al (1993) differs from the type lb by only one
nucleotide, and is therefore unlikely to distinguish between these two genes.
Type V
The type V DHFR was first detected in a study of Sri Lankan Enterobacteria isolates
(Sundstrom et al 1987). Forty-one out of 58 isolates were demonstrated to hybridise
to a 2.6-kb Aval fragment which harboured the type II DHFR from R388, however
some of these isolates expressed uncharacteristically high intracellular levels of DHFR
for a type II enzyme, and were more sensitive to trimethoprim. All the isolates failed
to hybridise with a smaller 275-bp £coRI-Sa«3Al fragment harbouring 153-bp of the
3' terminal of the type II DHFR. Restriction endonuclease analysis showed that the
enzyme was different from previously characterised enzymes. Nucleotide sequencing
of this DHFR revealed that the surrounding sequences of this enzyme were identical
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to those of Tn27 and R388 (Sundstrom et al 1988) which explains the high degree of
cross-hybridisation with the larger gene probe. Hybridisation experiments with a 500-
bp Hincll fragment of pLK09 which contains the type V DHFR gene (Towner et al
1988) have shown that this enzyme is extremely ubiquitous and has been detected in
most of the collections of isolates (Table 1.4). A proportion of the enzymes identified
as type V with this probe may be mis-identified type lb enzymes (Tait and Amyes
1994).
Type VI
The type VI DHFR was described in a urinary isolate of Proteus mirabilis from South
Africa (Wylie et al 1988). The prevalence of this gene in South Africa and other parts
of the world has not yet been determined. An intragenic oligonucleotide derived from
the type VI DHFR gene sequence (Wylie and Koornhof 1991) failed to hybridise to
isolates from Sweden, Finland, Nigeria and Sri Lanka (Sundstrom et al 1993).
Type VII
The type VII DHFR was first detected on plasmid pUN835 harboured in a veterinary
E. coli isolate from Nottinghamshire, UK, and was distinguished from other DHFRs
on the basis of its unique biochemical properties and its failure to hybridise to probes
of other known resistant DHFRs (Amyes et al 1989). Sundstrom et al (1993)
identified an identical gene integrated in a cassette-like manner on a Tn27-like
transposon which has been designated Tn50S6. A restriction map of the DHFR in
pUN835 (Towner and Carter 1990) showed that it was identical to that of Tn5086.
This gene was detected in Swedish clinical isolates from as early as 1974, and has
subsequently been detected with an intragenic oligonucleotide probe in isolates from
Finland, Nigeria and Sri Lanka (Sundstrom et al 1993).
Type II
Despite the widespread availability of the type II DHFR gene probes, the type II
DHFRs have been absent or detected at low frequencies in most of the collections of
isolates studied (Table 1.4). Since most of the resistant DHFR genes including those
from R388 and R67 occur flanked by sequences identical to Tn27 (Huovinen et al
1995), it has been demonstrated that DHFR gene probes that contain these flanking
sequences can cross-hybridise with DHFR genes located within these surroundings
(Sundstrom et al 1987; Agodi et al 1990). The data obtained by Fling et al (1982)
and Campbell et al (1986) who detected a high incidence of the type II DHFR genes
is unlikely to be reliable since a 2.5-kb EcoRl-BamHl fragment of R67 was used for
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the type II DHFR gene probe. A shorter 800-bp fcoRI fragment also detected a high
incidence of this gene in French isolates (Papadopoulou et al 1986; Goldstein et al
1986). The 275-bp EcoRI-SauSAl fragment of pWZ820 (derived from R388)
described by Towner et al (1991) and the 0.28-kb Nhel-EcoRl fragment from plasmid
R751 described Heikkilii et al (1990a) do not appear to cross-hybridise with other
DHFRs.
Type Ilia
The type Ilia was first detected on a 5.2 MDa transferable plasmid from a strain of
Salmonella typhimurium phage type 179 isolated in New Zealand (Anderson 1980)
and in a S. typhimurium isolate of the same phage type in the United Kingdom (Fling
et al 1982). This DHFR has subsequently been detected on a plasmid from a urinary
E. coli isolate from Nottinghamshire (Thomson et al 1990c). A 700-bp EcoRl-Pstl
fragment harbouring this DHFR was used as a gene probe to detect this gene in 20%
and 1% of trimethoprim-resistant urinary Enterobacteriaceae isolated from 1987-
1988 and 1992 in Nottingham respectively (Towner et al 1990; Towner et al 1994).
Despite the widespread use of type Ilia DHFR gene probes, this DHFR has not been
detected in most of the surveys conducted (Table 1.4).
Type IUb
The type Illb was first isolated from an outbreak of trimethoprim-resistant S. sonnei
at a nursing home in the USA. A 1.6kb Pstl fragment harbouring this gene was shown
to hybridise to one other isolate of S. sonnei from Hawaii (Barg et al 1990).
Type IV
The type IV DHFR gene has been detected on plasmids from both urine and faecal
E. coli isolates from South India (Young et al 1986a; Tait and Amyes 1994). Gene
probing with a 1.7kb Clal fragment of pUKl 148 as described by Towner et al (1988)
showed that 19% of plasmids isolated from commensal faecal flora from this region
harboured this gene (Tait and Amyes 1994).
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Type lIIc/VIll
The type VIII DHFR appears to be widespread in the USA. CDC isolates of Shigella
sonnei from eight different states hybridised to a probe constructed from a 1.8kb Pstl
fragment harbouring the type VIII DHFR (Barg et al 1990). The type VIII has also
been detected in Sweden in urinary isolates of E. coli (Sundstrom et al 1991a).
Type XI
This enzyme was first isolated from E. coli during an outbreak of porcine diarrhoea in
Sweden (Jansson and Skold 1991). Hybridisation experiments with an intragenic
oligonucleotide probe showed that this gene occurred in 11% of trimethoprim-
resistant veterinary isolates from Sweden. To monitor the prevalence of this gene in
human isolates, resistant organisms from Sweden (222), Finland (46), Texas (14),
Ethiopia (26), Nigeria (80) and Thailand (46) were probed: only one isolate from
Sweden harboured this DHFR (Jansson et al 1993).
TypeX
The type X DHFR was isolated during an outbreak of gentamicin resistant E. coli at a
Sydney hospital. The DHFR gene was shown to be inserted in a cassette-like manner
in the In7 integron on a large conjugative plasmid pDGOlOO (Parsons et al 1991).
This DHFR has not been detected in any other studies.
Type XII
The type XII DHFR was first detected in the USA in faecal isolates of E. coli.
Subsequent hybridisation experiments with a 100-bp Alul intragenic fragment
detected the type XII gene in 21% of commensal faecal isolates from children
attending day-care centres (Singh et al 1992b). Sequence analysis of a Finnish isolate
harbouring the type XII DHFR revealed flanking sequences that differed from those
surrounding the DHFR isolated in the USA (Heikkila et al 1993). The Finnish isolate
was demonstrated to be cassette mediated, and was located within the integron of a
Tn2i-like element. Heikkila et al (1993) showed that 2.7% (4/150) Finnish urinary
E. coli isolates and 2.3% (4/175) isolates of Shigella spp. hybridised to an intragenic
oligonucleotide probe for the type XII. Three of the Shigella isolates were isolated
from travellers returning from Thailand and the fourth came from a Vietnamese
immigrant. These two studies suggest that although this DHFR type is not highly
prevalent, it is widely distributed amongst Enterobacteriaceae.
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1.7 The commensal faecal flora: a reservoir of resistance
The gastro-intestinal tract is the largest reservoir of bacteria associated with the
human body. The intestinal flora form a diverse and dynamic ecosystem consisting of
numerous species of Gram-negative anaerobes, Gram-positive cocci, members of the
Enterobacteriaceae, fungi and viruses (Tancr&de 1992). The relationship between
commensal bacteria and man appears to have many far reaching consequences. One of
the positive aspects of gastrointestinal colonisation is the phenomenon of colonisation
resistance (Tancrede 1992). Van der Waaij et al (1971) showed that the commensal
flora play a role in preventing the colonisation of the gut by potentially pathogenic
bacteria by competitive exclusion. The commensal faecal flora are also associated with
disease. When the hosts defences are disrupted, for instance during neutropenia,
members of the family of the Enterobacteriaceae can translocate and cause Gram-
negative bacteremia (Tancrede and Andremont 1985). Anaerobes such as Bacteroides
spp. are often isolated from blood cultures if the host's barriers are broken such as
during bowel surgery. The faecal flora have also been implicated as the source of
infection of the urinary tract (Brumfitt et al 1971; Bettelheim et al 1971).
There are extensive data on the prevalence of antimicrobial resistance in pathogens in
hospitalised patients (O'Brien et al 1987); however little attention has been focused on
the origins and reservoirs of these resistance factors in the open population (Hawkey
1986). The administration of antimicrobial agents is the most common cause of
disturbances in the normal micro flora. It leads to the inhibition of sensitive
commensal organisms followed by the selection and subsequent overgrowth of
resistant strains. There is also potential for re-colonisation by exogenous resistant
organisms (Datta et al 1971; Shaw et al 1973). There is also growing evidence to
suggest that the commensal flora are the largest reservoir of antibiotic resistant
determinants. Most of the surveys performed on resistance levels in commensal faecal
flora have focused on resistance in the Enterobacteriaceae, E. coli being the most
frequendy isolated pathogen in hospital acquired infections (Bettelheim et al 1971;
Huovinen et al 1982). Bacterial diarrhoeal disease caused predominantly by
Enterobacteriaceae is also the greatest cause of mortality and morbidity in third
world countries (Kunin et al 1987).
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1.7.1. Epidemiology of resistance in commensal flora
Developed countries
Early studies showed that resistance carriage rates in Gram-negative aerobic
commensal faecal flora were high. A study by Moorehouse (1969) of 100 Irish
infants showed that 81% carried resistant strains. Datta (1969) found that 52% of pre¬
admission patients at a London hospital carried resistant coliforms. Resistant strains
predominated in 28% of the patients. A similar study from a male urological ward in
Denmark showed a 67% incidence of resistant E. coli in the bowel flora (Spgaard
1975). A study of adults and children from rural and urban populations in the United
Kingdom showed that 55% carried resistant strains. Higher carriage rates were
associated with children, and rural populations involved with animals (Linton et al
1972).
More recent studies from developed countries have shown that not only is the
incidence of antimicrobial resistance in the commensal faecal flora increasing, but also
the range of antimicrobials to which these organisms are resistant. There has also been
an increase in the numbers of multi-resistant strains that have been isolated in
commensal faecal flora. Studies from the Netherlands have shown that the incidence
of resistance in commensal faecal flora was 66%. No differences in resistance levels
between different age groups were detected (Degener et al 1983). Bonten et al
(1990) showed that the incidence of resistance in faecal samples from Dutch students
to sulphonamides, ampicillin, tetracycline and trimethoprim was 86%, 76%, 47% and
25% respectively. A further study by Bonten et al (1992) showed that the frequency
of resistance in populations from two Dutch cites was as follows: in Maastricht,
resistance to ampicillin, tetracycline, sulphonamides and trimethoprim occurred in
62%, 68%, 71%, and 45% of faecal isolates respectively, and in Zwolle resistance to
ampicillin, tetracycline, sulphonamides and trimethoprim occurred in 89%, 49%, 49%,
42% of faecal isolates respectively. Seventy-seven percent of these isolates were
resistant to more than one antimicrobial agent, 31% of which were resistant to five or
more antimicrobial agents. A 15 week follow up survey conducted by London et al
(1993) showed that there were no significant changes in the carriage rate of resistant
flora in individuals over the study period. In a study of commensal faecal flora from
healthy populations in Scotland, carriage rates of resistant organisms were 42%,
27%, 12% and 2% for ampicillin, tetracycline, trimethoprim and nalidixic acid
respectively.
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In the USA, Levy et al (1988) showed that 60% of healthy volunteers carried
resistant flora. Resistant organisms dominated (>50%) the faecal flora in 34% of the
volunteers. A more recent study by Lester et al (1990) showed that the faecal carriage
rates of resistant organisms was about 54% in Boston. Resistance to trimethoprim
was detected in 3% of the stools. Reves et al (1987) showed that in infants attending
day-care centres in the United States the faecal carriage rates of ampicillin and
trimethoprim resistance were 65% and 28% respectively. A further study by Reves et
al (1990) showed that the faecal carriage rate of trimethoprim resistance was 30% in
children attending day-care centres. This was significantly higher than in the control
group of children (6%) and medical students (8%). These data suggest that the high
levels of trimethoprim resistance in day care centres are due to the greater likelihood
of the introduction of resistant organisms to the pool, the greater potential for spread
due to the low standards of personal hygiene of the infants, and/or to prolonged
survival of strains. Fornasini et al (1992) showed that family members of children
attending day-care centres were at a greater risk of faecal colonisation by
trimethoprim-resistant organisms. Table 1.5 shows the data for the incidence of
resistance to individual antibiotics.
Developing countries
The situation in developing countries appears to be far more serious. Studies from
China and Venezuela involving 41 and 53 healthy children respectively showed that
faecal carriage of resistant organisms was almost universal. Resistance to
trimethoprim occurred in 64% and 61 % of healthy children respectively (Lester et al
1990). In India faecal carriage of organisms resistant to ampicillin, trimethoprim and
chloramphenicol is almost universal (Amyes et al 1992a). In a one year study of
commensal organisms in children from Bangladesh (Mamun et al 1993) the average
incidence of antimicrobial resistance to the following drugs: ampicillin, trimethoprim,
tetracycline, and sulphonamide was 72%, 45%, 65% and 62% respectively. In all but
two months over 50% of the children were colonised with coliforms resistant to three
or more antibiotics. The incidence of resistance was higher during the monsoon
season, and it has been suggested that this is most likely due to the contamination of
the water supply by resistant organisms during the wet season.
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Table 1.5. Antimicrobial resistance in commensal faecal flora at different
centres.
Survey Percentage of isolates resistant to Reference
Ap Tp NA Cm Tc Sx Sm Km Gm
Developed
Ireland 62 - 0 16 76 - - 63 - Moorhouse (1969)
UK 17 - - 8 34 38 27 1 - Datta (1969)
UK 25 - - 5 22 17 21 - - Linton et al (1972)
UK 48 - - - 61 - - - - Shaw et al (1973)
Denmark 18 - 9 46 54 53 - - Spgaard (1975)
Netherlands 26 - - - 42 46 - - - Degener et al (1983)
Netherlands 76 25 - - 47 86 - - - Bonten et al (1990)
Netherlands 76 44 - - 59 61 - - Bonten et al (1992)
USA 35 8 1 4 31 - 34 21 5 Levy et al (1988)
USA 23 3 - 15 33 36 38 8 - Lester et al (1990)
Scotland 42 12 2 27 1 Shanahan et al (1994b)
Developing
Venezuela 85 61 - 56 93 93 95 56 - Lester et al (1990)
China 47 64 - 42 92 87 79 26 32 Lester et al (1990)
India 98 98 23 97 - - - - - Amyes et al (1992)
South Africa 87 74 10 53 - - - - 8 Shanahan et al (1993)
Bangladesh 72 45 - 63 65 62 78 - - Mamun et al (1993)
In South Africa, the levels of resistance in commensal faecal flora amongst the
urbanised and rural black communities (ampicillin 87%, trimethoprim 74%,
chloramphenicol 53%) appear to be similar to those of other developing countries
(Shanahan et al 1993). The study populations were associated with a low standard of
living and significant overcrowding; however South Africa is unique in that there is
little unprescribed use of antimicrobial agents and the water supply is often
uncontaminated, suggesting that these two factors need to be re-evaluated with
respect to the role played in the spread of resistance factors in a community. It is
worth noting that appropriately prescribed antimicrobials does not guarantee patient
compliance (Shanahan et al 1994a).
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1.7.2 Selection of resistant bacteria in faecal flora
Different antimicrobial agents have been shown to exert different selective pressure
for drug res'ctance in the commensal faecal flora. Datta et al (1971) showed that in
comparison to ampicillin and sulphonamides, tetracycline therapy had a greater effect
on the selection and excretion of resistant organisms. It was shown that an increase in
resistance to other antimicrobials after tetracycline therapy occurred as the result of
the selection for multiply resistant strains. Lincoln et al (1970) showed that treatment
with sulphonamides resulted in the disappearance of sulphonamide sensitive serotypes
from the bowel followed by the emergence of resistant serotypes, some of which
carried R-factors for multiple antibiotic resistance.
Trimethoprim is rapidly absorbed after oral administration and absorption from the
gut is almost complete, as a result faecal concentrations of trimethoprim are low
(Brumfitt et al 1969; Schwartz & Rieder 1970). A number of studies have
investigated the effects of co-trimoxazole and trimethoprim therapy on the commensal
faecal flora. A study by Brumfitt and Pursell (1972) and Brumfitt et al (1973) showed
that trimethoprim and co-trimoxazole do not lead to the colonisation of the gut by
resistant strains. These findings were supported by Pancoast et al (1980) who
demonstrated that both therapies effectively cleared the introitus and rectal areas of
Enterobacteriaceae. In the few individuals who had strains resistant to trimethoprim
or co-trimoxazole before initiation of therapy, these organisms did not persist once
therapy began. Guerrant et al (1981) showed that both trimethoprim and co-
trimoxazole therapy resulted in a 4-log suppression of total coliforms during therapy.
Both these regimens had no effect on the anaerobic commensal flora. During
trimethoprim and co-trimoxazole therapy, resistant Gram-negative aerobes occurred
in 58% and 22% of the patients respectively. Of the 158 resistant organisms isolated,
only one incidence of a resistant Enterobacteriaceae was found. The majority of the
resistant isolates were Pseudomonas and Acinetobacter species, which did not
increase significantly in numbers during therapy.
A study by Stamey et al (1977) of the effects of long term trimethoprim therapy for
the prophylaxis of urinary tract infections showed that therapy resulted in the
elimination of Enterobacteriaceae from the gut and vaginal flora from most of the
patients. E. coli were isolated from 27% of the faecal samples 8.8% of which were
resistant to trimethoprim. Pearson et al (1979) found that during long-term treatment
of urinary tract infection with co-trimoxazole, only 5% of resistant isolates examined
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carried transferable trimethoprim resistance (MICs>1024mg/l). Reves et al (1990)
showed that colonisation of trimethoprim-resistant flora in the USA is rare, even
among individuals consuming trimethoprim. Contrary to these data, Huovinen et al
(1985a) demonstrated that the incidence of resistant Enterobacteria in stool specimens
increased three and four-fold during trimethoprim and co-trimoxazole therapy
respectively: the original resistance levels were restored within one month after
therapy.
Only one study has examined the effect of trimethoprim or co-trimoxazole therapy on
the faecal flora in developing countries. In a study of American students taking
prophylactic trimethoprim or co-trimoxazole on a visit to Mexico, Murray et al
(1982) showed that trimethoprim and co-trimoxazole therapy did not change the
numbers of total faecal Enterobacteriaceae. Virtually all the strains isolated expressed
high-level trimethoprim and sulphamethoxazole resistance. In these isolates E. coll
was the predominant organism, of which 95% carried resistance to at least four
antimicrobial agents, and 25% were resistant to seven. Forty-one percent of these
isolates carried transferable resistance; 60% of these shared the same epidemic
plasmid (Rudy and Murray 1984). It appears that in areas where there is a high faecal
carriage rate of resistant organisms especially those carrying transferable R-factors,
therapy results in the disappearance of sensitive serotypes from the bowel followed by
the emergence of resistant serotypes.
Antimicrobial agents which reach the lower bowel at significant concentrations in an
active form are far more likely to select out resistant bacteria. A large proportion of
ceftriaxone is biliarly excreted after injection. In a study with volunteers treated with
lg/d for 5 days with this antimicrobial, Leonard et al (1989) found that two different
phenomena occurred. In one group, 1.8-2.0mg/g of ceftriaxone was detected in faeces
and concomitantly, faecal counts of anaerobes dropped while those of Candida
species increased 100-fold. In the second group, ^-lactamase activity was high during
ceftriaxone administration and as a result no ceftriaxone was detected in faeces. There
were no significant changes in faecal counts of anaerobes or Candida species in this
group.
Amyes and Gould (1984) showed that a change in prescribing policy at a small
general hospital in Edinburgh from ampicillin to trimethoprim for the first line
treatment of urinary tract infection resulted in a decrease in both ampicillin and
trimethoprim resistance. It appears that ampicillin was therefore more effective at
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selecting bacteria that were not only ampicillin resistant but trimethoprim-resistant as
well. Since ampicillin is poorly absorbed in the gut, a considerable quantity of active
drug reaches the large intestine which leads to strong selection pressure for resistant
strains and results in the selection of multi-resistant strains. Reves et al (1990)
suggested that trimethoprim resistance is an excellent indicator of the presence of
multi-resistance plasmids and is a better indicator than ampicillin or sulphonamide
resistance.
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1.8 Clinical environment: a reservoir of resistance
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The clinical environment is now a well-established reservoir of antibiotic-resistance
genes. The extensive use of antimicrobials in clinical practice has created a high
degree of selection pressure whereby bacterial strains resistant to a given antibiotic
are selected for among strains being treated with that particular agent (Shanahan et al
1994a). When bacterial resistance data from different studies are compared, attention
should be paid to sources of the isolates and the susceptibility testing methods used
(Huovinen 1987). Although data for hospitalised and out-patients should be reported
separately, this division has not always been done. Wide variations in bacterial
resistance can be observed in different geographical areas and, even in the same area,
can depend on the material studied. In addition, recording of data for repeat samples
from the same patient may influence records of resistance levels (Huovinen 1986).
1.8.1 Developed countries
Urinary isolates
In the 1970's resistance to trimethoprim in urinary isolates in out-patients rarely
exceeded 10% (Fleming et al 1972; Griineberg 1976; Grey et al 1979; Dornbusch and
Toivanen 1981; Hamilton-Miller et al 1981; Towner and Wise 1983; Mayer et al
1985). In the 1980's reports showed an increase in trimethoprim resistance, some
centres reaching up to 20% (Huovinen et al 1982; Brumfitt et al 1983; Maskell 1983;
Huovinen 1984; Mayer et al 1985; Kraft et al 1985; Huovinen and Toivanen 1986;
Towner and Slack 1986; Heikkila et al 1990a; Harnett 1992a). Increases in the levels
of resistance to trimethoprim have levelled off at some centres in the 1980's and at
some centres have even decreased (Huovinen et al 1985b; Amyes et al 1986b;
Towner and Slack 1986; Heikkila et al 1990b).
At Turku city hospital where trimethoprim use has been higher than in other parts of
Finland (Huovinen and Toivanen 1980), resistance in E. coli isolated from the urinary
infections of in-patients increased from 10-30% in the 1970's, and then increased
further to 41% in 1984 (Huovinen et al 1986). Resistance has remained at a plateau of
40% from 1984-1988 (Heikkila et al 1990b). Tsakris et al (1991) showed that
trimethoprim resistance in Enterobacteria isolated from urine specimens of in-patients
from Greek Hospitals was 30%. Resistance levels were generally shown to be higher
in Proteus spp. and Klebsiella spp. than in E. coli (Huovinen and Toivanen 1980;
Hamilton-Miller et al 1981; Towner and Wise 1983). Resistance levels in hospitalised
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patients were usually double those of out-patients (Griineberg 1976; Huovinen and
Toivanen 1980; Brumfitt et al 1983; Towner et al 1983; Maskell 1983). The figures
for resistance in Gram-negative bacilli from various infections isolated from in- and
out-patients from Saint-Joseph Hospital, Paris from 1972 to 1979 showed a steady
increase in resistance from 15% to around 25% (Acar and Goldstein 1982).
Enteric pathogens
Trimethoprim resistance among Shigella spp. has provided one of the most illustrative
examples of the spread of trimethoprim resistance. In the Netherlands, resistance in
Shigella flexneri rose from 7.6% in 1984 to above 25% in 1986 and has remained at
that level from 1986 to 1989. In Shigella sonnei, the incidence of resistance rose
steadily from 16% in 1984 to 46% in 1989. Over the same study period, resistance in
Shigella boydii and Shigella dysenteriae isolates was 20% and 9.2% respectively
(Voogd et al 1992). Harnett (1992b) showed that the levels of resistance in Canadian
isolates of S. flexneri, S. sonnei, S. dysenteriae and S. boydii were 39.4%, 37.6%,
29.2% and 26.7% respectively. In a Spanish survey, 89% of S. sonnei isolates were
resistant to trimethoprim (Palenque et al 1983). Resistance to Salmonella spp. is
considerably lower (<10%) than in E. coli and Shigella spp. (Palenque et al 1983;
Ward et al 1990). Resistance to trimethoprim in enteropathogenic E. coli isolated in
the UK was 6% (Gross et al 1982).
1.8.2 Developing countries
Urinary isolates
The incidence of resistance to trimethoprim in developing countries is considerably
higher than in developed countries despite a lower per capita antimicrobial use (Col
and O'Connor 1987). There are little published data for the incidence of trimethoprim
resistance in the 1970's in developing countries, however figures from the 1980's have
shown that resistance levels have far exceeded those of developed countries. A study
by Young et al (1986b) showed that the incidence of resistance to trimethoprim in
South India in Enterobacteriaceae isolated from infected urines was 64%. Levels of
resistance in Nigeria were similar at 63% (Lamikanra and Ndep 1989). In South
Africa resistance in Enterobacteriaceae isolated from urine specimens at three
hospitals was 38%, 53% and 60% (Wylie and Koornhof 1989). In Taiwan 34%, 30%
and 42% of urinary isolates were resistant to trimethoprim in 1987, 1988 and 1989
respectively (Chang et al 1992).
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Resistance to trimethoprim in E. coli from predominantly urine isolates in Chile,
Thailand, Honduras, and Costa Rica was 44%, 40%, 38% and 48% respectively
(Murray et al 1985). Amyes and Young (1987) showed that the incidence of
trimethoprim resistance in Enterobacteriaceae isolated from all types of Gram-
negative infection in Tanzania was 36%. A more recent study in Tanzania by Gillespie
et al (1992) showed that trimethoprim resistance in E. coli and Proteus spp. was
64.5% and 61.5% respectively. In a similar study in Chile, Urbina et al (1989)
reported that resistance to trimethoprim in clinical isolates of E. coli and Klebsiella
pneumoniae was 25% and 41% respectively.
Enteric pathogens
Murray et al (1985) reported that the incidence of trimethoprim resistance in Shigella
spp. in Brazil and Bangkok was 22.8% and 24% respectively. In Chile resistance in
Shigella spp. was 37% (Urbina et al 1989). Reports from Bangladesh showed that
from 1983 to 1990 the incidence of trimethoprim resistance in Shigella dysenteriae 1
isolates was >70%, however resistance in non-5, dysenteriae 1 isolates rose steadily
from <2% in 1983 to 38% in 1990 (Bennish et al 1992). A study of resistance in
Shigella spp. isolated from Finnish travellers returning from developing countries
showed that resistance to trimethoprim rose steadily from 3% in 1975-83 to 42% in
1988 (Heikkila et al 1990c).
The incidence of resistance in Salmonella spp. at many centres appears to be lower
than in Shigella spp. Chugh (1985) reported that in Shigella spp., diarrheogenic E.
coli and Salmonella spp. isolated in Kuwait, 43%, 59% and 15% of these isolates
were resistant to trimethoprim respectively, while in Bangkok, 16% of Salmonella
spp. were resistant. In Brazil however, resistance to Salmonella spp. and
enteropathogenic E. coli was 76% and 50% respectively (Murray et al 1985). In
Tanzania, resistance in Salmonella spp. was 53% (Gillespie et al 1983). Lamikanra et
al (1990) reported that 38% of Nigerian isolates of diarrheogenic E. coli were
trimethoprim-resistant. Transferable plasmids conferring trimethoprim resistance have
been isolated from Vibrio cholerae in Tanzania (Young and Amyes 1986b) and in
South India (Jesudason and John 1990).
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1.9 Farming environment: a reservoir of resistance
The farming environment has been suggested as being another potential reservoir of
antimicrobial resistance determinants. It has been reported that half the antibiotics
produced in the United States are used in animal practice, either as therapeutic agents
or as supplements in animal feeds (Levy 1984). It was thought that the development
of resistance has been particularly encouraged by the use of antimicrobials at sub¬
therapeutic concentrations as supplements in animal feeds. These supplements were
aimed at: infection prophylaxis, decreasing feed requirement and increasing the rate of
weight gain (DuPont and Steele 1987). The Swann Report (Swann, 1969)
recommended the restriction of the use of clinical antibiotics in animal feeds in the UK
in order to reduce the high incidence of resistance associated with rearing livestock.
Trimethoprim-resistant E. coli have been isolated in 16% and 17% of porcine isolates
in Sweden (Jansson et al 1992) and Scotland (Amyes 1987) respectively. Mee and
Nikoletti (1983) showed that human and porcine isolates from Perth, Australia, shared
a number of identical E. coli biotypes and both groups contained transferable
R-factors of the same incompatibility group. Identical plasmids and resistant DHFRs
have been shown to occur in both clinical and veterinary isolates (Amyes 1987;
Jansson et al 1992). Linton et al (1972) reported that the incidence of faecal carriage
of resistant organisms was significandy higher in people whose occupation involved
contact with farm animals (63%) than in the control population (29%). These data
suggest that conditions of modern stock breeding create large interconnecting
bacterial populations with the potential for the development and spread of resistant
organisms (Jansson et al 1993). A study conducted in Northern India by Singh et al
(1992a) showed that the incidence of resistance was higher in human clinical isolates
than in veterinary isolates and it was suggested that these differences occurred as a
result of the infrequent use of antimicrobials in animal husbandry in India.
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1.10 Mechanisms of spread of trimethoprim resistance genes
1.10.1 Clonal spread
Increases in the incidence of resistance as a result of the spread of a single resistant
clone have been well documented. Wingard et al (1993) showed that in nursing home
patients, 68% of acquired infections caused by trimethoprim-resistant Gram-negative
bacilli occurred as the result of cross-colonisation. Since high levels of cross-
colonisation were correlated with a lower functional level in the patients, it has been
suggested that since these patients require a considerably greater amount of attention
from health care workers, they are at higher risk of exposure to cross-colonisation.
Other vehicles of spread have been identified outside the clinical environment. Food
contaminated with resistant organisms has resulted in outbreaks of infection caused by
resistant strains (Voogd et al 1992). As a result of human and animal faecal
contamination, drinking water in many developing countries and recreational waters in
developed countries have been shown to contain resistant Enterobacteriaceae and are
thought to enhance the spread of resistance genes into food, animal and human
populations (Young 1993).
1.10.2 Conjugation
The presence of R-factors conferring high levels of resistance to trimethoprim was
first identified by Fleming et al (1972). It was shown that these plasmids were capable
of transferring trimethoprim resistance in vitro to plasmid free strains of E. coli and
Salmonella typhimurium. Studies from the early 1970's showed that high-level
resistance (MIC>1000mg/1) which is indicative of the production of an additional
resistant DHFR occurred in less than 12% of trimethoprim-resistant isolates
(Jobanputra and Datta 1974; Brumfitt et al 1980; Hamilton-Miller et al 1981). In
most of these isolates high-level resistance was transferable (Jobanputra and Datta
1974; Grey et al 1979). While the incidence of low and intermediate levels of
resistance (MIC<1000mg/l) has not increased significantly over time, by the late
1970's and early 1980's, the incidence of high-level resistance to trimethoprim had
increased and accounted for between 60% and 86% of resistant isolates (Towner et al
1980; Brumfitt et al 1980; Hamilton-Miller et al 1981; Murray et al 1982; Kraft et al
1983; Kraft et al 1984; Towner and Wise 1983; Kraft et al 1985; Huovinen et al
1985b). The transfer of high-level resistance occurred in 59%-64% of these isolates
(Grey et al 1979; Kraft et al 1982; Kraft et al 1983; Kraft et al 1985). This suggests
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that the increase in the incidence of resistance to trimethoprim has occurred as the
result of the subsequent spread of plasmid mediated DHFRs. Studies conducted in the
1980's and early 1990's on clinical isolates of Enterobacteriaceae from centres around
the world have shown that high-level resistance to trimethoprim still occurs in the
majority (57%-100%) of isolates (Chugh 1985; Young et al 1986b; Urbina et al 1989;
Wylie and Koomhof 1989; Lamikanra and Ndep 1989; Lamikanra et al 1990; Tsakris
et al 1991; Harnett 1992a). Resistance was transferable in 36% to 76% of these
isolates.
Rudy and Murray (1984) demonstrated the presence of a transferable 'epidemic'
trimethoprim resistance plasmid in 12/20 faecal isolates from Mexico. The plasmids
were isolated from E. coli strains which represented five different serotypes,
suggesting that horizontal transfer by conjugation has enhanced the spread of this
plasmid. The phenomenon of different host strains harbouring identical plasmids has
also been demonstrated in clinical isolates of Enterobacteriaceae (Mayer et al 1985)
and between isolates from human and animal populations (Campbell et al 1986).
Whilst the prevalence studies have usually shown a high incidence of transferability to
laboratory recipient strains, the relevance of this to transfer rates in vivo is not clear
(Lacey 1975). It is probable that the transfer of R-plasmids amongst members of the
commensal flora in the gut is a rare event and is therefore difficult to study in vivo.
Experimental support for the rare nature of this transfer event was produced by
Anderson et al (1973) who fed four normal subjects with about 10" potential
recipient E. coli then a few hours later with a similar number of donor E. coli, and
looked for plasmid transfer. On the 16 occasions these experiments were performed,
no plasmid transfer occurred. It was suggested that Bacteroides spp. in the gut flora
were interfering with plasmid transfer. However, administration of an appropriate
antibiotic resulted in transfer at high frequency (Anderson et al 1973; Anderson
1974). Despite the fact there is only one reliable report of in vivo plasmid transfer
without selection pressure (Petrocheilou et al 1976), the potential for resistance
transfer without antimicrobial selection pressure should not be eliminated.
1.10.3 Transformation and transduction
Transformation and transduction have been suggested as possible mechanisms by
which resistance genes can spread between different species of bacteria (Levy 1982).
Transformation has been demonstrated to occur naturally in species such as
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Streptococcus pneumoniae, Haemophilius influenzae and Neisseria meningitidis
(Dowson et al 1989; Powell and Livermore 1990; Spratt et al 1989). The importance
of this type of transfer has been demonstrated by the occurrence of 'mosaic' genes
which are interspersed with related fragments of foreign DNA and encode penicillin
binding proteins which have a reduced affinity to P-lactam antibiotics. In
N. meningitidis the transformed DNA fragments were found to be homologous to
those of Neisseria flavescens (Spratt et al 1989), however the origins of the DNA
fragments in S. pneumoniae have not been traced (Dowson et al 1989). It is thought
that this mechanism of gene exchange may be of no importance in Enterobacteriaceae
since they require considerable laboratory manipulation in order to be transformed
(Murray 1991).
The best described examples of transduction are antibiotic resistance plasmids of
Staphylococcus aureus that can be transduced by phage from strain to strain (Novick
and Morse 1967). In theory, phage can transduce resistance genes from the
chromosome of one species to another, or the resistance gene can originate from the
phage itself. Since T4 phage encode a DHFR that forms both part of its structural and
soluble portions (Matthews 1971) it was though that phage may be the source of
trimethoprim-resistant DHFRs (Fling and Elwell 1980). However the T4 enzyme was
shown to be very sensitive to inhibition by folate analogues (Mathews 1971). Other
phage types however should not be ruled out as potential sources of resistant DHFRs.
1.10.4 Transposable elements
As the structures involved in genetic recombination and rearrangement of resistance
genes are elucidated, their increasing importance in the role played in the emergence
and spread of resistance genes is being recognised. A number of different mechanisms
have been identified: these include insertion sequences (IS-elements), various classes
of transposons, and the more recently identified element which is capable of site-
specific insertion, the integron (Stokes and Hall 1989).
Insertion sequences
Insertion sequences are a special class of transposable elements ranging between
0.7-2kb and contain perfect or nearly perfect inverted terminal repeat sequences. The
central region flanked by the terminal repeats contains at least one open reading
frame, presumably for the transposase protein (Carlos and Miller 1980). One
evolutionary implication derives from their ability to cause insertion mutations. These
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mutations have the potential to inactivate genes, or if inserted into a suitable site, can
activate cryptic genes or increase the expression of nearby genes (Sawyer et al 1987).
Neis et al (1986) demonstrated that the presence of multiple copies of the IS-element
IS160 in the resistance plasmid pBP16 resulted in various types of rearrangements of
the plasmid and its derivatives. These included inversion, deletion, replicon fusion and
transposition. Since IS-elements are common in R-factors, it is likely that they are one
of the main reasons for plasmid instability, and that they are involved in a major way
in plasmid evolution.
Transposable elements
A pair of insertion sequences flanking a central sequence can transpose as a unit and
give rise to what are called class I transposons. Such composite transposons
containing antibiotic-resistance genes such as Tn5, Tn9 and Tn70, are well
documented (Carlos and Miller 1980). Class II or complex transposons are flanked by
short inverted repeats of 30-40bp, but do not have IS-elements at their ends. In these
elements the central sequence contains transposition genes and frequently
antimicrobial resistance genes. Well documented examples of these are Tn3 which
carries ampicillin resistance and Tn27 which has been shown to carry resistance to
sulphonamides, trimethoprim, mercuric ions and streptomycin (Schmitt 1986). Unlike
IS-elements and class I transposons which replicate conservatively, class II
transposons are though to transpose via the formation of a cointegrate intermediate
and replication of the transposon occurs during cointegrate formation (de la Cruz and
Grinsted 1982). Transposons can also transpose into plasmids and remould their
structure, and in general change the genetic capabilities of plasmids. By providing
sites for replicon fusion they can also enable the transfer of non-conjugative plasmids
during conjugation (Sawyer et al 1987). Several other structures bearing a complex
array of transposition genes have been identified and are unrelated to the before
mentioned groups. One such example of these is Tn7 (Barth et al 1976).
Integrons
Recently a new type of element, the integron has been described in plasmids and
transposons of Gram-negative bacteria, which may have great importance for the
development of multiple resistance on a single mobile genetic element. Integrons are
characterised by conserved 5' and 3' ends which flank a variable DNA segment. A
gene coding for an enzyme, integrase, is located at the 5' end, and mediates site-
specific integration of defined gene cassettes within the variable region of the
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integron. The 3' end encodes two open reading frames of unknown function and a
gene for sulphonamide resistance (Stokes and Hall 1989).
The cassettes which are integrated into the variable region are flanked by a highly
conserved seven base element GTTRRRY (R=G or A; Y=C or T) at the 5' end, and a
sequence of nucleotides known as the 59-base element located 3' to the structural
gene (Hall et al 1991). Only 13 conserved bases of the proposed 59-base element
have been estimated to be necessary for recombination to occur (Ziihlsdorf and
Weidemann 1993). Cassettes present within integrons can be excised through the
action of integrase and have been identified as circular molecules within the cytoplasm
of cells (Collis and Hall 1992). They are however, unable to replicate autonomously
and must, therefore, be incorporated back into an integron structure to ensure
maintenance and survival. A number of different resistance-gene cassettes have been
found inserted within integrons: they include ^-lactamase genes such as OXA and
PSE, aminoglycoside modifying enzymes, chloramphenicol resistance genes
(Bissonnette and Roy 1992) and trimethoprim-resistant DHFRs la, II, V, VII, X and
XII (Huovinen et al 1995). The integration system described in Tn27 has been shown
to occur coupled with a number of other previously described Tn27-like structures. It
has also been shown to occur without the presence of these structures, suggesting that
the integrase system has evolved separately from these structures (Ziilsdorf and
Weidemann 1992). Integrons have been shown to be common in recently isolated
clinical bacteria and have been shown to possess a number of different combinations
of resistance genes (Levesque et al 1995).
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1.11 Aims of this thesis
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Between January and March 1992, a survey was conducted by Shanahan et al (1993)
to determine the incidence of antimicrobial resistance in the commensal faecal flora of
healthy individuals resident in South Africa. Seventy-four percent of the population
harboured trimethoprim-resistant organisms, from which 357 resistant strains were
isolated. The aims of this thesis were to:
• Identify the trimethoprim-resistant isolates and characterise the resistance
determinants associated with trimethoprim resistance.
• Determine whether trimethoprim resistance in these isolates was transferable to an
E. coli recipient strain, and to determine which resistance determinants
co-transferred with trimethoprim.
• Determine the MICs of trimethoprim for the wild-type isolates and their
transconjugants.
• Develop oligonucleotide probes capable of identifying and discriminating between
closely related DHFR genes.
• Determine the incidence of known trimethoprim-resistant DHFR genes in these
isolates and to identify their potential mechanisms of spread.
• Identify and characterise by nucleotide sequence and biochemical properties any
novel DHFR genes in the population.
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2.0 MATERIALS AND METHODS
"Everything is vague to a matter of degree, you do not realise until you have tried to
make itprecise. "
2.1 Chemical reagents
All reagents were supplied by Sigma chemicals (Dorset, UK) unless otherwise stated.
2.2 Bacteria strains and plasmids
The bacterial strains and plasmids used are listed in table 2.1.
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2.3 Collection of trimethoprim-resistant isolates
Between January and March 1992, a survey was conducted by Shanahan et al (1993)
to determine the incidence of antimicrobial resistance in the commensal faecal flora of
healthy indiviouals resident in South Africa. The study examined eight separate
population groups from both rural and urban areas. In the urban area the four groups
comprised infants attending either a childminder or a crbche in SOWETO (0-5 years),
urban children (6-11 years) and urban teenagers (12-19 years) attending a school in
Kagiso, a town on the West Rand, and urban adults (>19 years) who resided in
SOWETO. The rural population was composed of infants attending a 'well baby' clinic
at Middelplaas in the KaNgwane district, rural children and rural teenagers attending a
school at Hekpoort in the Magaliesburg district and lastly adults resident in
KaNgwane district. A map showing the regions from which the specimens were
collected from appears in figure 2.1.
Figure 2.1. Map showing the study area from which specimens were collected.
A total of 361 specimens were obtained. Following the protocol established for such
studies (Amyes et al 1992a), each specimen was plated onto modified Difco Mueller
Hinton Agar (Detroit, USA) plates containing lOmg/L trimethoprim as described by
Amyes and Gould (1984). Seventy five percent of the specimens contained
trimethoprim-resistant organisms, from which 357 resistant strains were isolated.




Table 2.2. Trimethoprim-resistant organisms isolated from each population
group (Shanahan et al 1993).






Urban infants SOWETO 45 42 56
Urban children Kagiso 42 34 39
Urban teenagers Kagiso 47 23 26
Urban adults SOWETO 44 35 43
Rural infants KaNgwane 50 40 53
Rural children Hekpoort 47 23 26
Rural teenagers Hekpoort 36 34 44
Rural adults KaNgwane 50 41 70
Total 361 272 357
2.4 Bacterial identification
Bacterial isolates were identified with standard biochemical tests (Collee et al 1989).
The identification of 25 isolates which displayed unusual biochemical profiles was
confirmed with the API20E (Bio Merieux, France) identification kit.
2.5 Disc susceptibility testing
Antibiotic sensitivity tests were performed by the Kirby-Bauer disk diffusion method
according to the guidelines set by the National Committee for Clinical Laboratory
Standards (1990) on Iso-sensitest agar (Oxoid, UK). Disks (Mast Merseyside, UK)
contained ampicillin (lOgg), trimethoprim (5(lg), piperacillin (lOOgg), amikacin (30g
g), tetracycline (30gg), gentamicin (lOgg), tobramycin (lOgg), ceftazidime (30gg),
cephazolin (30gg), cefotaxime (30gg), netilmicin (30gg), ciprofloxacin (5gg),
sulfisoxazole (300gg), nalidixic acid (30gg), nitrofurantoin (300gg), streptomycin (10
gg), spectinomycin (lOOgg), (UpJohn, USA) and chloramphenicol (30gg), (Abtek
Biologicals, UK). The plates were incubated at 37°C for 16h.
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2.6 Determination of minimum inhibitory concentrations
The MIC of trimethoprim for each isolate was determined by the agar dilution method
according to the guidelines set by the National Committee for Clinical Laboratory
Standards (19C0). Davis Mingioli minimal medium (Davis and Mingioli 1950)
supplemented with glucose 2.8g/L and appropriate concentrations of trimethoprim
(Wellcome Medical Division, Crewe, UK) was used. Isolates that did not grow on this
medium were tested on Davis Mingioli minimal medium containing thymidine
(25mg/l) and appropriate concentrations of trimethoprim (Amyes and Smith 1974c).
Organisms that failed to grow on this supplemented medium were re-tested on Iso-
sensitest Agar (Oxoid, U.K.) with appropriate concentrations of trimethoprim. The
Davis Mingioli minimal medium and the Iso-sensitest plates were incubated at 37°C
for 40h and 16h, respectively.
2.7 Conjugation
Conjugation experiments were performed in liquid media by the method of Amyes and
Gould (1984). Escherichia coli K-12 strain J62-2 (his, trp, pro, Rifr) was used as the
recipient. Isolates resistant to rifampicin were mated with E. coli K-12 strain J62-1
(his, trp, pro, NAr). The selective medium used was Davis Mingioli minimal medium
(Davis and Mingioli 1950) with glucose 2.8g/L, trimethoprim lOmg/L, rifampicin
25mg/L (Gruppo Lepetit, Milan, Italy) or nalidixic acid 20mg/L (Sanofi Winthrop,
Guildford, UK), supplemented with L-histidine 50mg/L, L-proline 50mg/L and
L-tryptophan 50mg/L. Colonies were purified on selective medium and their
auxotrophic requirements checked on Davis Mingioli minimal agar supplemented with
glucose 2.8 g/L. For the isolates which did not transfer trimethoprim resistance to the
recipient strain, the mating was repeated with the inclusion of transfer factor X+ as
described by Young et al (1986b).
Filter matings were performed with a rifampicin resistant mutant of E. coli K802
(Wood 1966). Matings were prepared by passing 1ml of a 1:10 mixture of an
overnight culture of donor and recipient strain respectively through sterile 13mm
cellulose nitrate filters (pore size 0.45|im). The filters were placed onto the surface of
Iso-sensitest agar and incubated overnight at 22°C or 37°C. The filters were placed in
10ml of Davis Mingioli minimal medium and shaken vigorously. A lOOpl of cell
suspension was plated out onto Iso-sensitest Agar with trimethoprim lOmg/L and
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rifampicin 25mg/L. The auxotrophic requirements of the transconjugants were
confirmed on Davis Mingioli minimal agar supplemented with glucose 2.8 g/L.
2.8 Transformation
Plasmids from transconjugants which contained two or more plasmids were
transformed into E. coli K12 C600 in order to isolate the plasmid which conferred
trimethoprim resistance. Transformation experiments were done with a standard
CaCl2 transformation protocol (Maniatis et al 1982).
2.9 Plasmid isolation and restriction analysis
Plasmids were isolated according to the method of Birnboim and Doly (1979) with
the following modifications: The volumes of culture, lysozyme solution, lysing
solution and high salt solution were doubled. Protein in the cleared lysate was
extracted with phenol/chloroform (1:1). The DNA was precipitated with one volume
of isopropanol and spun in an Eppendorf 5415 microcentrifuge at 15 OOOxg for 10
min at room temperature. The pellet was washed with 70% ethanol and dried. The
plasmid DNA was resuspended in 30(il distilled water with 20|ig/ml RNase. The DNA
was digested for 2h at 37°C with 10U of FcoRI restriction endonuclease (Boehringer
Mannheim, Germany) according to the manufacturer's instructions. The digested
DNA was analysed by electrophoresis on a 0.8% agarose gel run overnight at 3V/cm.
Plasmid size was determined on agarose gels by comparing the electrophoretic
mobility of the fragments of restricted plasmids with restricted X DNA fragments of
known molecular weight.
2.10 DNA hybridisation protocols
2.10.1 Probe construction
Probes to distinguish between the type lb and V DHFRs were used as described by
Young et al (1994). The region used is very heterogeneous between these two genes.
Considerable heterogeneity occurs in the same region throughout all resistant DHFRs
and this region was selected for the construction of 30-bp oligonucleotide probes for
the type la, lb, Ilia, V, VI, VII, VIII, IX, X, and XII DHFR genes. Figure 2.2 shows
the alignment of the amino acid sequence of these DHFR genes and the respective
regions from which the oligonucleotide probes were derived. The nucleotide sequence
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DHFR 60 70 80 90 100 110 120
Ia NRKYAWTRSSFTSDNENVLIFPSIKDALTN-LKKITD HVIVSGGGEIYKSLIDQVDTLHI
Ib NRKYAWTRSGWTSNDDNVWFQSIEEAMDR -LAEFTG HVIVSGGGEIYRETLPMASTLHL
V NRKYAWTRSAWTADNDNVIVFPSIEEAMYG -LAELTD HVIVSGGGE IYRETLPMASTLHI








DHFR 130 140 150 160 170 180 190
la STIDIEPEGDVYFPEI-PSNFRPVFT-QDFASN INYSYQIWQKG










Figure 2.2. Alignment of the amino acid sequence of the types la, lb, V, VI, VII,
Ilia, VIII, IX, X, XII and the chromosomal DHFR from E. coli K12. The
underlined region represents the heterogeneous region from which the DHFR
oligonucleotide probes were selected.
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Table 2.3. Oligonucleotides for DHFR gene probes.
DHFR Oligonucleotide sequence Origin/Reference
la 5'-CAAGlTlTACATCTGACAATGAGAACGTAT-3' Nucleotide 429-459 (Fling
and Richards 1983)
lb 5 '-GTTGGACATCAAATGATGACAATGTAGTTG-31 Nucleotide 430-460 (Young
et al 1994)
Ilia 5'-ATCCCCAATGGCAGGCCGAAGGGGTGGAGG-3' Nucleotide 298-328 (Fling
et al 1988)
VIII 5'-AAGCGCTGGAGCTTCCGGGTGTTCGTGACG-3' Nucleotide 779-809 (Barg et
al 1995)
V 5'-CCTGGACGGCCGATAATGACAACGTAATAG-3' Nucleotide 1501-1531
(Sundstrom et al 1988)
VI 5'-CTAAAATTATCTCGAATGACCCTGATGTTG-3' Nucleotide 528-558 (Wylie
and Koomhof 1991)
VII 5'-GAATTTCAAGCTCAAATGAAAATGTATTAG-3' Nucleotide 789-819
(Sundstrom et al 1993)
IX 5'-CAGTACCACCCACCCAGAACACTGATCAAG-3' Nucleotide 924-954
(Jansson et al 1992)
X 5'-CAACTATCACAGAGCACGAAGTGCTCAACA-3' Nucleotide 848-878
(Parsons et al 1991)
XII 5'-AAGCTAACTACCGCGCCACTGGCTGCGTAG-3' Nucleotide 414-444 (Singh
et al 1992b)
of the 30mer oligonucleotide probes for the DHFRs appear in Table 2.3. All of the
oligonucleotide probes were tested for homology with other DNA sequences on the
GenBank database. The probe for the integrase gene of Tn7 was previously described
(Heikkila et al 1991). The probe for the integrase gene of Tn27 was a 22mer
oligonucleotide probe 5'-GTCAAGGTTCTGGACCAGTTGC-3' derived from the
nucleotide sequence of the integrase gene of Tn2/ (Sundstrom et al 1993). The
oligonucleotides were synthesised by Oswel DNA service (Edinburgh University).
The oligonucleotide probes were labelled with the ECL Oligo labelling and detection
kit (Amersham, UK). The type II gene probe consisted of a 275-bp EcoRI, Sau3Al
intragenic fragment of pWZ820 (Zolg et al 1978) and was labelled with the ECL
Randomprime labelling and detection kit (Amersham, UK). Table 2.4 shows the
control strains that were used with the probes.
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Table 2.4. Control plasmids used in hybridisation protocols.
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Plasmid DHFR Reference
pFE506 dhfr la (Fling and Richards 1983)
pUK163 dhfr lb (Young et al 1994)
R67 dhfr IIa (Smith et al 1979)
R388 dhfr lib (Swift et a/1981)
R751 dhfr lie (Flensburg and Steen 1986)
pAZl dhfr Ilia (Flingef al 1988)
pBH600 dhfr IIlb (Barg et al 1990)
pBH700 dhfr llIc/VIII (Barg et al 1990)
pUKl 123 dhfr IV (Young and Amyes 1986a)
pLMO20 dhfrV (Sundstrom et al 1987)
pUK672 dhfr VI (Wylie etal 1988)
pLM027 dhfr VII (Sundstrom et al 1987)
pCJOOl dhfrIX (Jansson et al 1992)
pMAQ41 dhfrX (Parsons etal 1991)
pBEM155 dhfrXII (Singh et al 1992b)
2.10.2 DNA isolation
Plasmid DNA was isolated as described previously in 2.9. Total DNA was isolated by
the following method. All manipulations were carried out at room temperature in
1.5ml micro centrifuge tubes unless otherwise stated. Cells were harvested from 0.5ml
of overnight Luria broth (1% Difco Bacto-tryptone, 0.5% Difco yeast extract and 1%
NaCl, pH7.0) culture and resuspended in 350|il of high Tris, EDTA (HTE) buffer
(50mM Tris-Cl, pH8.0, 20mM EDTA). An equal volume of 2% /V-lauroylsarcosine in
HTE buffer was added and incubated at 55°C for 30 min to lyse the cells. The lysate
was cooled to room temperature then extracted with one volume of
phenolxhloroform (1:1, equilibrated with 0.5M Tris-Cl, pH8.0). One volume of
isopropanol was added to the supernatant and the DNA was precipitated for 10 min
prior to centrifugation. The DNA pellet was resuspended in 50pl of H20 with RNase
20fig/ml.
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2.10.3 Dot blotting procedure
The concentration of plasmid and total DNA samples were estimated by agarose gel
electrophoresis. Samples were denatured by the addition of one volume of 1M NaOH.
Approximately 20ng of plasmid DNA or 500ng of total DNA was spotted onto nitro¬
cellulose membranes (DuPont Genescreen, Germany). The membranes were dried
then baked at 80°C for two hours.
2.10.4 Hybridisation with oligonucleotide probes
Oligonucleotide ECL Oligo labelling and detection kit (Amersham, UK). The
hybridisation was performed for two hours at 53°C according to the manufacturer's
recommendations. Stringency washes were performed as described previously by
Heikkila et al (1991).
2.10.5 Hybridisation with gene probes
Gene probes were labelled and positive hybridisation results were detected by means
of the ECL Randomprime labelling and detection kit (Amersham, UK). The blots
were hybridised overnight at 62°C according to the manufacturer's recommendations
with the following stringency washes: two 15 minute washes with lx SSC and 0.1%
SDS followed by two 15 minute washes with 0.05x SSC and 0.1% SDS at 62°C.
2.10.6 Southern Hybridisation
Plasmid and total DNA samples were run on 0.8% agarose gels and Southern blotted
onto nitrocellulose membranes (Amersham, Hybond C-Extra) according to the
method of Southern (1975). Total DNA that was restricted with EcoRl or BamHl
was run on 1% agarose gels before Southern blotting.
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2.11.1 Preparation of dihydrofolate reductase.
Three litres of bacterial culture were grown overnight in Luria broth on a shaking
platform at 37°C. The bacteria were harvested by centrifugation (3800g at 4°C for
lOmin). All further manipulations were carried out at 4°C. The bacterial pellet was
washed with 100ml buffer A (50mM sodium phosphate buffer pH 7.4 containing
lOmM P-mercaptoethanol and ImM EDTA). The pellet was finally resuspended in
20ml ice cold buffer A. The suspension was sonicated for 3x45 sec with lmin
intervals using a MSE Soniprep 150 then clarified by centrifugation at 40 000g for
45min. The resultant supernatant was the crude enzyme preparation. Nucleic acids
were removed by the addition of 0.1 volume of 10% streptomycin sulphate followed
by centrifugation at 20 OOOg for 30min. After centrifugation, ammonium sulphate was
added to 50% saturation. The precipitate was removed by centrifugation at 20 OOOg
for 30min. Ammonium sulphate was added to 80% saturation and the precipitate was
removed by centrifugation at 20 OOOg for 30min. The pellet which contained most of
the DHFR activity and hardly any NADPH oxidase activity was resuspended in 3ml
buffer A and stored at -20°C.
2.11.2 Protein estimations
Estimation of protein concentrations in crude lysates were determined by the method
of Waddel (1956). The absorbance of a diluted sample was measured at OD215 and
OD225- The protein concentration was then ascertained by comparing the difference
between these readings with a previously prepared standard curve.
2.11.3 Sephadex gel-exclusion chromatography
The enzyme was separated at 4°C on a Sephadex G-75 column (2cm2 cross sectional
area x 90cm) by the method of Andrews (1964). Buffer A was washed through the
column at a constant rate of 10ml per hour. Two millilitres of sample were applied to
the column, and 2ml fractions were collected every 12min.
The column was calibrated by the method of Andrews (1964) with three proteins of
known molecular weight: ovalbumin (Mr=45 000), chymotrypsinogen (Mr=25 500)
and cytochrome C (Mr=12 384). Fifty milligrams of each protein were dissolved in
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2ml buffer A and applied to the column. The protein concentration of each fraction
was measured at OD280. A standard curve was derived by plotting the eluted volume
against the log of the molecular weight of the peak fractions of eluted protein.
2.11.4 Dihydrofolate reductase assays
Dihydrofolate reductase assays were performed according to the method of Osborn
and Huennekens (1958). A Perkin Elmer lambda 2 spectrophotometer, with heated
cuvette carriage (37°C) was used to measure the decrease in absorbance at OD340.
This is caused by the oxidation of NADPH to NADP in the reduction of dihydrofolate
to tetrahydrofolate by the activity of DHFR. When both substrates are acted upon
stoichiometrically, 52% of this combined fall in absorbance is a result of the reduction
of dihydrofolate (Matthews et al 1963). With this qualification, the rate of enzyme
activity is expressed in molar terms of dihydrofolate reduction to tetrahydrofolate.
The reaction was performed in 1ml quartz cuvettes containing 40mM sodium
phosphate buffer pH 6.0, lOmM (Tmercaptoethanol, 0.08mM NADPH, enzyme and
distilled water to 950|il (Amyes and Smith 1978). A blank, which did not contain
NADPH, and the sample were placed in the spectrophotometer and allowed to
equilibrate for 3min. Any decrease in absorbance measured at this stage was taken as
DHF-independent NADPH oxidase activity and was deducted from the final reading.
Dihydrofolate was then added to both cuvettes and the decrease in absorbance was
measured for 3min or until a zero reading was recorded.
2.11.5 Specific activity
The specific activity of the crude protein preparation was determined by dividing the




The eluted fractions from the Sephadex G75 column which displayed maximum
DHFR activity were pooled for further assay. The following assays were performed:
2.12.1 Drug inhibition
The dose of trimethoprim or methotrexate required to inhibit DHFR activity by 50%
(ID50) was assayed as above, in the presence of increasing concentrations of the two
drugs.
2.12.2 Temperature sensitivity
To determine the exposure time at 45°C required to inhibit enzyme activity to 50%
(TD50), the enzyme was pre-treated at 45°C for time spans increasing from 0.5-12 min
prior to each assay.
2.12.3 Michaelis constant
To determine the Michaelis constant (Km) which is a measure of the enzyme's affinity
for the substrate or, the substrate concentration at which the rate of reaction is half
the maximum velocity, the enzyme was assayed in the presence of decreasing
dihydrofolate concentrations. The results were then analysed by the method of
Lineweaver and Burke: where the reciprocal of the substrate concentration 1/[S] is
plotted against the rate of enzymic reaction 1/V. When extrapolated, the interception
on the abscissa gives the negative reciprocal of the Km (Zubay 1993).
2.12.4 Trimethoprim inhibition constant
The inhibitor constant (Ki) is analogous to the enzyme substrate constant (Km), and is
defined as the dissociation constant of the enzyme-inhibitor complex (Zubay 1993).
This was determined by repeating the assays for the Km, in the presence of
trimethoprim and then plotting the 1/[S] against 1/V as before. As a result of
competitive inhibition of trimethoprim, the line intercepts the ordinate at the same
point as the Km, but the interception of the abscissa is nearer to the origin, as the
reaction is slowed down as a result of trimethoprim inhibition. The negative reciprocal
of the point of interception gives an apparent Km, (the Kp) in the presence of the
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inhibitor. The K, is then determined from the following equation (Zubay 1993), where





Cloning procedures were performed as described by Maniatis et al (1982). Plasmid
DNA from transconjugant and vector (pUC18) were isolated as described in 2.9. The
DNA was restricted for two hours at 37°C with appropriate restriction enzymes and
the recommended buffers as supplied by GibcoBRL (UK). Restricted DNA that was
to be sub-cloned was separated on 0.8% agarose gels and the appropriate DNA
fragments from the gel were excised and purified with the GeneClean kit (Bio 101, La
Jolla, USA). Restricted fragments were ligated with T4 DNA ligase (Gibco-BRL,
UK) for 16 hours at 12°C. The ligated DNA was transformed into competent E. coli
HB101 as prepared by a CaCl2 transformation protocol described by Maniatis et al
(1982). Putative transformants were selected on Iso-sensitest agar containing
ampicillin 50mg/L and trimethoprim 20mg/L.
2.14 Nucleotide sequencing and analysis
The plasmid DNA containing the cloned fragment to be sequenced was isolated by a
alkali lysis method described by Maniatis et al (1982). The DNA sample was further
purified by agarose gel electrophoresis - the closed circular DNA was excised from
the gel and purified with the GeneClean kit (BiolOl, La Jolla, USA).
The template DNA was quantified by agarose gel electrophoresis. For each labelling
reaction 3-5(tg of plasmid DNA was denatured by the addition of 0.1 volumes of 2M
NaOH and incubated for 30min at 37°C. The mixture was neutralised by adding 0.1
volumes of 3M sodium acetate (pH 4.8) and the DNA precipitated with two volumes
of ethanol (-70°C, 15 min). The DNA pellet was washed with 70% ethanol and
resuspended in 7fil of distilled water.
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The sequencing reaction based on the chain termination method described by Sanger
et al (1977), was performed using the SEQUENASE Version 2.0, DNA Sequencing
kit (United States Biochemical, Cleveland, USA) and [35S]-dATP (Amersham) label.
The M13 -40 forward primer was supplied with the labelling kit, and the reverse
primer 5'-GGAAACAGCTATGACCATG-3' was a gift from Dr H.-K. Young,
Dundee University. Further primers were derived from the previously determined
nucleotide sequences and were synthesised by Oswel DNA service (Edinburgh
University). For each primer, two sequencing reactions were performed: for longer
sequences, the labelling reaction time was extended to ten minutes and for
determining sequences close to the primer the labelling reaction was performed for
three minutes with the addition of lpl Mn2+ buffer supplied with the kit.
The samples were electrophoresed for 2-5 hours at 60W with a Biorad sequencing
apparatus. The gels were fixed for 30min and dried with a Biorad gel drier for two
hours at 80°C under vacuum. Autoradiography was carried-out for 24 hours at room
temperature with Amersham hyperfilm MP. The development of the film was kindly
performed by the Edinburgh Royal Infirmary X-ray department.
Sequence comparisons were performed using the GCG sequence analysis software.
Nucleotide sequences were compared with all bacteria sequences in the GenBank and
EMBL databases using the FASTA search programme.
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3.0 RESULTS
"The most savage controversies are those about matters as to which there is no good
evidence either way."
Bertrand Russell
3.1 Identification of isolates
The majority of the 357 trimethoprim-resistant organisms which were isolated and
identified were Escherichia coli, 297 (83.2%). The Klebsiella spp. were less frequent
46 (12.9%), followed by Enterobacter spp. 7 (2%), Shigella sonnei 3 (0.8%) and a
single isolate each of Proteus vulgaris, Kluyvera spp., Citrobacter freundii and
Pseudomonas aeruginosa. The three S. sonnei isolates were isolated from volunteers
who were asymptomatic.
3.2 Transfer of trimethoprim resistance
Trimethoprim resistance was transferable to an E. coli J62-2 (three plasmids from
rifampicin resistant isolates were transferred into J62-1) recipient strain by
conjugation in 184 (51.5%) of the 357 isolates. An X+ factor was required to
mobilise resistance in a further 12 (3.4%) isolates. Table 3.1 shows the proportion of
isolates for each species that transferred trimethoprim resistance to the recipient
strain.
Table 3.1. Number of transconjugants for each species.
Donor species No. of isolates Transconjugants(%) X+ Factor(%)
Escherichia coli 297 151 (50.8) 12 (3.4)
Klebsiella spp. 46 27 (58.7) 0
Enterobacter spp. 7 2 (28.6) 0
Shigella sonnei 3 3 (100) 0
Other genera^ 4 1 (25) 0
Total 357 184 (51.5) 12 (3.4)
t Kluyvera spp. (n=l), Proteus vulgaris (n=l), Pseudomonas aeruginosa (n=l) and
Citrobacterfreundii (n=l).
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The proportion of E. coli and Klebsiella spp. isolates that could transfer resistance by
conjugation was similar (between 50-60%). In contrast all three of the S. sonnei
isolates and only 29% of the Enterobacter spp. isolates transferred resistance.
3.3 Antibiotic resistance associated with trimethoprim resistance
The trimethoprim-resistant isolates were tested, by the disk diffusion method, for
resistance to the following antimicrobials: ampicillin, trimethoprim, piperacillin,
amikacin, tetracycline, gentamicin, tobramycin, ceftazidime, cephazolin, cefotaxime,
netilmicin and ciprofloxacin at the concentrations listed in the materials and methods.
Resistance to two or more of these agents occurred in 94% of the isolates. Seventy-
one percent of the isolates were resistant to three or more antimicrobials and 62%
carried resistance to four or more agents. Only 12% of the isolates were resistant to
five or more agents.
Tetracycline resistance was associated with trimethoprim resistance in 88% (317/357)
of the isolates. Resistance to ampicillin occurred in 71.4% (255/357) and piperacillin
in 66.7% (238/357) of the trimethoprim-resistant isolates. Piperacillin resistance was
always associated with ampicillin resistance. Aminoglycoside resistance was
uncommon as gentamicin resistance occurred in 3.4% (12/357), tobramycin in 3.4%
(12/357), netilmicin in 1.4% (5/357) and amikacin in 0.3% (1/357) of the isolates.
Resistance to first and third generation cephalosporins was also uncommon. Of the
cephalosporins, resistance to cefazolin was the most common and occurred in 12.9%
(46/357) of the isolates. Cefotaxime and ceftazidime resistance occurred in 1.7%
(6/357) and 1.4% (5/357) of isolates. All the isolates were susceptible to
ciprofloxacin. The combination of resistance to trimethoprim, tetracycline, ampicillin
and piperacillin was the most prevalent and occurred in 48% of the isolates. Twenty-
three percent of the isolates were resistant to a combination of trimethoprim and
tetracycline. The antibiograms of the wild-type isolates are shown in table 3.2.
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Table 3.2. Antibiograms of wild-type trimethoprim-resistant isolates.


















3.4 Resistance associated with transferable trimethoprim resistance
The transconjugants were tested by the disk diffusion method for resistance to
ampicillin, piperacillin, amikacin, tetracycline, gentamicin, tobramycin, ceftazidime,
cephazolin, cefotaxime, netilmicin and ciprofloxacin.
Resistance to antibiotics including trimethoprim occurred at the following frequencies:
tetracycline 30% (59/196), ampicillin 55,6% (109/196), piperacillin 55.1% (108/196),
gentamicin 2.6% (5/196), tobramycin 1.5% (3/196), ceftazidime 1.5% (3/196),
cefotaxime 0.5% (1/196), cefazolin 0.5% (1/196). Resistance to netilmicin and
amikacin did not transfer from donor to recipient. Figure 3.1 shows the percentage of
transconjugants that were resistant to ampicillin, tetracycline, cefazolin and
gentamicin in comparison to the incidence of resistance in the respective plasmid
donors. Tetracycline, ampicillin, cefazolin, and gentamicin resistance co-transferred
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with trimethoprim resistance in 34%, 77%, 14% and 83% of the isolates which were








Figure 3.1. Antimicrobial resistance associated with trimethoprim resistance in
the transconjugants and their wild-type plasmid donors.
To differentiate further between the different antibiogram types, the transconjugants
were tested for resistance to sulfisoxazole, streptomycin, spectinomycin,
chloramphenicol, nalidixic acid and nitrofurantoin. Resistance to antibiotics including
trimethoprim occurred in the transconjugants at the following frequency: sulfisoxazole
90.8% (178/196), streptomycin 48% (94/196), spectinomycin 24% (47/196),
chloramphenicol 11.7% (23/196) and nalidixic acid 1% (2/196). All the
transconjugants were susceptible to nitrofurantoin.
Some resistance profiles occurred more frequently than others. Thirty-three percent
(65/196) of the transconjugants were resistant to a combination of trimethoprim and
sulfisoxazole. A combination of resistance to TpApPrlSxSm occurred in 19%
(37/196) of the isolates, and combinations of TpTcApPrlSxSm and
TpTcApPrlSxSmSpCm occurred in 8% (15/196) and 6% (12/196) of the isolates
respectively. The antibiograms of the transconjugants appear in table 3.3.
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Table 3.3. Antibiograms of the transconjugants.





























3.5 Minimum inhibitory concentrations of trimethoprim
The minimum inhibitory concentrations of trimethoprim in the wild-type isolates are
shown in table 3.4 High-level resistance (MIC >1024 mg/1) occurred in 98.6% of the
isolates. Seventy-nine percent of the isolates were resistant to more than 2048mg/l of
trimethoprim. These figures suggest that the vast majority of trimethoprim resistance
genes were of plasmid or transposon origin.
Table 3.4. Trimethoprim minimum inhibitory concentrations for the wild-type
isolates.
Trimethoprim MIC (mg/1)
Species >2048 2048 1024 512 256 16
E. coli (n=297) 233 60 2 2 0 0
Klebsiella spp (n=46) 41 4 0 0 0 1
Enterobacter spp (n=7) 5 0 0 0 2 0
S. sonnei (n=3) 2 1 0 0 0 0
Other genera^ (n=4) 2 2 0 0 0 0
Total (n=357) 283 67 2 2 2 1
f Proteus vulgaris (n=l), Kluyvera spp. (n=l), Citrobacter freundii (n=l) and
Pseudomonas aeruginosa (n=l).
Table 3.5 shows the MICs of trimethoprim in the transconjugants. The MICs of
trimethoprim were on average lower in the transconjugants than in the wild-type
isolates. High-level resistance (MIC >1024 mg/1) occurred in 85.7% of the
transconjugants and only 46% of the isolates were resistant to more than 2048mg/l of
trimethoprim. Differences between the trimethoprim MICs of the wild-type isolates
and their transconjugants were most likely due to differences in the media used for
susceptibility testing, (DM minimal medium and Iso-sensitest agar respectively) and
differences in the DHFR specific activity of the isolates.
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Table 3.5. Minimum inhibitory concentrations of trimethoprim for the
transconjugants.
Trimethoprim MIC (mg/1)
Species of plasmid donor >2048 2048 1024 512 256 128
E. coli (n=163) 65 46 24 17 10 1
Klebsiella spp. (n=27) 20 7 0 0 0 0
Enterobacter spp. (n=2) 2 0 0 0 0 0
S. sonnei (n=3) 2 0 1 0 0 0
Kluyvera spp. (n=l) 1 0 0 0 0 0
Total (n=196) 90 53 25 17 10 1
3.6 Plasmid analysis
Plasmids were extracted from the wild-type isolates and their corresponding
transconjugants to determine whether trimethoprim resistance was plasmid mediated.
All the transconjugants were demonstrated to have one or more plasmids of varying
size. Twenty-four percent (48/196) of the transconjugants contained two or more
plasmids. In order to obtain a restriction profile and antibiogram of the individual
plasmid harbouring trimethoprim resistance, plasmids were isolated from these 48
transconjugants and transformed into E. coli (C600). Forty-one (85%) plasmids from
these transconjugants could be transformed as single plasmids into an E. coli (C600)
recipient. This is a significant proportion considering that most of these plasmids
ranged between 50 and lOOkb in size. Plasmid restriction profiles were obtained for all
the transconjugants and transformants which had only one plasmid. A restriction
profile of the individual plasmid which conferred trimethoprim resistance could not be
determined from the remaining seven transconjugants bearing two or more plasmids.
A total of 107 different restriction profiles were recorded in the 189 transconjugants
and transformants with single plasmids. The restriction profiles of plasmids which
shared identical sized restriction fragments and elaborated identical antibiograms were
defined as being the same plasmid. Table 3.6 lists the plasmids whose restriction
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profile occurred in more than two transconjugants; the population group from which
they came; the wild-type organism from which the plasmids were isolated and the
resistance determinants carried by these plasmids. The restriction profiles of these
plasmids are shown in figure 3.2.
Table 3.6. Common restriction profiles, the associated antibiograms, and the
origin of the donor organism.
Plasmid Number of Population Identity of Plasmid Resistance
isolates (%) Group Donor Markers
pUK2301 26 (13.8) Urban infants (4) E. coli (24) TpSx

















PUK2317 6 (3.2) Urban infants (6) Klebsiella spp (6) TpTcSxSp
PUK2313 5 (2.6) Urban infants (5) E. coli (5) TpApSxSm
pUK2307 5 (2.6) Urban infants (5) E. coli (3)
Klebsiella spp (2)
TpSx
pUK2302 5 (2.6) Urban infants (1)
Urban children (1)
Rural children (2)
E. coli (5) TpSx
Rural adults (1)
E. coli (13) TpApSxSm
S. sonnei (1)
Results 70
pUK2314 4(2.1) Rural infants (3)
Rural adults (1)
E. coli (4) TpApSxSm
pUK2308 4(2.1) Rural adults (4) Klebsiella spp (2) TpSx
E. coli (1)
Enterobacter spp(l)
pUK2310 3(1.6) Rural children (2)
Rural teenagers (1)
E. coli (3) TpSx
pUK2303 2(1.1) Urban infants (1)
Rural infants (1)
E. coli (2) TpSx
PUK2304 2(1.1) Urban infants (2) E. coli (2) TpSx
pUK2305 2(1.1) Rural teenagers (2) E. coli (1)
Klebsiella spp (1)
TpSx
pUK2306 2(1.1) Urban teenagers(1)
Rural infants (1)
E. coli (2) TpSx
pUK2309 2(1.1) Rural adults (2) E.coli (1)
Klebsiella spp (1)
TpSx
pUK2315 2(1.1) Urban infants (2) E. coli (2) TpApSxSm
pUK2378 2(1.1) Urban infants (1)
Urban children (1)
E.coli (2) TpTcApSxSmSp
pUK2370 2(1.1) Urban children (1)
Rural teenagers (1)
E. coli (2) TpTcApSxSp
pUK2399 2(1.1) Rural adults (2) E. coli (1) TpTcApGmTnCaz
Klebsiellaspp (1) CtxSxSmSpCm
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Figure 3.2. A 0.8% agarose gel showing the .EcoRI restriction profiles of
plasmids listed in table 3.3. Lane 1: Hindlll restricted A DNA. Lane 2:
pUK2301. Lane 3: pUK2302. Lane 4: pUK2303. Lane 5: pUK2304. Lane 6:
pUK2305. Lane 7: pUK2306. Lane 8: pUK2307. Lane 9: pUK2310. Lane 10:
pUK2308. Lane 11: pUK2309. Lane 12: pUK2308 (Restricted with BamHI).
Lane 13: pUK2309 (Restricted with BamHI). Lane 14: pUK2311. Lane 15:
pUK2312. Lane 16: pUK2313. Lane 17: pUK2314. Lane 18: pUK2315. Lane 19:
Hindlll restricted A DNA. Lane 20: Hindlll restricted A DNA. Lane 21:
pUK2370. Lane 22: pUK2399. Lane 23: pUK2317.
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The two most common plasmids were pUK2301 and pUK2311. These two plasmids
occurred in 13.8% (26/196), and 7.9% (15/196) of the transconjugants respectively,
and were geographically ubiquitous, occurring in all the population groups studied,
with the exception of the urban adults from SOWETO. Almost all of these plasmids
were isolated from an E. coli host with the exception of two isolates of S. sonnei
which harboured pUK2301 and one isolate of S. sonnei which harboured pUK2311.
On the other hand, three plasmids pUK2317, pUK2307 and pUK2313 occurred in
3.2% (6/196), 2.6% (5/196) and 2.6% (5/196) of the transconjugants respectively,
and were only isolated from one population, urban infants. Plasmids pUK2317 and
pUK2313 were harboured only in Klebsiella spp. and E. coli isolates respectively.
Plasmid pUK2307 occurred in more than one species, E. coli (n=3) and Klebsiella
spp. (n=2).
3.7 DNA hybridisation
The oligonucleotide probes discriminated well between the different trimethoprim-
resistant DHFRs and no cross-hybridisation was observed with any of the negative
control plasmids. The gene probe for the type II DHFRs that was constructed from
R388 was shown to hybridise at high stringency (0.05x SSC at 62°C) to the type II
DHFRs of R388 and R751 but not R67. At lower stringency, (0.2x SSC at 62°C) this
probe hybridised to the control plasmids of most of the resistant DHFR types. Figure
3.3 shows the hybridisation of this probe to the resistant DHFR control plasmids with
different stringency washes.
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Figure 3.3. Shows the effect of different stringency washes on the hybridisation
of the type II gene probe (R388) to the resistant DHFR control plasmids.
3.7.1 Incidence of trimethoprim-resistant DHFR genes in the transconjugants
Plasmid DNA from the 196 isolates that transferred trimethoprim resistance to an
E. coli J62 recipient was hybridised with the DHFR probes described in 2.10.1 and
with the probe for the integrase gene of Tn21. The most prevalent DHFR in these
plasmids was the type lb which hybridised to 29.6% (58/196) of the plasmids. Other
prevalent DHFRs were the type IIIc/VIII 23% (45/196) and the type V, 12.8%
(25/196). The types la, VII and XII DHFRs occurred in only 11, 5 and 1 plasmid(s)
respectively. None of the isolates hybridised to the intragenic gene probe for DHFRs
lib and lie that was constructed from R388, or to the oligonucleotide probes for the
types Ilia, VI, IX, and X DHFRs. The plasmids of 26.5% (52/196) of the isolates did
not hybridise to any of the DHFR probes. The prevalence of each DHFR and the
number of different plasmid restriction profiles which hybridised to each DHFR probe
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are shown in table 3.7. To determine whether any of the plasmid mediated DHFRs
were possibly inserted in a cassette-like manner into an integron structure of a
potentially mobile element, the plasmids were probed with an oligonucleotide probe
for the integrase gene of Tn27. Twenty-one percent (41/196) of the plasmids
hybridised to this probe.
Table 3.7. Frequency of DHFR genes and the number of restriction profiles
representing each DHFR.
DHFR No. of plasmids (%) No. of different restriction profilesf
Type la 11 (5.6) 11
Type lb 58 (29.6) 24(1)
Type II 0 0
Type Ilia 0 0
Type IIIc/VIII 45 (23) 14
Type V 25 (12.8) 15(1)
Type VI 0 0
Type VII 5 (2.6) 3(2)
Type IX 0 0
TypeX 0 0
Type XII 1 (0.5) 1
No hybridisation 52 (26.5) 39 (3)
Total 196* 107
*One isolate hybridised with both the type VIII and V DHFR probes,
t The figure in brackets denotes the number of transconjugants in which more than
two plasmids occurred and hence no restriction profile could be determined.
Table 3.8 shows the plasmids which hybridised to the probe for the type lb DHFR
gene. The high prevalence of the type lb was due partially as a result of the presence
of the geographically ubiquitous plasmid pUK2301 which occurred in 45% (26/58) of
these plasmids. Plasmids pUK2303, pUK2304, pUK2305 and pUK2306 are closely
related to and share restriction fragments of similar size to those of pUK2301
(Figure 3.2).
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Table 3.8. Plasmids which hybridised to the probe for the type lb DHFR gene,
their resistance profde, and their association with In21.
Plasmid Isolates DHFR In21 Antibiogram
pUK2327 1 lb + Tp
pUK2301 26 lb - TpSx
pUK2302 5 lb - TpSx
pUK2303 2 lb - TpSx
pUK2304 2 lb - TpSx
pUK2305 2 lb - TpSx
pUK2306 2 lb - TpSx
pUK2318 1 lb - TpSx
pUK2319 1 lb - TpSx
pUK2320 1 lb - TpSx
pUK2342 1 lb - TpSx
pUK2321 1 lb - TpSx
pUK2331 1 lb - TpSx
pUK2330 1 lb - TpSx
pUK2333 1 lb - TpSx
pUK2400 1 lb + TpSx
pUK2324 1 lb - TpSx
pUK2354 1 lb - TpAp
pUK2360 1 lb + TpApSx
pUK2366 1 lb - TpApSxSp
pUK2347 1 lb + TpApSxSm
pUK2348 1 lb + TpApSxSm
pUK2351 1 lb + TpApSxSm
pUK2359 1 lb + TpTcApSxSm
not determined* 1 lb - TpSxf
*No restriction pattern was obtained because more than one plasmid was present in
the transconjugant. f Antibiogram of the transconjugant.
The majority (49/58) of the plasmids which hybridised to the probe for the type lb
DHFR were resistant to only trimethoprim and sulphonamides and were not
associated with the integrase gene of Tn27. Five out of seven of the plasmids which
were associated with ampicillin resistance hybridised to a probe for the integrase gene
of Tn27.
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The plasmids which hybridised with the probe for the type IIIc/VIII DHFR are shown
in table 3.9. Three-quarters of these plasmids were represented by four restriction
profiles which accounted for 15/45, 10/45, 5/45 and 4/45 of the plasmids which
hybridised with the probe for the type IIIc/VIII DHFR respectively. All the plasmids
carried ampicillin resistance determinants, the majority (42/45) of which conferred
resistance to sulphonamides and streptomycin. None of these plasmids were carried
with the integrase gene of Tn2i.
Table 3.9. Plasmids which hybridised to the probe for the type VIII DHFR gene,
their resistance profile, and their association with In21.
Plasmid Isolates DHFR In21 Antibiogram
pUK2406 1 VIII TpAp
pUK2357 1 VIII TpApSx
pUK2358 1 VIII TpApSx
pUK2311 15 VIII TpApSxSm
pUK2312 10 VIII TpApSxSm
pUK2313 5 VIII TpApSxSm
pUK2314 4 VIII TpApSxSm
pUK2315 2 VIII TpApSxSm
pUK2343 1 VIII TpApSxSm
pUK2344 1 VIII TpApSxSm
pUK2345 1 VIII TpApSxSm
pUK2350 1 VIII TpApSxSm
pUK2352 1 VIII TpApSxSm
pUK2362 1 VIII/V TpApSxSm
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The plasmids which hybridised to the probe for the type V DHFR gene are listed in
table 3.10. Ubiquitous plasmids carrying the type V DHFR gene were less prevalent in
this group of plasmids than those associated with the type lb and VIII DHFR genes.
All the plasmids except one carried resistance to sulphamethoxazole. Resistance
determinants associated with these plasmids were: tetracycline, (four plasmids),
ampicillin, (four plasmids) and streptomycin (three plasmids). The integrase gene of
Tn2i was associated with 60% (15/25) of these plasmids. None of the plasmids which
conferred resistance to ampicillin or streptomycin were associated with the integrase
gene of Tn27.
Table 3.10. Plasmids which hybridised to the probe for the type V DHFR gene,
their resistance profile, and their association with In21.
Plasmid Isolates DHFR In21 Antibiogram
pUK2326 1 V + Tp
pUK2307 5 V - TpSx
pUK2308 4 V + TpSx
pUK2310 3 V + TpSx
pUK2309 2 V + TpSx
pUK2338 1 V + TpSx
pUK2325 1 V + TpSx
pUK2323 1 V + TpSx
pUK2340 1 V + TpTcSx
pUK2339 1 V + TpTcSx
pUK2356 1 V - TpApSx
pUK2362 1 V/VIII - TpApSxSm
pUK2374 1 V - TpTcApSxSm
pUK2368 1 V - TpTcApCzSxSm
not determined* 1 V - TpSxf
*No restriction pattern was obtained because more than one plasmid was present in
the transconjugant. f Antibiogram of the transconjugant.
Results 78
As shown in table 3.11, all eleven plasmids which hybridised to the probe for the type
la DHFR elaborated a different restriction profile. Only three of these plasmids
conferred resistance to sulphonamides one of which was associated with the integrase
gene of Tn27.
Table 3.11. Plasmids which hybridised to the probe for the type la DHFR gene,
their resistance profile, and their association with In21.
Plasmid Isolates DHFR In21 Antibiogram
pUK2336 1 la Tp
pUK2337 1 la TpSmSp
pUK2329 1 la TpSmSp
pUK2334 1 la TpSmSp
pUK2408 1 la TpSmSp
pUK2353 1 la TpAp
pUK2405 1 la TpAp
pUK2355 1 la TpAp
pUK2349 1 la TpApSxSm
pUK2346 1 la TpApSxSp
PUK2364 1 la + TpApSxSmSp
Of the five transconjugants which hybridised to the type VII DHFR probe, two
harboured more than one plasmid and, as a result no restriction profiles could be
obtained for these isolates. The remaining three transconjugants had unique restriction
profiles. The resistance markers harboured by these transconjugants are shown in
table 3.12. All of these plasmids hybridised to the probe for the integrase gene of
Tn27.
Only one transconjugant harbouring plasmid pUK2316 hybridised to the type XII
DHFR probe. This plasmid conferred resistance to trimethoprim, streptomycin and
spectinomycin, and hybridised with the probe for the integrase gene of Tn2i.
Results 79
Table 3.12. Plasmids which hybridised to the probe for the type VII DHFR
gene, their resistance profile, and their association with In21.
Plasmid Isolates DHFR In21 Antibiogram
pUK2405 1 VII + TpApSx
pUK2382 1 VII + TpApTcSxSm
pUK2402 1 VII + TpApTcSxSmCm
not determined* 2 VII + TpApTcSxSmf
*No restriction patterns was obtained because more than one plasmid was present in
the transconjugants. t Antibiogram of the transconjugants.
The association of the resistant DHFRs with the minimum inhibitory concentrations of
trimethoprim expressed by the transconjugants is shown in table 3.13. The
transconjugants which hybridised to probes for the DHFRs type la, lb, V, VII and XII
were all resistant to high concentrations of trimethoprim (MIC > 1024mg/l). Of the
transconjugants which hybridised to the type VIII DHFR probe, 62% (28/45)
conferred resistance to intermediate concentrations of trimethoprim (MIC<1024mg/l).
All the transconjugants which did not hybridise to any of the DHFR probes were
resistant to high concentrations of trimethoprim (MIC > 1024mg/l), the majority of
which (87%) were resistant to >2048mg/l of trimethoprim.
Table 3.13. Trimethoprim MIC for each DHFR type.
Trimethoprim MIC (mg/1)
DHFR >2048 2048 1024 516 256 128
Type la 9 1 1 - - -
Type lb 18 29 11 - - -
Type VIII 1 7 9 17 10 1
Type V 15 9 1 - - -
Type VII 2 1 2 - - -
Type XII 1 - - - - -
No hybridisation 45 6 1 - - -
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3.7.2 Prevalence of non-transferable DHFRs
Of the 357 isolates of trimethoprim-resistant Gram-negative commensal faecal flora,
resistance was transferable to a recipient strain E. coli J62 in a liquid mating in 196
(55%) of the isolates. Total DNA from the 161 (45.1%) isolates, which did not
transfer their resistance to a recipient strain, was probed for the presence of the types
la, lb, lib, lie, Ilia, V, VI, VII, VIII, IX, X and XII DHFR genes. The frequency of
hybridisation of the DHFR gene probes to the isolates which did not transfer
trimethoprim resistance by conjugation to an E. coli J62 recipient strain, is shown in
table 3.14.
Table 3.14. Frequency of resistant DHFRs in isolates which did not transfer
trimethoprim resistance to an E. coli J62 recipient
DHFR No. of isolates (%) % of total isolates
Type la 41 (25.5) 11.5
Type lb 20(12.4) 5.6
Type nb/IIc 0 0
Type Ilia 0 0
Type Illc/Vm 2(1.2) 0.6
Type V 3(1.9) 0.8
Type VI 0 0
Type VII 62 (38.5) 17.4
Type IX 0 0
Type X 0 0
Type XE 0 0
No hybridisation 38 (23.6) 10.6
Total 161 45%
Of the isolates which did not transfer their resistance, the most prevalent DHFR type
was the type VII which occurred in 38.5% (62/161) of the isolates. The second most
prevalent DHFR was the type la 25.4% (41/161), followed by the type lb 12.4%
(20/161), the type V, three isolates and the VIII, two isolates. The species distribution
of the isolates, which hybridised to each probe is shown in table 3.15. The type la
DHFR probe hybridised to DNA from the widest range of different species. These
included E. coli, Klebsiella spp., Enterobacter spp., Citrobacter freundii and Proteus
vulgaris. Five isolates hybridised to more than one DHFR probe, four of which
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hybridised to both the type la and VII DHFR probes and one isolate to the types la
and VIII DHFR probes. Sinee there was no cross hybridisation with the control
strains, one possibility is that two resistant DHFR genes are present in these isolates.
None of the isolates hybridised to the probes for the types II, Ilia, VI, IX and XII
DHFR genes. Thirty-eight isolates did not hybridise to any of the DHFR probes.
Table 3.15. Frequency of non-transferable DHFRs and the organism of origin.
DHFR Hybridisation (%) Species





Type lb 20(12.4) E. coli (14)
Klebsiella sp (6)
Type V 3(1.9) E. coli (1)
Klebsiella sp (2)
Type VII 62 (38.5) E. coli (57)
Klebsiella sp (3)
Enterobacter sp (2)
Type VIII 1 (0.6) Citrobacter freundii (1)





Of the isolates which hybridised to the type la probe, four also hybridised with the
type VII probe and one hybridised with the type VIII probe.
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3.7.3 Genetic location of non-transferable resistant DHFRs
To determine the genetic location of the resistant DHFR genes, representative isolates
carrying each DHFR type were randomly selected. Plasmid and total DNA from each
isolate was separated on a 0.8% agarose gel, Southern blotted and probed to
determine the genetic location of the DHFR gene. The type VII DHFR gene was
found located on the chromosome in all the isolates tested (n=9). Figure 3.4 shows
the agarose gel and the Southern blot of seven of these isolates. Sixteen isolates
harbouring a non-transferable type VII DHFR gene including these nine isolates were
further analysed by Southern blotting a BamWl restriction of the chromosomal DNA
and probing it with oligonucleotide probes for the type VII DHFR (Figure 3.5) and
the integrase gene of Tn2i (results not shown). For each isolate both probes
hybridised to fragments of the same size. This suggests that in these isolates, the
DHFR gene was located within an integron which is integrated into the chromosome
of the host bacterium.
Results 83
A
^12 345 6 7
X VII P ip TP TPT PTTPT P
Figure 3.4. (A) 0.8% Agarose gel of plasmid and total DNA preparations from
seven isolates which hybridised to the probe for the type VII DHFR. (B)
Southern blot showing the chromosomal location of the type VII DHFR gene.
X-Hind III restricted X DNA; VH-PIasmid pLM0226 control; P-Plasmid DNA;
T-Total DNA.
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Figure 3.5. (A) 1% Agarose gel of restricted total DNA preparations from
isolates which hybridised to the probe for the type VII DHFR. (B) Southern blot
showing the fragment sizes which hybridised to the type VII DHFR probe.
Lane 1, Hind III restricted X DNA; Lane 2, BamH I restricted pLM0226
control DNA; Lanes 3-18, BamH I restricted total DNA from isolates which
hybridised to the type VII DHFR probe; 19, EcoR I restricted pLM0226
control DNA.
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Plasmid and chromosomal DNA from nine isolates which hybridised to the type la
DHFR probe, but could not transfer resistance, were selected for Southern
hybridisation. The chromosomal DNA probed positive in eight out of nine isolates
which hybridised to the type la DHFR probe (Figure 3.6). In the remaining isolate the
type la DHFR was located on a plasmid. Since the electrophoretic mobility of this
plasmid is similar to that of the chromosomal DNA, it cannot be accurately
determined whether the DHFR might also be located on the chromosome. A Southern
blot of £coRI restricted chromosomal DNA from these isolates revealed a number of
fragments of variable size which hybridised to the type la DHFR probe (Figure 3.7).
The probe for the integrase gene of Tn7 hybridised to fragments of the same size in all
of the chromosomal mediated dhfrla bearing isolates (results not shown). The plasmid
carrying the type la DHFR gene probed positive for the integrase gene of Tn21 (Table
3.16). Attempts to mobilise this plasmid into a restriction endonuclease deficient
recipient (E. coli K802) in a filter mating at 22°C and 37°C were not successful.
Southern hybridisations of plasmid and total DNA from seven isolates that probed
positive for the type lb DHFR gene revealed that the type lb DHFR gene in these
isolates was plasmid mediated (Figure 3.8). A small 9kb plasmid was present in five
out of seven of these isolates. The two larger plasmids hybridised to the integrase
gene of Tn27 (results not shown). All three isolates which hybridised to the type V
DHFR probe were found to be plasmid-mediated (Figure 3.9) and hybridised with the
integrase gene of Tn27 (results not shown). None of these plasmids bearing the type
lb and V DHFR genes could be mobilised into E. coli K802 in a filter mating at 22°C
and 37°C.
Table 3.16. Genetic location of DHFR genes and associated integrase genes.
DHFR (n) Location of DHFR Associated transposon
Type la 9 Chromosome (8) Tn7 (8)
Plasmid (1) Tn2/(1)
Type lb 7 Plasmid (7) Tn27(2)
Type V 3 Plasmid (3) Tn27 (3)
Type VII 9 Chromosome (9) Tn27 (9)
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Figure 3.6. (A) 0.8% Agarose gel of plasmid and total DNA preparations from
nine isolates which hybridised to the probe for the type la DHFR. (B) Southern
blot showing the plasmid and chromosomal location of the type la DHFR gene.




Figure 3.7. (A) 1% Agarose gel of restricted total DNA preparations from eight
isolates which hybridised to the probe for the type la DHFR. (B) Southern blot
showing the fragment sizes which hybridised to the type la DHFR probe.
Lane 1: Hind III restricted A, DNA. Lane 2: EcoR I restricted pFE506 control
DNA. Lanes 3-10: £c«R I restricted total DNA from eight isolates which
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Figure 3.8. (A) 0.8% Agarose gel of plasmid and total DNA preparations from
seven isolates which hybridised to the probe for the type lb DHFR. (B)
Southern blot showing the plasmid location of the type lb DHFR gene.
X-Hind III restricted X DNA; Ib-Plasmid pUK163 control; P-Plasmid DNA;
T-Total DNA.
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Figure 3.9. (A) 0.8% Agarose gel of plasmid and total DNA preparations from
three isolates which hybridised to the probe for the type V DHFR. (B) Southern
blot showing the plasmid location of the type V DHFR gene. P-Plasmid DNA;
T-Total DNA; V-Plasmid pLMO20 control.
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3.8 Detection of a novel trimethoprim resistance determinant
The plasmids which did not hybridise to any of the probes for the resistant DHFR
genes were sorted according to their restriction profiles and resistance markers
(Table 3.17). Only three plasmids occurred in two or more transconjugants. Of these
plasmids, the most frequently isolated was pUK2317 which occurred in six isolates of
Klebsiella spp., all isolated from a creche in SOWETO. Plasmid pUK2378 was
isolated from two different urban populations, and both isolates carrying pUK2399
were isolated from rural adults.
Despite the lack of geographically ubiquitous plasmids harbouring the unknown
resistant DHFR genes, many of these plasmids shared identical antimicrobial
resistance profiles. The restriction profiles of some of these plasmids elaborated
several restriction fragments of similar molecular weight indicating that some
homology existed between some of the plasmids. Two groups emerged from these
comparisons. The largest group comprised twelve plasmids which conferred
resistance to trimethoprim, tetracycline, ampicillin, sulphonamides, streptomycin,
spectinomycin and chloramphenicol but did not hybridise to the probe for the
integrase gene of Tn2i. The restriction profiles of eight of these plasmids (pUK2384,
pUK2385, pUK2387, pUK2388, pUK2392, pUK2394, pUK2395 and pUK2396)
shared some homology (Figure 3.10). Two plasmids, pUK2386 and pUK2389 of this
resistance group also shared a few restriction fragments similar molecular weight
(Figure 3.10).
The second group of six plasmids hybridised to the probe for the integrase gene of
Tn27 and conferred resistance to trimethoprim, tetracycline, ampicillin,
sulphonamides, streptomycin and spectinomycin. The plasmids pUK2378, pUK2380
and pUK2381 from this group shared several restriction fragments of similar
molecular weight and are shown in figure 3.10. Plasmid pUK2385 from the first
group and plasmid pUK2381 from the second group were selected for cloning and
further study.
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Table 3.17. Plasmids conferring unknown trimethoprim-resistant DHFRs, their
resistance profile, and their association with In21.
Plasmid Isolates In21 Antibiogram
pUK2326 1 - Tp
pUK2322 1 - TpSx
pUK2342 1 - TpSx
pUK2363 1 - TpSxSp
pUK2341 1 - TpSmSp
pUK2328 1 + TpTcSp
pUK2317 6 - TpTcSxSp
pUK2335 1 - TpTcGmSx
pUK2369 1 - TpTcApSxSp
pUK2370 1 - TpTcApSxSp
pUK2403 1 - TpTcApStSp
pUK2367 1 + TpApSxSmSp
pUK2365 1 - TpApSxSmSp
pUK2371 1 + TpTcApSxSm
pUK2372 1 - TpTcApSxSm
pUK2373 1 + TpTcApSxSm
pUK2361 1 + TpApSxSmSpCm
pUK2376 1 - TpTcApSxSmSp
pUK2375 1 + TpTcApSxSmSp
pUK2378 2 + TpTcApSxSmSp
pUK2379 1 + TpTcApSxSmSp
pUK2380 1 + TpTcApSxSmSp
pUK2381 1 + TpTcApSxSmSp
pUK2383 1 - TpTcApSxStCm
pUK2384 1 - TpTcApSxSmSpCm
pUK2385 1 - TpTcApSxSmSpCm
pUK2404 1 - TpTcApSxSmSpCm
pUK2387 1 - TpTcApSxSmSpCm
pUK2388 1 - TpTcApSxSmSpCm
pUK2395 1 - TpTcApSxSmSpCm
pUK2396 1 - TpTcApSxSmSpCm
pUK2391 1 + TpTcApSxSmSpCm
pUK2392 1 - TpTcApSxSmSpCm
pUK2394 1 - TpTcApSxSmSpCm
pUK2386 1 - TpTcApSxSmSpCm
pUK2389 1 - TpTcApSxSmSpCm
pUK2390 1 - TpTcApSxSmSpCm
pUK2397 1 - TpTcApGmSxSmStSpCm
pUK2398 1 - TpTcApGmTnCazSxSmStSpCm
pUK2399 2 - TpTcApGmTnCazCtxSxSmStSpCm
not determined 1 + TpTcApSxCm
not determined 1 - TpApSxSmCm
not determined 1 - TpTcApSxSmSpCm
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Figure 3.10. A 0.8% agarose gel showing the JEcoRI restriction profiles of
plasmids which harbour unknown DHFR genes. Lane 1: Hindlll restricted A,
DNA. Lane 2: pUK2378. Lane 3: pUK2380. Lane 4: pUK2381. Lane 5:
pUK2384. Lane 6: pUK2385. Lane 7: pUK2387. Lane 8: pUK2388. Lane 9:
pUK2392. Lane 10: pUK2394. Lane 11: pUK2395. Lane 12: pUK2396. Lane 13:
pUK2386. Lane 14: pUK2389. Lane 15: Hindlll restricted A. DNA.
Results 93
3.8.1 Cloning the DHFR
Purified DNA of pUK2385 and pUK2381 was restricted with Pstl, BamHl, and
ZscoRI and ligated into appropriately restricted pUC18. No resistan' clones were
derived from pUK2385 after complete digesdon with any of these restriction
enzymes. The trimethoprim-resistant DHFR of the 70kb plasmid pUK2381 as
determined by the cumulative sizes of the restricted fragments, could be cloned into
pUC18 either as a 3.3kb BamHl fragment, or as a 4.5kb Pstl fragment. The
restriction map of the 3.3kb BamHl fragment of pUK2381 which expressed a
resistant DHFR gene that was cloned into pUC18 (pUK2408) is shown in figure 3.11.
Plasmid pUK2408 was restricted with EcoRl, and the large fragment was religated to
produce pUK2409. The subsequent cloning strategy used to produce the 1225-bp
PvulVHincll fragment from pUK2409 that was sub-cloned into the Smal site of
pUC18 to produce plasmid pUK2410 is shown in figure 3.11.
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Figure 3.11. The restriction map of the 3.3kb BamHI fragment of pUK2381 and
the strategy of cloning plasmids pUK2408, pUK2409 and pUK2410.
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3.8.2 Nucleotide Sequence
The nucleotide sequence of the novel DHFR was determined from plasmid pUK2410.
Figure 3.12 shows the direction of sequencing of the cloned fragment by primer
















" Ml3 Reverse primer
■ Reverse priiner number 2: nucleotide 145-163
" Forward primer, Tn21 probe: nucleotide 513-534
Forward primer number 3: nucleotide 843-62
Forward primer number 2: nucleotide 1067-87
-40 M13 forward primer
Figure 3.12 The direction of sequencing of the 1225-bp Pvull/Hincll fragment of
pUK2381.
Table 3.18. Oligonucleotide primers used in sequencing reactions.
Primer Nucleotides Oligonucleotide sequence
Reverse #2 145-163 5'-CGTTCCATACAGAAGCTGG-3'
Forward #4 513-534 5'-GTCAAGGTTCTGGACCAGTTGC-3'
Forward # 3 843-862 5-CCATAACGACCACTTTGCTC-3'
Forward #2 1067-1087 5'-GTACCTCAGATAGAAAGACG-3'
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The nucleotide sequence of the cloned section of pUK2410 was compared with all the
bacterial DNA sequences in the GenBank and EMBL databases. The region from
nucleotide 0 to 573 was identical to that of the first 191 amino acids of the open
reading frame of the integrase gene of Tn27 and other Tn2/-like-transposons such as
those carrying the resistance genes dhfrV (Sundstrom et al 1988), dhfrXII (Heikkila et
al 1993), OXA-2 borne on R46 (Hall and Vockler 1987), dhfrVII borne on Tn5086
(Sundstrom et al 1993) and InO from pVSl (Bissonnette and Roy 1992).
Downstream of the In21 ORF was a 498-bp ORF potentially encoding a polypeptide
of 165 amino acids. The start of the ORF began with an ATG start codon at positions
718-720 (Figure 3.13). The ORF terminated with a TAA stop codon (positions 1213
to 1215, figure 3.13). The ORF showed a high degree of homology (85%) the
nucleotide sequence of the type XII DHFR (Singh et al 1992b; Heikkila et al 1993.
The upward arrow in figure 3.13 marks the sequence (GTTPuPu) a few bases
upstream of the DHFR ATG start codon, and indicates the point of site-specific-
insertion of the DHFR gene cassette at the end of the integron specific sequence. The
135-bp region from nucleotide 573-708 that occurs between the integrase ORF and
the novel DHFR gene cassette was almost identical to the integron specific sequences
of Tn2/-like elements located upstream of resistance genes located in a cassette-like
manner within an integron. These identical sequences contain the site for integration
of resistance gene cassettes, the promoter for these cassettes, and the start of the
integrase gene.
Figure 3.13. (Following Page) Nucleotide sequence of dhfrXIII and the upstream
flanking region of the int gene of Tn27. The vertical arrow indicates the
GTTPuPu sequence which occurs at the beginning of the dhfrXIII cassette.
Asterisk denotes stop codon.
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Pvu n
CTGCTCGCGC AGGCTGGGTG CCAAGCTCTC GGGTAACATC AAGGCCCGAT 50
CCTTGGAGCC CTTGCCCTCC CGCACGATGA TCGTGCCGTG ATCGAAATCC 100
AGATCCTTGA CCCGCAGTTG CAAACCCTCA CTGATCCGCA TGCCCGTTCC 150
ATACAGAAGC TGGGCGAACA AACGATGCTC GCCTTCCAGA AAACCGAGGA 200
TGCGAACCAC TTCATCCGGG GTCAGCACCA CCGGCAAGCG CCGCGACGGC 250
CGAGGTCTTC CGATCTCCTG AAGCCAGGGC AGATCCGTGC ACAGCACCTT 300
GCCGTAGAAG AACAGCAAGG CCGCCAATGC CTGACGATGC GTGGAGACCG 350
AAACCTTGCG CTCGTTCGCC AGCCAGGACA GAAATGCCTC GACTTCGCTG 400
CTGCCCAAGG TTGCCGGGTG ACGCACACCG TGGAAACGGA TGAAGGCACG 450
AACCCAGTGG ACATAAGCCT GTTCGGTTCG TAAGCTGTAA TGCAAGTAGC 500
GTATGCGCTC ACGCAACTGG TCCAGAACCT TGACCGAACG CAGCGGTGGT 550
AACGGCGCAG TGGCGGTTTT^CATCGCTTGT TATGACTGTT TTTTTGTACA 600
GTCTATGCCT CGGGCATCCA AGCAGCAAGC GCGTTACGCC GTGGGTCGAT 650
GTTTGATGTT ATGGAGCAGC AACGATGTTA CGCAGCAGGG CAGTCGCCCT 700
AAAACAAAGT TAGCCGT ATG AAC CCG GAA TCG GTC CGC ATT TAT 744
T Met Asn Pro Glu Ser Val Arg lie Tyr 9
CTG GTC GCT GCC ATG GGT GCC AAT CGG GTT ATT GGC AAT GGT 786
Leu Val Ala Ala Met Gly Ala Asn Arg Val lie Gly Asn Gly 23
CCC GAT ATC CCC TGG AAA ATC CCA GGT GAG CAG AAG ATT TTT 828
Pro Asp lie Pro Trp Lys lie Pro Gly Glu Gin Lys lie Phe 37
CGC AGG CTC ACC GAG AGC AAA GTG GTC GTT ATG GGC CGC AAG 870
Arg Arg Leu Thr Glu Ser Lys Val Val Val Met Gly Arg Lys 51
ACA TTT GAG TCC ATA GGC AAG CCC TTA CCA AAC CGC CAC ACA 912
Thr Phe Glu Ser lie Gly Lys Pro Leu Pro Asn Arg His Thr 65
GTG GTG CTC TCG CGC CAA GCT GGT TAT AGC GCT CCT GGT TGT 954
Val Val Leu Ser Arg Gin Ala Gly Tyr Ser Ala Pro Gly Cys 79
GCA GTT GTT TCA ACG CTG TCA CAC GTA TCG CCA TCG ACA GCC 996
Ala Val Val Ser Thr Leu Ser His Val Ser Pro Ser Thr Ala 93
GAA CAC GGC AAA GAA CTC TAC GTA GCG CGC GGA GCC GAG GTA 1038
Glu His Gly Lys Glu Leu Tyr Val Ala Arg Gly Ala Glu Val 107
TAT GCG CTG GCG CTA CCG CAT GCC AAC GGC GTC TTT CTA TCT 1080
Tyr Ala Leu Ala Leu Pro His Ala Asn Gly Val Phe Leu Ser 121
GAG GTA CAT CAA ACC TTT GAG GGT GAC GCC TTC TTC CCA GTG 1122
Glu Val His Gin Thr Phe Glu Gly Asp Ala Phe Phe Pro Val 134
CTT AAC GCA GCA GAA TTC GAG GTT GTC TCA TCC GAA ACC ATT 1164
Leu Asn Ala Ala Glu Phe Glu Val Val Ser Ser Glu Thr lie 149
CAA GGC ACA ATC ACG TAC ACG CAC TCC GTC TAT GCG CGT CGT 1206
Gin Gly Thr lie Thr Tyr Thr His Ser Val Tyr Ala Arg Arg 163
AAC GGC TAA CAAGTCCGTC




The translated polypeptide for the DHFR is shown in figure 3.13. The novel DHFR
gene has been tentatively named dhfrXIII and the encoded polypeptide, the type XIII
DHFR (EBML accession number Z50802 ECIN1DHFR). The amino acid sequence
was compared with the sequence of all the other amino acid sequences in the
SwissProt database. The 31 best scores were all DHFR genes. The amino acid
sequence of the type XIII DHFR shared the highest identity with the type XII DHFR
(82.4%). With the exception of the type XII DHFR, homology between the type XIII
DHFR and the other DHFRs ranged between 15 and 36%.
3.9 Biochemical properties of the type XIII DHFR
3.9.1 Specific DHFR activity
The specific DHFR activity of crude protein extracts from, the wild-type E. coli
isolate RA33-2 which harboured plasmid pUK2381 that expresses dhfrXIII, the
corresponding J62-2 transconjugant; the pUC18 clone of dhfrXIII (pUK2410) and the
plasmid host strains E. coli J62-2 and HB101 are shown in table 3.19.
Table 3.19. Specific activity of the strains harbouring the type XII DHFR.
Host strain Plasmid Specific activity *
E. coli J62-2 - 1.40
E. coli HB101 - 0.88
E. coli RA33-2 pUK2381 4.04
E. coli J62-2 pUK2381 2.79
E. coli HB101 PUK2410 30.07
* Specific activity expressed as nmol DHF reduced /min/mg protein.
As a result of the expression of pUK2381 encoded dhfrXIII, the increase in the
specific DHFR activity produced by the resistant DHFR in the transconjugant was
equivalent to that produced by the J62-2 host chromosomal DHFR. As a result of the
high copy number of pUC18 the pUK2410 clone of dhfrXIII produced an
approximately thirty-four-fold increase in the specific DHFR activity in comparison to
the E. coli HB101 host chromosomal DHFR.
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3.9.2 Sephadex gel-exclusion chromatography
The crude protein extract of HB101 harbouring pUK2410 was precipitated by
ammonium sulphate saturation. The 50-80% saturated fraction contained most of the
DHFR activity, and was virtually free of NADPH oxidase activity. This traction was
dialysed and applied to a Sephadex G75 column. Figure 3.14 shows the OD2g0 of the
fractions of the molecular weight standards and the DHFR activity of the eluted























Molecular weight standard -+-DHFR Activity
Figure 3.14. The OD28o of the fractions of the molecular weight standards and
the change in OD^q of the eluted sample.
The peak fractions of the molecular weight standards and the peak DHFR activity was
plotted on a graph (Figure 3.15) and from the graph, the molecular weight of the type
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Figure 3.15. Estimation of molecular weight of the type XIII DHFR.
3.9.3 Drug inhibition
The activity of the type XIII DHFR was assayed in the presence of increasing
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Figure 3.16. The percentage activity of partially purified type XIII DHFR (■)
and the chromosomal DHFR from E. coli (HB101) (A) in the presence of
increasing concentrations of trimethoprim.
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The concentration of trimethoprim required to inhibit the activity of the type XIII
DHFR by 50% (ID50) was extremely high (800|iM) and in comparison to the
chromosomal DHFR of E. coli (HB101) (ID5o=0.007|iM) the type XIII DHFR was
more than 100 OOOx more resistant to trimethoprim. The type XIII DHFR was 1 700x
more resistant to inhibition by methotrexate (ID5o=5pM) than the chromosomal
DHFR of E. coli (HB101) (ID5o=0.003|iM). However, the ID5q for methotrexate
was low enough to suggest that the binding site of dihydrofolate was not dissimilar to
that of other DHFR genes.
log [Mtx] (M)
Figure 3.17. The percentage activity of partially purified type XIII DHFR (■)
and the chromosomal DHFR from E. coli (HB101) (A) in the presence of
increasing concentrations ofmethotrexate.
3.9.4 Temperature sensitivity
The loss of DHFR activity of the type XIII DHFR as a result of exposure to 45°C is




Figure 3.18. Temperature inhibition of the type XIII DHFR at 45°C.
3.9.5 Michaelis and trimethoprim inhibition constant
The Lineweaver-Burke plots used to determine the Michaelis constant and the
inhibitor constant for trimethoprim are shown in figure 3.19.
Figure 3.19. Lineweaver-Burke plots: the reciprocal of the dihydrofolate
concentration (1/[S]) is plotted against the reciprocal of the rate of DHFR
activity (1/V) in the presence and absence of trimethoprim. (A) No
trimethoprim. (•)250|iM trimethoprim. (■) 500|iM trimethoprim.
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From the intercepts on the X-axis of the plots (the most wayward point of each series
was ignored), the K,„ for the type XIII DHFR was calculated as (l/-0.03)=33.3|iM
DHF. The apparent K,„ values in the presence of trimethoprim (Kp) were (1/-
0.0125)=80(iM and (l/-0.008)=125|iM at trimethoprim concentrations of 250p.M and
500|iM respectively. From the equation in 2.12.4 the K, values at these trimethoprim
concentrations were 178(iM and 182|iM respectively (Mean K, =180|iM DHF).
3.10 Prevalence of the type XIII DHFR
3.10.1 Development of a dhfrXIII specific probe
The nucleotide sequences of the closely related DHFRs XII and XIII were aligned to
determine regions of maximum heterogeneity (Figure 3.20). The least homologous
region between these two genes (10-bp over a 23-bp stretch) occurred between
nucleotides 218 to 240. This region overlapped the region from which the
oligonucleotide probe for dhfrXII was selected (underlined in figure 3.20). A 30mer
oligonucleotide probe 5-AAGCTGGTTATAGCGCTCCTGGTTGTGCAG-3' from
the identical region from which the dhfrXII probe was derived was used as the probe
for dhfrXIII.
3.10.2 DNA hybridisation
Of the 90 isolates which did not hybridise to the probes for any of the DHFR genes,
50% (45/90) hybridised to the probe for the type XIII DHFR. Fifty-eight percent
(30/52) of self transmissible plasmids, hybridised to the probe for dhfrXIII. Of the
isolates which did not transfer trimethoprim resistance 39% (15/38) hybridised to the
probe for the type XIII DHFR. The plasmids which hybridised to the probe for the
type XIII DHFR are shown in table 3.20.
Multiple resistance was extremely prevalent amongst the plasmids which harboured
the type XIII DHFR. Most of these plasmids conferred resistance to five or more
antimicrobial agents. Resistance to ampicillin, tetracycline, sulphonamides and
streptomycin was virtually ubiquitous. Spectinomycin resistance occurred in (23/30)
of the plasmids, and resistance to chloramphenicol occurred in (17/30) of the
plasmids. Forty percent (12/30) of the isolates hybridised to a probe for the integrase
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gene of Tn27. With the exception of one isolate with an MIC of 2048 mg/1, the MICs
of trimethoprim conferred by these plasmids were greater than 2048 mg/1.
50
dhfrxiii ATGAACCCGGAATCGGTCCGCATTTATCTGGTCGCTGCCATGGGTGCCAA
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dhfrxii GCTGTAATTTCCGTACACCCACTCCGTTTATGCGCGCGAAACGGCTAA
Figure 3.20. The alignment of the nucleotide sequence of the types XII and XIII
DHFR genes: the underlined region shows the heterogeneous region from which
the oligonucleotide probes for the respective DHFR genes were selected.
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Table 3.20. Plasmids which hybridised to the probe for the type XIII DHFR
gene, their resistance profile, their association with In21 and the identity of the
plasmid donor.
Plasmid Plasmid donor Isolates In21 Antibiogram
pUK2328 Enterobacter spp. 1 + TpTcSp
pUK2367 E. coli 1 + TpApSxSmSp
pUK2365 Kluyvera spp. 1 - TpApSxSmSp
pUK2361 Klebsiella spp. 1 + TpApSxSmSpCm
pUK2371 E. coli 1 + TpTcApSxSm
pUK2372 E. coli 1 - TpTcApSxSm
pUK2373 E. coli 1 + TpTcApSxSm
pUK2376 E. coli 1 - TpTcApSxSmSp
pUK2375 E. coli 1 + TpTcApSxSmSp
pUK2378 E. coli 2 + TpTcApSxSmSp
pUK2379 E. coli 1 + TpTcApSxSmSp
pUK2380 E. coli 1 + TpTcApSxSmSp
pUK2381 E. coli 1 + TpTcApSxSmSp
pUK2384 E. coli 1 - TpTcApSxSmCm
pUK2385 E. coli 1 - TpTcApSxSmCm
pUK2404 Klebsiella spp. 1 - TpTcApSxSmSpCm
pUK2387 E. coli 1 - TpTcApSxSmSpCm
pUK2388 E. coli 1 - TpTcApSxSmSpCm
pUK2395 E. coli 1 - TpTcApSxSmSpCm
pUK2396 E. coli 1 - TpTcApSxSmSpCm
pUK2391 Klebsiella spp. 1 + TpTcApSxSmSpCm
pUK2392 E. coli 1 - TpTcApSxSmSpCm
pUK2394 E. coli 1 - TpTcApSxSmSpCm
pUK2386 E. coli 1 - TpTcApSxSmSpCm
pUK2389 E. coli 1 - TpTcApSxSmSpCm
pUK2390 E. coli 1 - TpTcApSxSmSpCm
not determined* E. coli 1 - TpApSxSmCmf
not determined* E. coli 1 + TpTcApSxCmf
not determined* E. coli 1 - TpTcApSxSmSpCmf
*No restriction patterns was obtained because more than one plasmid was present in
the transconjugant. f Antibiogram of the transconjugant.
Of the isolates which hybridised to the type XIII DHFR probe, but did not transfer
trimethoprim resistance, the majority were E. coli (11/15). The remaining isolates
were Klebsiella spp. (3/15) and Enterobacter spp. (1/15). All these isolates were
resistant to more than 2048 mg/1 of trimethoprim with exception of one E. coli
(MIC=2048mg/l) and one Enterobacter spp. (MIC=256 mg/1).
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4.0 DISCUSSION
"In the beginners mind there are many possibilities. In the experts mind there are
few."
Shunryu Suzuki - Zen Mind, Beginners Mind
The high incidence of trimethoprim resistance in Gram-negative commensal faecal
flora in South Africa (74%) is similar to that experienced in other developing
countries such as China (61%), Venezuela (64%) (Lester et al 1990), Bangladesh
(45%) (Mamun et al 1993) and India (98%) (Amyes et al 1992a). This has challenged
a number of theories which relate to our understanding of the reasons for the high
levels of resistance in commensal faecal organisms in developing countries. For
instance, South Africa is fairly unique amongst developing countries in that there is no
'over the counter' policy for the sale and distribution of antimicrobial agents and, as a
result, the abuse of these agents that is associated with this phenomena is restricted.
This suggests that 'over the counter' policies play a minor role in encouraging the
development of resistance in a population. Since the water supply in South African
populations studied was not contaminated with resistant organisms, it appears that
this is not a major contributing factor towards the spread of resistant organisms as
suggested by Young (1993). The single common factor shared between the
developing countries studied, is a low standard of living which is usually associated
with overcrowding, poor sanitation and a low standard of personal hygiene. This is
supported by work by Reves et al (1990), who has shown that overcrowding, and the
low levels of hygiene associated with infants attending day care centres were major
factors contributing to the spread of resistant organisms. Ignorance concerning the
use of antimicrobials is a factor not restricted to developing countries.
The Gram-negative aerobic bacilli commonly found in stool specimens of healthy
individuals are Escherichia coli, Klebsiella, Enterobacter, Citrobacter, Proteus and
Pseudomonas species (Jawetz et al 1982). In this study, trimethoprim resistance was
recorded in all the above species as well as Klyvera spp. and Shigella sonnei isolates.
The high incidence of resistance associated with these organisms is of great concern
since these organisms are often implicated as the source of infection in urinary tract,
enteric and other opportunistic infections (Brumfitt et al 1971; Bettelheim et al 1971).
The relationship between the incidence of resistance in commensal flora and clinical
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isolates is reflected in a number of studies. In developed countries, the incidence of
trimethoprim resistance in hospital isolates ranges from 5-20% (Brumfitt et al 1983;
Maskell 1983; Mayer et al 1985; Kraft et al 1985; Huovinen and Toivanen 1986;
Towner and Slack 1986; Heikkila et al 1990a; Harnett 1992a) and likewise, the
corresponding figure for commensal flora is similar 3-25% (Bonten et al 1990, Levy
et al 1988; Shanahan et al 1994). In developing countries a similar relationship exists
between the incidence of resistance in commensal flora and clinical isolates; in South
India 64% of Gram-negative bacteria isolated from urinary infections were resistant to
trimethoprim (Young et al 1986b) and, in the same study area, faecal carriage of
resistant commensal organisms was ubiquitous (Amyes et al 1992a). In South Africa
the incidence of trimethoprim resistance is lower than in South India; however a
similar relationship exists, with 38%, 53% and 60% resistance being recorded in
clinical isolates from three different centres (Wylie and Koornhof 1989) compared
with 74% resistance in commensal faecal isolates.
The incidence of resistance associated with trimethoprim resistance in commensal and
clinical isolates and their plasmids from various studies is shown in table 4.1. In South
African faecal isolates and plasmids, chloramphenicol and gentamicin resistance
associated with trimethoprim resistance occurred less frequently than in any of the
other surveys of clinical and commensal isolates from both developed and developing
countries. The incidence of resistance to ampicillin, tetracycline, streptomycin and
chloramphenicol, associated with trimethoprim in plasmids isolated from faecal
isolates, was lower in South Africa than in South India. In contrast, sulphonamide and
spectinomycin resistance co-transferred on plasmids more frequently in the South
African isolates. The relationship between the associated resistance factors of faecal
and urinary isolates in the Indian isolates was similar, with a slightly higher incidence
of resistance in the clinical isolates. This pattern differed in Nigeria, where associated
resistance was more prevalent in plasmids from diarrhoeal isolates than urinary
isolates. In South Africa, this relationship cannot be determined since there are no
published data available for the incidence of resistance associated with trimethoprim
resistance in clinical isolates from South Africa. Furthermore comparisons are difficult
to make since the break-points/ disc concentrations and media employed in the testing
differed between the studies.
A further concern regarding the high prevalence of trimethoprim and associated
resistance factors in commensal flora is the potential for the horizontal spread of these
resistance factors between members of the Enterobacteriaceae including potential
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Table 4.1. Resistance associated with trimethoprim resistance in isolates of
commensal and pathogenic organisms and their plasmids.
% Resistance
Country, year Isolates Sx Tc Ap Sm Sp Gm Cm Reference
Developed countries
Ontario, Canada 1990 E. coli UTI 100 83 87 - - - 43 Harnett (1992a)
London, UK 1978-79 Clinical plasmids 48 28 60 59 - - 32 Towner et al (1980)
Paris, France 1981-84 UTI plasmids 94 - 75- 75- - - 65- Papadopoulou et al
90 90 80 (1986)
Athens, Greece 1989 UTI Plasmids 44 57 47 23 20 20 39 Tsakris et al (1991)
Developing countries
Mexico, 1981 Faecal E. coli 88 90 80 94 - - 52 Murray et al (1982)
Chile, 1983 E. coli UTI 100 53 88 100 - 6 69 Murray et al (1985)
Chile, 1983 E. coli UTI, Plasmids 100 0 71 100 - 0 29 Murray et al (1985)
Chile, 1983-84 Enterobacteria 71 82 72 47 - 71 82 Urbina et al (1989)
Plasmids
Bangkok,Thailand, 1984 E. coli UTI 95 93 85 97 - 18 77 Murray et al (1985)
Bangkok,Thailand, 1984 E. coli UTI, Plasmids 75 50 50 75 - 0 50 Murray et al (1985)
Nigeria, 1987 Hospital UTIs 100 72 86 69 46 21 62 Lamikanra and Ndep
(1989)
Nigeria, 1987 Hospital UTI, 63 18 47 35 16 13 39 Lamikanra and Ndep
Plasmids (1989)
Nigeria, 1988 E. coli diarrhoea 85 91 60 66 78 82 70 Lamikanra et al (1990)
Plasmids
South India, 1984 un 99 96 98 100 45 55 85 Young et al (1986b)
South India, 1984 UTI, Plasmids 84 43 76 71 41 43 47 Young et al (1986b)
South India, 1990 Faecal flora 95 92 77 97 38 - 60 Tait and Amyes (1994)
South India, 1990 Faecal, Plasmids 58 67 70 72 22 - 19 Tait and Amyes (1994)
South Africa, 1992 Faecal flora - 88 72 - - 3.1 - This Study
South Africa, 1992 Faecal, Plasmids 91 30 56 48 24 2.6 12 This Study
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pathogens such as Salmonella spp., Shigella spp. and enteropathogenic E. coli. In the
isolates studied, the frequency of transfer of trimethoprim resistance by conjugation
(55%) occurred within the normal range of 35-75% demonstrated in several studies of
clinical and commensal isolates of Enterobacteriaceae (Chugh 1985; Young et al
1986b; Urbina et al 1989; Lamikanra and Ndep 1989; Lamikanra et al 1990; Isakris
et al 1991; Harnett 1992a). Of the 107 different plasmid restriction profiles that were
demonstrated in the transconjugants, seven plasmids occurred in more than one
species of Enterobacteria suggesting that horizontal transfer of plasmids conferring
trimethoprim resistance occurs between different commensal species. Furthermore,
two of these plasmids occurred in both E. coli and potentially pathogenic S. sonnei
isolates. Although there is no evidence to determine in which species these plasmids
originally evolved, the high prevalence of these two plasmids in the commensal flora
(26/357 and 15/357) suggests that these plasmids may have evolved and dispersed in
the commensal flora and then spread to the S. sonnei isolates. The presence of these
plasmids reinforce the importance of the commensal flora as a reservoir of resistance
genes.
The advantage of studying commensal faecal flora is that one can obtain a broader
sample of the gene pool of resistant organisms, since the collection of clinical isolates
is often associated with a number of biases. For example, sporadic outbreaks of
infection caused by one particular organism as described by Barg et al (1990) and
Voogd et al (1992) can result in an underestimation of the size of the pool of
resistance genes. Isolates from in-patients are also associated with sample biases,
since these usually contain a number of repeat specimens (Huovinen 1986) and,
furthermore, a large proportion of the infections of inpatients are acquired from the
resident flora within the hospital itself (Wingard et al 1993). Huovinen (1984) found
that the incidence of trimethoprim resistance in urinary tract infections, in inpatients at
a Finnish hospital, was double that in catheter related infections. This suggests that
the patients were susceptible to colonisation by the more resistant resident hospital
flora.
The localised spread of resistant strains and/ or plasmids was only evident in two of
the populations. Three plasmids, which were harboured by more than one isolate,
were isolated only from the rural adults. Notably, the rural adults were all associated
with the hospital at Shongwe Mission and, consequently, were in contact with
patients. This particular population consisted of healthy mothers feeding sick children,
mothers attending a nutrition centre for children and finally escorts to patients visiting
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the out-patients department. One of these plasmids pUK2399 conferred resistance to
most classes of antimicrobials including third-generation cephalosporins and was
resistant to TpTcApGmTnCazCtxSxSmSpCm. Since aminoglycosides and third-
generation cephalosporins are usually restricted to hospital use it is likely that this
plasmid originated from within the hospital. Five other plasmids which were
harboured by more than one isolate were isolated only from the urban infants. This
group was made up of individuals attending either a childminder or a creche in
SOWETO. The most prevalent of these plasmids occurred in six Klebsiella spp.
isolates which exhibited identical biochemical and antimicrobial resistance profiles,
suggesting that this was the same isolate v/hich has spread within the childminder or
creche. A similar phenomenon has been observed in day care centres in Texas by
Reves et al (1987) and Singh et al (1992b).
Gene probing for trimethoprim-resistant DHFRs has been plagued with a number of
problems which can potentially result in erroneous data. The most significant setback
being the nature of the DHFR gene probes. The high degree of homology found in the
conserved regions of DHFRs especially in the type I like enzymes (la, lb, V, VI, VII)
and the type XII and XIII DHFRs suggest that it is essential to use accurate
oligonucleotide probes for the detection and discrimination between different DHFR
genes. The use of DHFR gene probes containing regions which extend upstream or
downstream of the DHFR can lead to false positive identifications of DHFRs. This is
because many different DHFRs are found as cassette-like structures in the integration
site of Tn27. There may, therefore, be hybridisation of the gene probe with the
flanking regions of the integron; for example the region of Tn27 which surrounds the
type lib DHFR on R388 is almost identical to that of the type V DHFR of pLMO20
(Sundstrom et al 1988). The following DHFRs have been observed to contain the
characteristic repeats that suggest that the gene forms part of a cassette: la, Ha, lib,
lie, V, VI, VII (Sundstrom et al 1993), the type lb (Young et al 1994), the type XII
(Heikkila et al 1993) and the type XIII (this thesis). As a result of the use of
trimethoprim in the form of co-trimoxazole, DHFR genes are often associated with
the sull gene which predominantly occurs as a gene cassette within an integron
(Radstrom et al 1991). The close association between these two genes can result in
sections of the sull gene being incorporated into a DHFR gene probe. This may
increase the incidence of false positives in the gene probing of DHFRs and thus
underestimate the variability of the DHFRs in a population. The use of the highly
specific oligonucleotide probes in this study, in conjunction with control strains for all
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the published plasmid and transposon mediated DHFRs are far less likely to produce
compromised data on the prevalence and distribution of DHFR genes.
The distribution of DHFR genes in South Africa is distinctly different from that
recorded in any previous study. The type la which has been shown to be the most
prevalent DHFR in Europe (Figure 1.7), occurred in only 14.6% of the South African
isolates. This is not unusual, since a low prevalence of this DHFR gene has been
recorded in most studies conducted outside Europe including Sri Lanka (Sundstrom
et al 1987), USA (Singh et al 1992b), India (Tait and Amyes 1994) and Thailand
(Chatkaeomorakot et al 1987).
Despite the low prevalence of the type la DKFR, the molecular epidemiology of this
DHFR is very similar to that recorded at other centres. As shown in table 4.2,
trimethoprim resistance was not transferable by conjugation in the majority of the
isolates which harboured the type la DHFR. In most of the isolates tested, the type la
DHFR was located within the chromosome, and was associated with the integrase
gene of Tn7. The high prevalence of this DHFR located within the chromosome and
its association with Tn7 has been observed previously in a number of studies (Heikkila
et al 1991; Chatkaeomorakot et al 1987; Towner et al 1994). The different size
restriction fragments of chromosomal DNA which hybridised to probes for the type la
DHFR and the integrase gene of Tn7 in each isolate suggest that the DHFR is not
located within a complete Tn7 transposon, or is integrated into different sites within
the chromosome. Both these phenomena have been observed previously (Heikkila et
al 1991). Only one isolate was found to harbour this DHFR on a non-transferable
plasmid which hybridised to a probe for the integrase gene of Tn2i. The association
of the dhfrla gene cassette with the integrase gene of Tn27 has been reported
previously (Heikkila et al 1991; Sundstrom and Skold 1990; Towner et al 1994). All
the transferable plasmids harbouring the type la DHFR exhibited distinct restriction
profiles. This suggests that its wide dissemination may be due to transposase or
integrase activity. Four of these plasmids conferred resistance to streptomycin,
spectinomycin and trimethoprim but not sulphonamides suggesting that the type la
DHFR may be located on Tn7 in these isolates. Only one of these plasmids hybridised
to the integrase gene of Tn21.
Contrary to most previous data, the type lb DHFR, which occurred in 21.8% of the
isolates, was shown to be the most prevalent DHFR in South African isolates of
commensal faecal flora. Since the development of the type lb oligonucleotide probe,
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the type lb DHFR has been shown to occur in several centres around the world at
considerable frequency. Young et al (1994) found it to be the dominant DHFR on
transferable trimethoprim resistance plasmids in Dundee. The same probe has shown
that the type lb has been found in 14% of faecal isolates conferring transferable
trimethoprim resistance from South India (Tait and Amyes 1994). Hybridisation
between the type lb DHFR with the whole gene probe for the type V DHFR has been
observed (Tait and Amyes 1994; Young et al 1994). Because of the high degree of
homology shared between the type V and lb (88%) at the nucleotide level (Young et
al 1994) this has probably led to the type lb being overlooked at the expense of the
type V DHFR. It appears that the type lb and V occur concurrently at most centres.
Table 4.2. Frequency of resistant DHFRs in South African commensal faecal
flora.
DHFR Transferred by conjugation (%) Non-Transferable (%) Total (%)
Type la 11(3.1) 41 (11.5) 52(14.6)
Type lb 58 (16.2) 20 (5.6) 78 (21.8)
Type V 25 (7.0) 3 (0.8) 28 (7.8)
TypeVI 0 0 0
Type VII 5 (1.4) 62 (17.4) 67 (18.8)
Type Ilb/c 0 0 0
Type Ilia 0 0 0
Type Vni 45 (12.6) 1 (0.3) 46 (12.9)
Type IX 0 0 0
TypeX 0 0 0
Type Xn 1 (0.3) 0 1 (0.3)
Type Xffl 30 (8.4) 15 (4.2) 45 (12.6)
Unknown 22 (6.2) 23 (6.4) 45(12.6)
Total 196 161 357
In the South African isolates, the plasmids harbouring the type lb DHFR transferred
by conjugation in 75% (58/78) of the isolates which harboured this DHFR gene. The
high incidence of the type lb DHFR gene on self-transmissible plasmids in South
Africa results partly to the presence of one plasmid, pUK2301 which accounted for
(26/78) of the type lb bearing isolates. The large number of different plasmids
carrying the type lb (24) suggest that this gene may have disseminated amongst these
plasmids via transposase or integrase activity. The type lb DHFR gene was initially
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isolated from a Tn7 like transposon Tn4J32. Downstream of this gene is a 59-base
element similar to that of the type V DHFR suggesting it forms part of a cassette-like
structure (Young et al 1994). In this study, some of the plasmids harbouring the type
lb DHFR including two which could not be mobilised by conjugation, hybridised to a
probe for the integrase gene of Tn27 suggesting that the DHFR may be inserted into
different integron structures in a similar manner to dhfrla as reported by Sundstrom
and Skold (1990). This association of dhfrlb with the integrase gene of Tn27 has been
reported previously by Tait and Amyes (1994).
In contrast to the type la DHFRs, the DHFR genes, which probed positive for the
type lb DHFR but did not transfer by conjugation, were located on plasmids and not
on the chromosome in the isolates that were tested. These plasmids appear to be
stable and could not transfer their resistance by conjugation under a variety of
conditions. The origins and mechanisms of dispersal of these plasmids is difficult to
determine. One possible explanation is in the nature of the plasmids: the plasmids
entering the cell by conjugation, may have undergone subsequent modification by a
number of potential mechanisms which change the nature of a plasmid thus causing it
to lose its ability to transfer to a recipient strain. These include insertion, deletion or
rearrangement of the plasmids by various insertion sequences or by transposase or
integrase activity (Carlos and Miller 1980). Another possible reason for the failure of
these plasmids to transfer by conjugation is the failure of the host bacterium to
develop the necessary conjugative structures with the recipient bacterium. It appears
that plasmids may account for a larger proportion of non-transferable resistance
factors than previously expected.
The type VII DHFR was the second most prevalent DHFR in South Africa. The
presence of the type VII DHFR in South Africa is consistent with the findings of other
workers. Its prevalence is widespread and has been isolated in Sweden, Finland,
Nigeria, Sri Lanka (Sundstrom et al 1993) and in the UK (Amyes et al 1989). What is
unusual, is that the incidence of the type VII DHFR recorded in this study is
considerably higher than that found in any previously studied population. More
fascinating is the contrast between the small number, out of the total sample of 357
isolates, bearing this gene on self transmissible plasmids (5/67) in comparison to the
large number of isolates that harbour this gene on the chromosome. The number of
different species carrying the type VII DHFR gene and the different fragment sizes
which hybridised to the type VII DHFR and Tn27 integrase genes, suggest that the
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widespread dissemination of this DHFR gene is not the result of the spread of a single
clone but rather the dispersal of this gene on mobile DNA elements.
The type VII DHFR has in previous studies been located within a Tn2/-like element
on transferable plasmids (Sundstrom et al 1993) although no other locations for the
type VII gene has been documented in the literature. The close association of the type
VII DHFR gene with the integrase gene of Tn27 in the South African population
suggests that the type VII DHFR gene is integrated into an integron-like structure.
The number of different sized restriction fragments that showed this combination of
these two genes suggest that the integrase may be incorporated into a number of
different deletion products or precursor structures of Tn2i-like transposons
(Ziihlsdorf and Wiedemann 1992) such as Tn8056 (Sundstrom et al 1993). Unlike
Tn7, site-specific insertion of Tn27 has not been documented which suggests that
these elements insert at random sites into the chromosome. It is unclear why the
integrase gene of Tn2i which is normally associated with DHFR genes on plasmids
(Sundstrom et al 1988; Sundstrom et al 1993; Heikkila et al 1991; Heikkila et al
1993) should show a preference for integration into the chromosome. Further
molecular characterisation of sequences flanking this DHFR and associated integrase
should clarify this phenomenon. This also raises questions surrounding the efficiency
of transfer of a transposable element from the chromosome of one organism to the
chromosome of another via a self-transferable plasmid intermediate.
Despite the recent discovery of the type VII DHFR, this DHFR has been detected in
isolates collected from as early as 1974 (Sundstrom et al 1993). There are a number
of reasons why this DHFR may have been overlooked: for one, this DHFR exhibits
similar biochemical properties to other type I like DHFRs, and from most of the
European studies, this enzyme appears to make up only a small percentage of
trimethoprim-resistant DHFRs that are detected (Sundstrom et al 1993; Towner et al
1991). Furthermore, if the infrequent occurrence of this DHFR on self-transmissible
plasmids in South Africa is consistent in other parts of the world it is likely that this
DHFR may not be detected or its prevalence underestimated in studies which have
only focused on plasmid mediated DHFRs, such as those by Towner et al (1991) and
Tait and Amyes (1994).
Little is known about the prevalence of the type IIIc/VIII DHFR. This gene was first
isolated after an outbreak of S. sonnei in North Carolina, USA and was subsequently
found to be widespread in S. sonnei isolates around the USA (Earg et al 1990). This
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DHFR gene has also been isolated from urinary isolates in Sweden (Sundstrom et al
1991a). In South African isolates of faecal flora it was shown to be second most
prevalent DHFR on transferable plasmids 23% (45/196) and the fourth most prevalent
DHFR overall 12.9% (46/357). In complete contrast to the type VII DHFRs, there
was a marked difference between the number of isolates that harboured the type VIII
DHFR on transferable plasmids (45/46) in comparison to only one isolate that was
unable to transfer this DHFR to a recipient strain. The presence of a number of
geographically ubiquitous plasmids harbouring the type VIII DHFR in South African
isolates suggests that these are the principal means of dispersal of the type VIII DHFR
in South Africa. The type VIII DHFR is one of the few trimethoprim-resistant DHFRs
which have not been found as gene cassettes associated within an integron.
The type VIII DHFRs accounted for all the transconjugants bearing intermediate
MICs of less than 1024mg/l though it did include some isolates with higher MICs.
Two different MICs for trimethoprim have been previously reported for this DHFR,
256mg/l (Barg et al 1990) and 1000mg/l (Sundstrom et al 1991a). The range of MICs
reported in this study are thought to result from differences in expression of the
DHFR by different plasmids and differences in plasmid copy number. With the
exception of one S. sonnei isolate, all the other isolates were from E. coll. The
American and most of the South African isolates carried resistance to trimethoprim,
ampicillin, streptomycin, and sulphamethoxazole (Barg et al 1990). It is not known
whether there is any common genetic link between these isolates. No other
prospective study has looked for this particular DHFR. Its ubiquitous presence in
South Africa and the USA suggest that it is a prevalent DHFR amongst faecal
organisms.
The type V DHFR is geographically widespread and has been isolated from most of
the studies of resistant DHFR genes at low-to-moderate frequency (Table 1.4);
however it should be kept in mind that some of these enzymes may have been
misidentified type lb DHFRs. In South Africa, the prevalence of this DHFR 7.8%
(28/357), is similar to that reported in other parts of the world. As shown in table 4.2,
89% (25/28) of the isolates harboured this DHFR on transferable plasmids. The
remaining three isolates harboured this DHFR on non-transferable plasmids. The
location of this DHFR on plasmids within the integron of Tn27 has been reported
previously (Sundstrom et al 1988; Tait and Amyes 1994). In the South African
isolates, 60% (15/25) of the transferable plasmids and all the non-transferable
plasmids hybridised to the probe for the integrase gene ofTn2i.
Discussion
In South Africa, the type XII DHFR was shown to be rare, and was isolated from
only one isolate. This newly discovered enzyme has been shown to occur at relatively
low frequency at a number of centres. It has previously been isolated in Finland from a
urinary isolate and from four Shigellas of Asian origin (Heikkila et al 1993). It has
also been detected in a number of isolates from children attending day-care centres in
Texas (Singh et al 1992b). The high level of homology between the nucleotide
sequence of the types XII and XIII DHFRs (85%) is similar to that shared between
the types lb and V DHFR genes (88%) which suggests that, like the type lb and V
DHFRs, a whole gene probe from either the type XII or XIII will cross-hybridise
between the two genes.
The novel type XIII DHFR was fairly prevalent in South Africa and occurred in
12.6% (45/357) of the isolates. Two-thirds of the isolates which hybridised to the
oligonucleotide probe for the type XIII DHFR could transfer the DHFR by
conjugation. The integrase gene of Tn27 was associated with the type XIII DHFR in
40% (12/30) of the plasmids. It appears that, like the type XII DHFR, the type XIII
DHFR can be located with or without the presence of the integrase gene of Tn27
(Heikkila et al 1993; Singh et al 1992b). Although only one plasmid harbouring this
DHFR gene was detected in more than one isolate, a number of restriction profiles of
plasmids harbouring this DHFR were similar and shared a number of identical sized
restriction fragments. This suggests that the plasmids which harboured this DHFR
gene have undergone a significant amount of rearrangement and divergent evolution.
The successful spread of this DHFR may be due to the extremely high incidence of
resistance associated with this DHFR gene. Considering that resistance to ampicillin,
tetracycline, sulphonamides, streptomycin, spectinomycin and chloramphenicol
occurred in more than half of the plasmids, which harbour the type XIII DHFR, it is
likely that antimicrobial therapy with any of these agents will exert strong selection
pressure for bacteria harbouring these plasmids. It is difficult to predict how widely
distributed the type XIII DHFR may be in other parts of the world. However, since
this DHFR was extremely widespread in South Africa, and was detected in all the
rural and urban population groups, it is thought that this DHFR may be widely
distributed in other parts of the world and may account for a proportion of the 10 to
68% of DHFR genes which were not identified in a number of studies (Heikkila et al
1990b; Jansson et al 1991; Singh et al 1992b; Chang et al 1992; Towner et al 1994).
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Probes for the type lib and lie DHFRs did not hybridise to any DHFRs from the
South African isolates. Despite a number of studies which showed a high prevalence
of type II DHFRs, the type II DHFRs were absent, or extremely rare in most of the
studies (Table 1.4). The high incidence of these DHFRs recorded in some of the
studies are most likely due to a number of factors. The large size of the gene probes
used in these studies have subsequently been shown to contain part of a Tn2/-like
transposon, and as a result are likely to hybridise with any of the DHFRs la, lb, II, V,
VII, X, XII and XIII which have been found associated with the integrase gene of
Tn2i. Furthermore, control strains from the more recently detected DHFRs (lb, IIIb,
IIIc/VIII, IV, V, VI, VII, IX, X, XII and XIII) were not available as adequate
controls for these early type II DHFR probes. As shown in figure 3.3. even with the
relatively small 280-bp type II DHFR gene probe, the stringency of the washes during
hybridisation are critical to preventing cross-hybridisation.
Despite the widespread use and availability of a gene probe for the type Ilia DHFR,
this DHFR has only been detected in one Salmonella typhimurium isolate from New
Zealand (Fling et al 1988) and at varying frequency in isolates from Nottingham, UK
(Towner et al 1994). The absence of the type Ilia DHFR from a number of studies
(Table 1.4) including South Africa suggest that this DHFR is fairly rare.
There are no epidemiological data for the prevalence of the type VI DHFR. Despite
the fact that this DHFR was first detected in a urinary isolate of Proteus mirabilis
from South Africa (Wylie et al 1988), it was not detected in any of the faecal isolates
from this study. A study by Sundstrom et al (1993) failed to detect type VI in a
collection of isolates from a number of countries which suggests that this DHFR is a
rare enzyme. There is no epidemiological data for the prevalence of the type X
DHFR. The failure to detect this DHFR in South Africa suggests that its distribution
may be localised. The absence of the type IX DHFR in South African populations and
others (Jansson et al 1992) suggest that the type IX DHFR is restricted to isolates
from swine and some human isolates in Sweden.
Of the 45 isolates which did not hybridise to any of the DHFR probes, half of these
isolates (22/45) transferred trimethoprim resistance to a recipient strain, suggesting
that in these isolates resistance was conferred by the production of an additional
resistant DHFR. The MIC for trimethoprim in all the transconjugants was >2048mg/l.
The high MICs of these unidentified DHFRs suggests that resistance was unlikely to
be conferred by either the type Illb or type IV DHFR. Although the type II DHFRs
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are known to confer high levels of resistance, the possibility of them being either a
type Ha or type II variant, which did not hybridise to the type lib DHFR probe, are
remote, since not only are these DHFRs rare and appear to be restricted to clinical
isolates, but these DHFRs are also usually associated with the integrase gene of Tn2/;
an association which did not occur in these isolates. These unknown enzymes are
most likely to be novel DHFRs, possibly a type I-like enzyme, or a variant of the
highly resistant type XII and XIII DHFRs. The large number of different restriction
profiles and antibiogram types representing the unknown DHFRs (Table 4.3) suggest
that there may be more than one novel DHFR gene amongst these isolates.
Table 4.3. Plasmids conferring unknown trimethoprim-resistant DHFRs, their
resistance profile, and their association with In21.















A number of mechanisms of resistance to trimethoprim have been considered in the 23
isolates which did not transfer trimethoprim resistance. Considering that (22/23) of
these isolates conferred trimethoprim MICs of >2048mg/l, it is most likely that
resistance is due to the production of either a plasmid or transposon mediated DHFR.
One of these isolates was a Pseudomonas aeruginosa which was most likely to be
intrinsically resistant to trimethoprim (Grey and Hamilton-Miller 1977). All of these
isolates grew on DM minimal medium and therefore cannot be thymine mutants. It is
also unlikely that these isolates are resistant as a result of membrane impermeability or
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mutations to the chromosomal DHFRs since these mechanisms of resistance usually
confer low to intermediate trimethoprim MICs (Gutmann et al 1985; Grey et al
1979). Only one isolate (Klebsiella spp.) was resistant to low levels of trimethoprim
(MIC=16mg/l).
When the amino acid sequence of the type XIII DHFR was compared to the
sequences of the other trimethoprim-resistant DHFRs, the highest degree of
homology shared with this DHFR was the type XII (82.4%) (Table 4.4) which
suggests that this DHFR is closely related to and may have arisen from the same
ancestor as the type XII. With the exception of the type XII, the type XIII DHFR
shared a limited amount of homology (22.4% to 34.5%) with the other resistant
DHFRs (Table 4.4). A similar level of homology (15.2% to 35.5%) occurred between
the type XIII DHFR and the DHFR genes of other species (Table 4.5). The most
closely related of these DHFRs to the type XIII DHFR was the chromosomal DHFR
of Bacillus subtilis (35.8%) and the DHFR genes of Enterobacteriaceae (34.5-
35.2%).
Table 4.4. Amino acid sequence identity of the type XIII DHFR with
trimethoprim-resistant DHFRs isolated from bacteria.












Staphylococcus aureus SI 30.3
From the limited number of DHFRs from different species that have been sequenced,
there are no enzymes that are closely related enough to the type XIII DHFR to make
an accurate assessment to determine the putative origins of this DHFR. However,
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since the type XIII DHFR is of a similar length and shares the closest homology with
bacterial DHFRs, the most likely ancestor of the type XIII DHFR is thought to be
bacterial. The presence of the type XIII DHFR and a number of other resistant
DHFRs as gene cassettes suggests that the promoter sequences of the original host of
the DHFR are not recognised in Gram-negative bacteria. Inserting such gene cassettes
into the promoters of integrons and other DNA elements, which are recognised in
Gram-negative bacteria, may be necessary for gene expression in these organisms.
Table 4.5. Amino acid sequence identity of the type XIII DHFR with other
chromosomal DHFRs.


















































The type XIII DHFR exhibited unique biochemical properties and, with the exception
of the type II DHFRs, is the most resistant DHFR to inhibition by trimethoprim that
has been characterised. The trimethoprim IDgg for the type XIII DHFR (800|im) was
considerably lower than the atypical type II enzymes (IDgo=20 000-80 0(X)|_tM) but
when compared to the other resistant DHFRs, with the exception of the type VI
(ID5o=200|iM), the ID50 was more than 10 times higher than the resistant type I-like
enzymes (ID5o=23-57|iM). The K, values which are a better indicator of the
performance of a DHFR, in the presence of trimethoprim, showed that the type XIII
DHFR (K,-180fiM) was resistant to a similar order of magnitude as the type lis (K,
=150-6100|iM) and was also more resistant than any other of the resistant DHFRs
including the type VI (K,=75|iM) which has often been described as having type II
like properties (Amyes et al 1992b).
What separates the type XIII DHFR more dramatically from the type II enzymes is
the sensitivity of the type XIII DHFRs and other DHFR types to methotrexate. The
methotrexate ID5q value for the type XIII is 5|iM in comparison to 750-1100|iM for
the type lis. The relative sensitivity of the type XIII DHFR to methotrexate confirms
that the active site is structurally homologous to that of the E. coli chromosomal
DHFR (Matthews et al 1986). Heat-sensitivity is another factor which separates the
type XIII DHFR (TDgo=7 min) from most other DHFRs because, with the exception
of the type I-like enzymes which are very unstable (TD5o=0.5-1.5 min), most other
DHFRs such as the type lis, Ilia, Illb, IV, SI and the chromosomal DHFRs show no
loss of activity after 12 min exposure at 45°C. Only the type VIII DHFR (TD50=8
min) shows a similar heat-sensitivity profile to the type XIII.
Overall, the most similar of the resistant DHFRs to the type XIII, in terms of their
biochemical properties, were the type I-like enzymes, a relationship which is reflected
to some extent by the level of similarity between the amino acid sequence of these
genes (Figure 4.1). Although amino acid identity was less spectacular, many of the
different amino acids in positions 1-80 were conservative replacements.
Most of the biochemical properties of the type XII DHFR have not yet been
determined. The only available data are a trimethoprim ID50 value of 700|lM, which
is almost identical to the type XIII DHFR. Structurally, the type XII and XIII DHFRs
are similar and, with the exception of one conservative amino acid replacement, all the
amino acids at the trimethoprim, methotrexate and NADPH cofactor binding sites are
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Figure 4.1. Amino acid sequence similarities between the type XIII, XII, la, lb,
V, VI, VII, Ilia, VIII, IX, X and the chromosomal DHFR from E. coli K12.
Positions containing identical amino acids with respect to the type Xin DHFR
are in bold script, and conserved replacements within the groups (D,E),
(F,W,Y), (H,K,R), (I,L,M,N), (N,Q) and (S,T) are in italics. Positions involved in
binding trimethoprim (♦), methotrexate (♦ and 0) and NADPH cofactor (■)
based on the E. coli K12 DHFR (Rouch et al 1989) are indicated.
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identical (Rouch et al 1989). The six consecutive amino acids from positions 88-94 of
the type XIII DHFR (Figure 4.1) are dissimilar to those of the type XII DHFR. The
first three amino acid substitutions are caused by a frame shift which occurs over six
nucleotides as a result of a base deletion at position 263 and a subsequent base
insertion at position 269 on the nucleotide sequence of the type XIII DHFR gene
(Figure 3.19). This substituted region suggests that the type XIII DHFR has diverged
from the type XII or a type XH-like ancestor, since the same region in the type XII
shares close homology to other DHFR types including the chromosomal DHFR of
E. coli. Furthermore, the amino acids at positions 80 and 151 of the type XIII DHFR
are dissimilar to the type XII and other resistant DHFR types which confirm this
evolutionary divergence. This pattern is not entirely consistent as the amino acids that
differ at positions 24 and 75 of the type XII and XIII DHFR are more conserved in
the type XIII DHFR.
Only half the trimethoprim binding sites on the trimethoprim sensitive chromosomal
DHFR of E. coli (as indicated by Rouch et al 1989) (Figure 4.1) were conserved in
the type XIII DHFR. Six of the amino acids, that are involved in binding trimethoprim
at positions 12, 13, 36, 54, 55 and 59, were identical. The binding sites at positions
11, 25, 32, and 121 were conservative substitutions, and the trimethoprim binding
sites at positions 33 and 102 were different. The significance of these alterations in the
trimethoprim binding sites in the type XIII is difficult to predict, without knowing the
three dimensional structure of the enzyme as determined by X-ray crystallography.
However, by comparing the differences between the trimethoprim binding sites of the
sensitive E. coli chromosomal enzyme, with those of a trimethoprim-resistant
vertebrate DHFR (chicken), for which a three dimensional structure is available for
both enzymes, a model for the differences in selectivity can be established.
The following model for selectivity has been described by Baccanari and Kuyper
(1993). In the E. coli chromosomal DHFR structure, trimethoprim forms five
hydrogen bonds with the enzyme, including an ionic interaction between the
pyrimidine ring of trimethoprim and the carboxylic acid side-chain of aspartic acid
(position 27) (Figure 4.2). This enzyme-ligand interaction cannot occur with the
substrate dihydrofolate and is, in part, responsible for the enhanced binding of
trimethoprim to the enzyme. The conformation of trimethoprim is different in
vertebrate enzymes such that when the ionic bond forms with the carboxylic acid
sidechain of glutamic acid (position 30) which is equivalent to aspartic acid at position
27 in the E. coli DHFR (Figure 4.2), the trimethoxyphenyl group is positioned in an
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alternative binding pocket (away from the cofactor) and cannot establish ligand-
cofactor interactions. The binding mode also abers the orientation of the pyrimidine
portion of trimethoprim. The pyrimidine is pushed further into the cleft such that its 4-
amino group cannot form a hydrogen bond with valine (position 115), the vertebrate
enzyme amino acid residue analogous to isoleucine (position 94) of the E. coli DHFR.
Thus, a combination of the altered conformation and hydrogen bonding pattern of
trimethoprim may in part, be responsible for species differences in affinity.
Figure 4.2. Comparison of the conformation and hydrogen bonding pattern of
trimethoprim in the E. coli and chicken DHFR ternary complexes (Figure from
Baccanari and Kuyper 1993).
Trimethoprim binding to the resistant type XIII DHFR is fairly analogous to that of
the vertebrate enzyme. The most significant similarity is the substitution of a glutamic
acid residue at position 32 of the type XIII DHFR for the aspartic acid residue which
corresponds to position 27 of the sensitive E. coli chromosomal DHFR. An identical
substitution also occurs in the corresponding position of the vertebrate, type I-like and
type XII DHFRs (Sundstrom et al 1993; Heikkila et al 1993). The amino acid
substitution at position 33 from leucine to glutamine of the type XIII DHFR may
enhance a change in orientation of the trimethoprim molecule when it binds to the
glutamic acid residue of the DHFR. This substitution is also present in the type I-like
and type XII DHFRs. Another significant change is the substitution of alanine for
isoleucine at position 102 of the type XIII (position 94 in E. coli). Since isoleucine at
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position 94 of the E. coli enzyme forms a hydrogen bond with the 2-amino group, a
substitution of a dissimilar amino acid at the corresponding position may prevent this.
The Km of the type XIII DHFR is approximately ten times higher than that of the
chromosomal DHFR of E. coli, and is one of the highest recorded for trimethoprim-
resistant DHFRs. This suggests that the changes within the active site which affect
trimethoprim binding have resulted in a reduction of the affinity of the substrate for
the type XIII DHFR. Despite the low turnover rate of tetrahydrofolate by the type
XIII DHFR, the high K; of the type XIII DHFR is sufficient to confer significant
MICs of trimethoprim (>2048mg/l).
The elements of secondary structure of the chromosomal DHFR of E. coli were
determined by X-ray crystallographic analysis and it was shown that DHFR enzymes
consist of a central eight stranded P-sheet, and four a-helices where the remaining
residues make up loops connecting these elements of secondary structure as reviewed
by Baccanari and Kuyper (1993). These features of secondary structure appear to be
similar between the different DHFRs and are marked according to the amino acid
sequence of E. coli (Figure 4.1). The secondary structure of the type XIII DHFR
differs from that of the E. coli chromosomal DHFR in that the loop structure between
P-sheet C and P-sheet D of the type XIII DHFR contains two amino acid insertions,
the start of a-helix E is shortened by one amino acid and the loop between a-helix E
and P-sheet E has an extra amino acid inserted.
One of the interesting features of the alignment of the amino acid sequence of the
trimethoprim-resistant DHFRs with the features of secondary structure, is that, with
the exception of the first 60 amino acids which contain most of the conserved
trimethoprim and NADPH cofactor binding sites, the most heterogeneous regions are
the loop structures that occur between the P-sheet and a-helix structures.
Evolutionary divergence at these loops as a result of genetic drift can be expected
since changes in amino acid structure in these regions are unlikely to affect DHFR
function. These regions are therefore perfect for the development of oligonucleotide
probes for distinguishing between resistant DHFR genes, because not only is the
heterogeneity clear between DHFR genes which have already been sequenced, but
also heterogeneity in undiscovered genes is more likely to be greater in these regions
than others.
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There are three loops which occur in DHFR genes which are ten or more amino acids
long and are therefore suitable for the construction of DHFR probes (Figure 4.1).
They are located between (3-sheet C and p-sheet D, between a-helix E and P-sheet E
and between P-sheet F and P-sheet G. The loop between P-sheet C and P-sheet D is
the most promising since not only does the length of this loop vary between the more
distantly related DHFRs, but also the nucleotide sequence of the most closely related
DHFRs such as the types lb and V and the types XII and XIII are the most
heterogeneous in this region. It was from this region of the gene that the
oligonucleotide probes for the DHFR genes used in this study were derived (Figure
4.3). The loop between a-helix E and P-sheet E is the most variable between the more
distantly related groups, which vary in loop length by as much as seven amino acids.
Unfortunately, in this region both the types XII and XIII and the family I DHFRs are
too conserved. The loop between P-sheet F and P-sheet G appears to be conserved
even between some of the more distantly related DHFRs such as the type Ilia, XIII,
the family I DHFRs and the chromosomal DHFR of E. Coli.
attachment sites of methotrexate (Williams 1995). The shaded region indicates




The commensal faecal flora of healthy individuals from South Africa form a large and
important reservoir of trimethoprim-resistant dihydrofolate reductase genes. This
presents a threat to the continued use of trimethoprim in South Africa, including a
number of antimicrobial agents which are linked to trimethoprim resistance.
The amino acid loops which link the elements of secondary structure of DHFR genes
are highly heterogeneous and are ideal regions for the development of discriminating
oligonucleotide probes for the detection of trimethoprim-resistant DHFRs.
Oligonucleotide probes developed from the nucleotide sequence of the loop between
3-sheet C and 3-sheet D were developed, and were shown to distinguish between
closely related DHFR genes, and did not hybridise with any of the DHFR related
sequences. The highly selective DHFR oligonucleotide probes were able to distinguish
between the closely related type XII and XIII DHFR genes and resulted in the
detection of the latter.
The epidemiology of resistant DHFR genes in South Africa is distinctly different from
the data from Europe where the type la is the predominant DHFR gene. The more
recently detected DHFR genes such as the type lb, VII, VIII and XIII were shown to
be highly prevalent in South Africa, and, from the recent data collected from other
parts of the world, suggest that these DHFRs are also prevalent in other parts of the
world.
The molecular epidemiology and genetic location of the DHFR genes differed
remarkably between the different DHFR types. The distribution of the DHFR genes
which could not transfer their resistance by conjugation is completely different from
the distribution of these genes located on transferable plasmids. The prevalence of the
type lb, V and VIII DHFR, which occurred predominantly on transferable and
non-transferable plasmids, was a complete contrast to the types la and VII DHFRs
which were located predominantly on the chromosome. This suggests that the genetic
structures associated with these genes such as Tn27 and Tn7 play an important role in
the dissemination and spread of these genes.
It is important that the levels of antibiotic resistance in South Africa are carefully
monitored as multiple resistant organisms continue to limit the choice of antimicrobial
agents available for therapy.
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